[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 91 of about 91
1. Tai CJ, Hsu CH, Shen SC, Lee WR, Jiang MC: Cellular apoptosis susceptibility (CSE1L/CAS) protein in cancer metastasis and chemotherapeutic drug-induced apoptosis. J Exp Clin Cancer Res; 2010;29:110
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular apoptosis susceptibility (CSE1L/CAS) protein in cancer metastasis and chemotherapeutic drug-induced apoptosis.
  • The cellular apoptosis susceptibility (CSE1L/CAS) protein is highly expressed in cancer, and its expression is positively correlated with high cancer stage, high cancer grade, and worse outcomes of patients.
  • CSE1L (or CAS) regulates chemotherapeutic drug-induced cancer cell apoptosis and may play important roles in mediating the cytotoxicities of chemotherapeutic drugs against cancer cells in cancer chemotherapy.
  • CSE1L was originally regarded as a proliferation-associated protein and was thought to regulate the proliferation of cancer cells in cancer progression.
  • However, the results of experimental studies showed that enhanced CSE1L expression is unable to increase proliferation of cancer cells and CSE1L regulates invasion and metastasis but not proliferation of cancer cells.
  • Recent studies revealed that CSE1L is a secretory protein, and there is a higher prevalence of secretory CSE1L in the sera of patients with metastatic cancer.
  • Therefore, CSE1L may be a useful serological marker for screening, diagnosis and prognosis, assessment of therapeutic responses, and monitoring for recurrence of cancer.
  • In this paper, we review the expression of CSE1L in cancer and discuss why CSE1L regulates the invasion and metastasis rather than the proliferation of cancer.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Cellular Apoptosis Susceptibility Protein / metabolism. Neoplasms / metabolism. Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2003 Oct 15;116(Pt 20):4077-85 [12972501.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Sep;22(3):461-70 [14582707.001]
  • [Cites] Gynecol Oncol. 2004 Jan;92(1):268-76 [14751170.001]
  • [Cites] J Neurosurg. 2004 Feb;100(2 Suppl Pediatrics):187-93 [14758948.001]
  • [Cites] Am J Pathol. 2004 Apr;164(4):1131-9 [15039201.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Mar;23(1):121-5 [15149160.001]
  • [Cites] Cancer Treat Res. 2004;119:175-87 [15164878.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Jun;23(2):325-32 [15354419.001]
  • [Cites] Surg Gynecol Obstet. 1977 Apr;144(4):537-46 [847609.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Jan;85(1):136-40 [3277169.001]
  • [Cites] Gastroenterol Clin North Am. 1990 Dec;19(4):793-810 [1702756.001]
  • [Cites] Mol Cell Biol. 1993 Aug;13(8):4691-702 [8336709.001]
  • [Cites] Int J Cancer. 1994 Feb 15;56(4):552-9 [8112891.001]
  • [Cites] Cell. 1995 Apr 21;81(2):269-78 [7736579.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10427-31 [7479798.001]
  • [Cites] Mol Med. 1995 Jan;1(2):206-16 [8529099.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2670-4 [8610099.001]
  • [Cites] Biochemistry. 1996 May 28;35(21):6891-9 [8639641.001]
  • [Cites] Genome Res. 1996 Mar;6(3):187-94 [8963895.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):25-30 [9006318.001]
  • [Cites] Int J Biochem Cell Biol. 1997 Mar;29(3):393-6 [9202418.001]
  • [Cites] Biochemistry. 1997 Aug 5;36(31):9493-500 [9235994.001]
  • [Cites] Oncol Res. 1997;9(5):237-48 [9306431.001]
  • [Cites] Cell. 1997 Sep 19;90(6):1061-71 [9323134.001]
  • [Cites] Am J Hum Genet. 1998 Mar;62(3):509-13 [9497270.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Apr;21(4):340-6 [9559346.001]
  • [Cites] Mol Biol Cell. 1999 Apr;10(4):947-59 [10198049.001]
  • [Cites] Am J Dermatopathol. 1999 Apr;21(2):125-8 [10218671.001]
  • [Cites] Scand J Gastroenterol. 2004 Aug;39(8):766-72 [15513363.001]
  • [Cites] J Exp Clin Cancer Res. 2004 Dec;23(4):641-50 [15743035.001]
  • [Cites] Biochimie. 2005 Mar-Apr;87(3-4):321-8 [15781319.001]
  • [Cites] Acta Biochim Biophys Sin (Shanghai). 2005 Aug;37(8):541-6 [16077901.001]
  • [Cites] Cell Cycle. 2005 Sep;4(9):1149-52 [16103753.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Sep;24(3):463-73 [16270534.001]
  • [Cites] Oncogene. 2006 Jan 5;25(1):91-102 [16158056.001]
  • [Cites] Traffic. 2006 Feb;7(2):109-16 [16420520.001]
  • [Cites] Eur J Cell Biol. 2006 Apr;85(3-4):159-64 [16546558.001]
  • [Cites] Int J Cancer. 2006 Aug 1;119(3):599-607 [16572426.001]
  • [Cites] Int J Mol Med. 2006 Jul;18(1):77-81 [16786158.001]
  • [Cites] Results Probl Cell Differ. 2006;42:1-29 [16903206.001]
  • [Cites] J Cell Physiol. 2006 Oct;209(1):13-20 [16741928.001]
  • [Cites] J Exp Clin Cancer Res. 2009;28:13 [19183492.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1570-7 [19383891.001]
  • [Cites] Mol Cell Biochem. 2009 Jul;327(1-2):163-70 [19224336.001]
  • [Cites] J Exp Clin Cancer Res. 2009;28:98 [19589137.001]
  • [Cites] Biomed Pharmacother. 2009 Aug;63(7):522-7 [18849138.001]
  • [Cites] J Exp Clin Cancer Res. 2009;28:125 [19737423.001]
  • [Cites] Crit Rev Biochem Mol Biol. 2009 Nov-Dec;44(6):367-92 [19929178.001]
  • [Cites] J Exp Clin Cancer Res. 2010;29:8 [20096120.001]
  • [Cites] J Exp Clin Cancer Res. 2010;29:16 [20181250.001]
  • [Cites] J Exp Clin Cancer Res. 2010;29:17 [20181269.001]
  • [Cites] Am J Pathol. 2010 Apr;176(4):1619-28 [20150437.001]
  • [Cites] J Exp Clin Cancer Res. 2010;29:30 [20380702.001]
  • [Cites] Neuro Endocrinol Lett. 2010;31(3):390-8 [20588233.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Dec;19(4):497-504 [11277329.001]
  • [Cites] J Mol Histol. 2010 Oct;41(4-5):259-66 [20734115.001]
  • [Cites] Exp Cell Res. 2010 Oct 15;316(17):2969-81 [20688056.001]
  • [Cites] J Int Med Res. 2010 Jul-Aug;38(4):1354-64 [20926008.001]
  • [Cites] Curr Biol. 2000 Sep 7;10(17):R624-6 [10996086.001]
  • [Cites] Int J Mol Med. 2001 May;7(5):489-94 [11295109.001]
  • [Cites] Lab Invest. 2001 May;81(5):717-23 [11351043.001]
  • [Cites] J Exp Clin Cancer Res. 2001 Jun;20(2):213-8 [11484977.001]
  • [Cites] J Exp Clin Cancer Res. 2001 Jun;20(2):253-6 [11484983.001]
  • [Cites] Mol Cell Biol. 2001 Oct;21(20):7020-4 [11564884.001]
  • [Cites] Int J Gynecol Pathol. 2001 Oct;20(4):359-67 [11603220.001]
  • [Cites] Mol Cell Biol Res Commun. 2001 Nov;4(6):353-8 [11703094.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4A):2413-7 [11724300.001]
  • [Cites] Int J Oncol. 2002 Mar;20(3):467-73 [11836556.001]
  • [Cites] Circ Res. 2002 Apr 19;90(7):784-91 [11964371.001]
  • [Cites] Mol Biol Cell. 2006 Nov;17(11):4736-47 [16943325.001]
  • [Cites] J Exp Clin Cancer Res. 2006 Sep;25(3):417-23 [17167983.001]
  • [Cites] J Biol Chem. 2007 Feb 23;282(8):5934-43 [17190831.001]
  • [Cites] J Exp Clin Cancer Res. 2007 Mar;26(1):91-9 [17550137.001]
  • [Cites] Cell. 2007 Aug 24;130(4):638-50 [17719542.001]
  • [Cites] J Exp Clin Cancer Res. 2007 Jun;26(2):241-51 [17725105.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1915-7 [17932335.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Oct;16(10):1918-20 [17932336.001]
  • [Cites] J Exp Clin Cancer Res. 2007 Dec;26(4):535-42 [18365550.001]
  • [Cites] BMB Rep. 2008 Mar 31;41(3):210-6 [18377724.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:15 [18597698.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:35 [18778462.001]
  • [Cites] J Neurooncol. 2008 Nov;90(2):133-40 [18618226.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:46 [18816410.001]
  • [Cites] Toxicology. 2008 Dec 30;254(3):147-57 [18694801.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:83 [19077278.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jun 21;294(4):900-5 [12061792.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Sep;21(3):357-61 [12385578.001]
  • [Cites] J Exp Clin Cancer Res. 2002 Sep;21(3):401-7 [12385585.001]
  • [Cites] Anal Cell Pathol. 2002;24(2-3):69-76 [12446956.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6803-7 [12460888.001]
  • [Cites] Am J Clin Pathol. 2002 Dec;118(6):922-9 [12472286.001]
  • [Cites] Apoptosis. 2003 Jan;8(1):39-44 [12510150.001]
  • (PMID = 20701792.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cellular Apoptosis Susceptibility Protein
  • [Other-IDs] NLM/ PMC2925819
  •  go-up   go-down


2. Faça VM, Ventura AP, Fitzgibbon MP, Pereira-Faça SR, Pitteri SJ, Green AE, Ireton RC, Zhang Q, Wang H, O'Briant KC, Drescher CW, Schummer M, McIntosh MW, Knudsen BS, Hanash SM: Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains. PLoS One; 2008;3(6):e2425
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of ovarian cancer cells reveals dynamic processes of protein secretion and shedding of extra-cellular domains.
  • We have characterized the cell surface proteome and the proteins released into the extra-cellular milieu of three ovarian cancer cell lines, CaOV3, OVCAR3 and ES2 and of ovarian tumor cells enriched from ascites fluid.
  • CONCLUSIONS AND SIGNIFICANCE: Protein profiles of the cell lines had substantial similarity to the profiles of human ovarian cancer cells from ascites fluid and included protein markers known to be associated with ovarian cancer.
  • Proteomic analysis indicated extensive shedding from extra-cellular domains of proteins expressed on the cell surface, and remarkably high secretion rates for some proteins (nanograms per million cells per hour).
  • Cell surface and secreted proteins identified by in-depth proteomic profiling of ovarian cancer cells may provide new targets for diagnosis and therapy.


3. Samuelson LE, Dukes MJ, Hunt CR, Casey JD, Bornhop DJ: TSPO targeted dendrimer imaging agent: synthesis, characterization, and cellular internalization. Bioconjug Chem; 2009 Nov;20(11):2082-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TSPO targeted dendrimer imaging agent: synthesis, characterization, and cellular internalization.
  • While it has become common practice for dendrimers to deliver imaging and therapeutic agents, there are few reported examples of cellular internalization of dendrimers.
  • Previously, we have delivered small molecule imaging agents into glioma and breast cancer cells by targeting the translocator protein (TSPO; formerly known as the peripheral benzodiazepine receptor or PBR) with a family of high-affinity conjugable ligands.
  • Here, we present the synthesis, characterization, and cellular internalization into C6 rat glioma cells of a TSPO targeted dendrimer imaging agent.

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Bioanal Chem. 2006 Feb;384(3):620-30 [16440195.001]
  • [Cites] Nat Med. 2005 Nov;11(11):1250-5 [16258537.001]
  • [Cites] Trends Pharmacol Sci. 2006 Aug;27(8):402-9 [16822554.001]
  • [Cites] Mol Cancer Ther. 2006 Aug;5(8):1909-17 [16928810.001]
  • [Cites] Magn Reson Med. 2006 Dec;56(6):1384-8 [17089356.001]
  • [Cites] Biochem Soc Trans. 2007 Feb;35(Pt 1):61-7 [17233602.001]
  • [Cites] Nanomedicine. 2006 Sep;2(3):137-49 [17292136.001]
  • [Cites] Bioconjug Chem. 2007 Jul-Aug;18(4):1118-22 [17552492.001]
  • [Cites] Pharm Res. 2007 Nov;24(11):2138-45 [17701324.001]
  • [Cites] Circulation. 2008 Mar 4;117(9):1153-60 [18268141.001]
  • [Cites] Brain. 2008 Apr;131(Pt 4):1123-33 [18234693.001]
  • [Cites] J Am Chem Soc. 2008 Apr 30;130(17):5626-7 [18393495.001]
  • [Cites] Bioconjug Chem. 2008 May;19(5):988-92 [18444670.001]
  • [Cites] Eur Radiol. 2003 Feb;13(2):231-43 [12598985.001]
  • [Cites] Magn Reson Med. 2004 Mar;51(3):480-6 [15004788.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Feb;84(3):891-5 [3027710.001]
  • [Cites] J Med Chem. 1987 Oct;30(10):1901-5 [2821259.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Dec 14;57(15):2106-29 [16305813.001]
  • [Cites] NMR Biomed. 2006 Feb;19(1):142-64 [16450332.001]
  • [Cites] J Biol Chem. 2008 Aug 8;283(32):22244-56 [18544534.001]
  • [Cites] J Med Chem. 2008 Oct 9;51(19):6014-20 [18839477.001]
  • [Cites] Neurochem Int. 2002 May;40(6):475-86 [11850104.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1388-93 [11888910.001]
  • [Cites] Org Lett. 2002 Apr 4;4(7):1075-8 [11922786.001]
  • [Cites] J Magn Reson Imaging. 2002 Oct;16(4):388-93 [12353254.001]
  • [Cites] J Neurooncol. 1992 May;13(1):35-42 [1319474.001]
  • [Cites] J Med Chem. 1997 Aug 1;40(16):2435-9 [9258348.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):831-42 [10029072.001]
  • [Cites] Bioconjug Chem. 2004 Nov-Dec;15(6):1403-7 [15546208.001]
  • [Cites] Bioconjug Chem. 2004 Nov-Dec;15(6):1488-95 [15546219.001]
  • [Cites] Drug Discov Today. 2005 Jan 1;10(1):35-43 [15676297.001]
  • [Cites] Bioconjug Chem. 2005 May-Jun;16(3):535-41 [15898719.001]
  • [Cites] J Neurovirol. 2005 Aug;11(4):346-55 [16162478.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Mar;26(3):435-41 [16373609.001]
  • (PMID = 19863077.001).
  • [ISSN] 1520-4812
  • [Journal-full-title] Bioconjugate chemistry
  • [ISO-abbreviation] Bioconjug. Chem.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / P20 GM072048; United States / NIGMS NIH HHS / GM / P20 GM072048-04; United States / NIGMS NIH HHS / GM / 5P20 GM072048-4
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dendrimers; 0 / Drug Carriers; 0 / Mitochondrial Proteins; 0 / Receptors, GABA; 0 / TSPO protein, human
  • [Other-IDs] NLM/ NIHMS156108; NLM/ PMC3038571
  •  go-up   go-down


Advertisement
4. Kim Y, Koo I, Jung BH, Chung BC, Lee D: Multivariate classification of urine metabolome profiles for breast cancer diagnosis. BMC Bioinformatics; 2010;11 Suppl 2:S4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multivariate classification of urine metabolome profiles for breast cancer diagnosis.
  • BACKGROUND: Diagnosis techniques using urine are non-invasive, inexpensive, and easy to perform in clinical settings.
  • The metabolites in urine, as the end products of cellular processes, are closely linked to phenotypes.
  • Since multiple genes or proteins would be involved in developments of complex diseases such as breast cancer, multiple compounds including metabolites would be related with the complex diseases, and multivariate methods would be needed to identify those multiple metabolite markers.
  • Moreover, because combinatorial effects among the markers can seriously affect disease developments and there also exist individual differences in genetic makeup or heterogeneity in cancer progressions, single marker is not enough to identify cancers.
  • Through this strategy, we identified five potential urinary biomarkers for breast cancer with high accuracy, among which the four biomarker candidates were not identifiable by only univariate methods.
  • We also proposed potential diagnosis rules to help in clinical decision making.
  • Besides, we showed that combinatorial effects among multiple biomarkers can enhance discriminative power for breast cancer.
  • CONCLUSIONS: In this study, we successfully showed that multivariate classifications are needed to precisely diagnose breast cancer.
  • After further validation with independent cohorts and experimental confirmation, these marker candidates will likely lead to clinically applicable assays for earlier diagnoses of breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plant Mol Biol. 2002 Jan;48(1-2):155-71 [11860207.001]
  • [Cites] Mol Cell Proteomics. 2009 Mar;8(3):558-70 [19008263.001]
  • [Cites] Nat Biotechnol. 2004 Nov;22(11):1459-66 [15529173.001]
  • [Cites] Toxicol Pathol. 2005;33(4):425-33 [16036859.001]
  • [Cites] BMC Bioinformatics. 2005;6:179 [16026613.001]
  • [Cites] Bioinformatics. 2006 Mar 1;22(5):634-6 [16403790.001]
  • [Cites] Lancet Oncol. 2006 Mar;7(3):230-40 [16510332.001]
  • [Cites] Lancet. 2006 Sep 16;368(9540):1012-21 [16980117.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10795-804 [17108116.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 23;104(4):1307-12 [17220270.001]
  • [Cites] Anal Biochem. 2007 Apr 15;363(2):185-95 [17316536.001]
  • [Cites] BMC Bioinformatics. 2007;8 Suppl 7:S3 [18047726.001]
  • [Cites] Am J Clin Nutr. 2007 Dec;86(6):1687-93 [18065587.001]
  • [Cites] J Proteome Res. 2008 Aug;7(8):3597-601 [18620448.001]
  • [Cites] Chem Res Toxicol. 2009 Jan;22(1):118-28 [19099400.001]
  • [Cites] Transplant Proc. 1995 Oct;27(5):2571-2 [7482830.001]
  • (PMID = 20406502.001).
  • [ISSN] 1471-2105
  • [Journal-full-title] BMC bioinformatics
  • [ISO-abbreviation] BMC Bioinformatics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC3165203
  •  go-up   go-down


5. Smith AM, Duan H, Mohs AM, Nie S: Bioconjugated quantum dots for in vivo molecular and cellular imaging. Adv Drug Deliv Rev; 2008 Aug 17;60(11):1226-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bioconjugated quantum dots for in vivo molecular and cellular imaging.
  • Here we discuss the synthesis and development of state-of-the-art QD probes and their use for molecular and cellular imaging.

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Biotechnol. 2005 Feb;16(1):63-72 [15722017.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):161-71 [15738981.001]
  • [Cites] Nano Lett. 2005 Feb;5(2):331-8 [15794621.001]
  • [Cites] J Thorac Cardiovasc Surg. 2005 Apr;129(4):844-50 [15821653.001]
  • [Cites] Chem Rev. 2005 Apr;105(4):1547-62 [15826019.001]
  • [Cites] J Mol Med (Berl). 2005 May;83(5):377-85 [15688234.001]
  • [Cites] Chest. 2005 May;127(5):1799-804 [15888861.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7583-8 [15897449.001]
  • [Cites] Nat Med. 2005 Jun;11(6):678-82 [15880117.001]
  • [Cites] Nat Rev Drug Discov. 2005 Jul;4(7):581-93 [16052241.001]
  • [Cites] J Gene Med. 2005 Aug;7(8):992-1009 [15920783.001]
  • [Cites] Nat Methods. 2004 Oct;1(1):73-8 [16138413.001]
  • [Cites] Nat Biotechnol. 2005 Nov;23(11):1418-23 [16244656.001]
  • [Cites] Nano Lett. 2007 Apr;7(4):970-7 [17388641.001]
  • [Cites] Breast Cancer Res Treat. 2007 May;103(1):23-8 [17028977.001]
  • [Cites] Angew Chem Int Ed Engl. 2007;46(14):2448-52 [17318931.001]
  • [Cites] Nano Lett. 2007 Jul;7(7):1839-45 [17536868.001]
  • [Cites] Annu Rev Biomed Eng. 2007;9:257-88 [17439359.001]
  • [Cites] Stem Cells. 2007 Aug;25(8):2128-38 [17495112.001]
  • [Cites] Nano Lett. 2007 Aug;7(8):2513-20 [17638392.001]
  • [Cites] Nanomedicine (Lond). 2006 Aug;1(2):209-17 [17716110.001]
  • [Cites] Nanomedicine (Lond). 2007 Feb;2(1):71-8 [17716192.001]
  • [Cites] Nanomedicine (Lond). 2007 Apr;2(2):153-67 [17716118.001]
  • [Cites] Int J Nanomedicine. 2006;1(4):473-81 [17722280.001]
  • [Cites] Environ Health Perspect. 2007 Sep;115(9):1339-43 [17805425.001]
  • [Cites] Small. 2007 Sep;3(9):1560-5 [17705315.001]
  • [Cites] Nano Lett. 2007 Sep;7(9):2865-70 [17685663.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 11;104(37):14753-8 [17785425.001]
  • [Cites] Bioconjug Chem. 2007 Sep-Oct;18(5):1391-6 [17630789.001]
  • [Cites] Bioconjug Chem. 2007 Sep-Oct;18(5):1424-33 [17760416.001]
  • [Cites] Nat Biotechnol. 2007 Oct;25(10):1165-70 [17891134.001]
  • [Cites] J Control Release. 2001 Jul 6;74(1-3):7-25 [11489479.001]
  • [Cites] Annu Rev Biomed Eng. 1999;1:241-63 [11701489.001]
  • [Cites] Adv Drug Deliv Rev. 2002 Jun 17;54(4):459-76 [12052709.001]
  • [Cites] Science. 2002 Jun 28;296(5577):2404-7 [12089446.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1536-40 [12202825.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):12617-21 [12235356.001]
  • [Cites] Science. 2002 Nov 29;298(5599):1759-62 [12459582.001]
  • [Cites] Nat Biotechnol. 2003 Jan;21(1):41-6 [12459735.001]
  • [Cites] Nat Biotechnol. 2003 Jan;21(1):47-51 [12459736.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Mar 14;302(3):496-501 [12615061.001]
  • [Cites] Nature. 2003 Mar 6;422(6927):37-44 [12621426.001]
  • [Cites] Science. 2003 May 30;300(5624):1434-6 [12775841.001]
  • [Cites] J Am Chem Soc. 2003 Jun 11;125(23):7100-6 [12783563.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2491-9 [12815134.001]
  • [Cites] Mol Imaging. 2003 Jan;2(1):50-64 [12926237.001]
  • [Cites] J Control Release. 2003 Aug 28;91(1-2):103-13 [12932642.001]
  • [Cites] Nat Mater. 2003 Sep;2(9):630-8 [12942071.001]
  • [Cites] J Am Chem Soc. 2003 Sep 24;125(38):11466-7 [13129327.001]
  • [Cites] Science. 2003 Oct 17;302(5644):442-5 [14564008.001]
  • [Cites] Curr Opin Chem Biol. 2003 Oct;7(5):626-34 [14580568.001]
  • [Cites] Nat Biotechnol. 2004 Jan;22(1):93-7 [14661026.001]
  • [Cites] Nat Biotechnol. 2004 Jan;22(1):47-52 [14704706.001]
  • [Cites] Pharmacol Rev. 2001 Jun;53(2):283-318 [11356986.001]
  • [Cites] Nat Biotechnol. 2004 Aug;22(8):969-76 [15258594.001]
  • [Cites] Nat Med. 2004 Sep;10(9):993-8 [15334072.001]
  • [Cites] Analyst. 2004 Aug;129(8):672-7 [15344262.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):343-9 [15372041.001]
  • [Cites] Cancer Res. 1986 Dec;46(12 Pt 1):6387-92 [2946403.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7297-301 [7638184.001]
  • [Cites] Toxicol Appl Pharmacol. 1996 Feb;136(2):260-8 [8619234.001]
  • [Cites] Int Arch Occup Environ Health. 1997;69(6):379-85 [9215923.001]
  • [Cites] Science. 1998 Sep 25;281(5385):2013-6 [9748157.001]
  • [Cites] Science. 1998 Sep 25;281(5385):2016-8 [9748158.001]
  • [Cites] J Cell Biol. 1999 Oct 4;147(1):135-50 [10508861.001]
  • [Cites] Circ Res. 2004 Dec 10;95(12):1154-66 [15591237.001]
  • [Cites] Chem Commun (Camb). 2005 Jan 7;(1):121-3 [15614393.001]
  • [Cites] Ann Thorac Surg. 2005 Jan;79(1):269-77; discussion 269-77 [15620956.001]
  • [Cites] J Am Chem Soc. 2005 Jan 12;127(1):34-5 [15631435.001]
  • [Cites] Annu Rev Med. 2005;56:401-23 [15660519.001]
  • [Cites] Science. 2005 Jan 28;307(5709):538-44 [15681376.001]
  • [Cites] J Am Chem Soc. 2005 Feb 16;127(6):1656-7 [15700997.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Feb 28;57(4):529-45 [15722162.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Feb 28;57(4):547-58 [15722163.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Feb 28;57(4):559-77 [15722164.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Feb 28;57(4):579-96 [15722165.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Feb 28;57(4):637-51 [15722168.001]
  • [Cites] J Am Chem Soc. 2006 Oct 18;128(41):13396-401 [17031951.001]
  • [Cites] Nat Chem Biol. 2006 Dec;2(12):711-9 [17108989.001]
  • [Cites] Methods Enzymol. 2006;414:211-28 [17110194.001]
  • [Cites] Toxicol Lett. 2006 Dec 15;167(3):191-200 [17049762.001]
  • [Cites] Pharm Res. 2007 Jan;24(1):1-16 [17109211.001]
  • [Cites] Nano Lett. 2007 Oct;7(10):3065-70 [17854227.001]
  • [Cites] J Nucl Med. 2007 Nov;48(11):1862-70 [17942800.001]
  • [Cites] Small. 2007 Nov;3(11):1840-54 [17943716.001]
  • [Cites] Nano Lett. 2007 Nov;7(11):3452-61 [17949046.001]
  • [Cites] J Am Chem Soc. 2007 Nov 28;129(47):14759-66 [17983227.001]
  • [Cites] J Am Chem Soc. 2008 Jul 16;130(28):9006-12 [18570415.001]
  • [Cites] Nat Nanotechnol. 2007 Jan;2(1):47-52 [18654207.001]
  • [Cites] Nat Biotechnol. 2004 Feb;22(2):198-203 [14704683.001]
  • [Cites] Nat Protoc. 2007;2(5):1152-65 [17546006.001]
  • [Cites] Nano Lett. 2007 Jun;7(6):1711-6 [17530812.001]
  • [Cites] Toxicol Sci. 2007 Jul;98(1):249-57 [17404394.001]
  • [Cites] FEBS Lett. 2007 Jun 26;581(16):2905-13 [17543952.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 30;314(1):46-53 [14715244.001]
  • [Cites] Bioconjug Chem. 2004 Jan-Feb;15(1):79-86 [14733586.001]
  • [Cites] Anal Biochem. 2004 Apr 15;327(2):200-8 [15051536.001]
  • [Cites] Nat Mater. 2005 Nov;4(11):826-31 [16379073.001]
  • [Cites] J Phys Chem B. 2005 Dec 29;109(51):24220-4 [16375416.001]
  • [Cites] Nano Lett. 2006 Jan;6(1):1-6 [16402777.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Mar;290(3):C728-32 [16236822.001]
  • [Cites] J Am Chem Soc. 2006 Mar 1;128(8):2526-7 [16492023.001]
  • [Cites] Expert Rev Mol Diagn. 2006 Mar;6(2):231-44 [16512782.001]
  • [Cites] Nat Biotechnol. 2006 Mar;24(3):339-43 [16501578.001]
  • [Cites] Nano Lett. 2006 Apr;6(4):669-76 [16608262.001]
  • [Cites] Nano Lett. 2006 Apr;6(4):800-8 [16608287.001]
  • [Cites] Crit Rev Toxicol. 2006 Mar;36(3):189-217 [16686422.001]
  • [Cites] Pharm Res. 2006 Jul;23(7):1417-50 [16779701.001]
  • [Cites] Nano Lett. 2006 Jul;6(7):1491-5 [16834436.001]
  • [Cites] Bioconjug Chem. 2006 Jul-Aug;17(4):865-8 [16848390.001]
  • [Cites] Bioconjug Chem. 2006 Jul-Aug;17(4):920-7 [16848398.001]
  • [Cites] Lancet Oncol. 2006 Aug;7(8):657-67 [16887483.001]
  • [Cites] Anal Chem. 2006 Aug 15;78(16):5925-32 [16906742.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1181-91 [16778828.001]
  • [Cites] Nat Rev Cancer. 2006 Sep;6(9):688-701 [16900224.001]
  • [Cites] Nano Lett. 2006 Sep;6(9):1863-9 [16967992.001]
  • [Cites] Nano Lett. 2006 Sep;6(9):2049-59 [16968024.001]
  • [Cites] Phys Chem Chem Phys. 2006 Sep 7;8(33):3895-903 [19817050.001]
  • [Cites] Nat Nanotechnol. 2007 Aug;2(8):469-78 [18654343.001]
  • [Cites] J Control Release. 2000 Mar 1;65(1-2):271-84 [10699287.001]
  • [Cites] Nat Biotechnol. 2001 Apr;19(4):316-7 [11283581.001]
  • [Cites] Chem Biol. 2005 Nov;12(11):1227-34 [16298302.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2006 Jan;290(1):R114-23 [16223849.001]
  • [Cites] Nucleic Acids Res. 2005;33(22):e190 [16352864.001]
  • [Cites] IEEE Trans Nanobioscience. 2006 Dec;5(4):263-7 [17181025.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jan;8(1):23-36 [17183358.001]
  • [Cites] Small. 2005 Jul;1(7):706-9 [17193510.001]
  • [Cites] Small. 2006 Dec;2(12):1412-7 [17192996.001]
  • [Cites] Biomaterials. 2007 Mar;28(8):1565-71 [17161865.001]
  • [Cites] Biophys J. 2007 Feb 15;92(4):1399-408 [17114225.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1138-44 [17283148.001]
  • [Cites] Langmuir. 2007 Feb 13;23(4):1974-80 [17279683.001]
  • [Cites] Nano Lett. 2007 Feb;7(2):312-7 [17297994.001]
  • [Cites] Environ Res. 2007 Mar;103(3):432-40 [17109840.001]
  • [Cites] Nat Rev Genet. 2007 Mar;8(3):173-84 [17304245.001]
  • [Cites] Microvasc Res. 2007 Mar;73(2):75-83 [17070560.001]
  • [Cites] Nat Med. 2007 Mar;13(3):372-7 [17322898.001]
  • [Cites] J Biomed Opt. 2007 Jan-Feb;12(1):014008 [17343483.001]
  • [Cites] J Am Chem Soc. 2007 Mar 21;129(11):3333-8 [17319667.001]
  • [Cites] Bioconjug Chem. 2007 Mar-Apr;18(2):389-96 [17263568.001]
  • [Cites] J Am Chem Soc. 2007 Apr 4;129(13):3848-56 [17358058.001]
  • (PMID = 18495291.001).
  • [ISSN] 0169-409X
  • [Journal-full-title] Advanced drug delivery reviews
  • [ISO-abbreviation] Adv. Drug Deliv. Rev.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / U01 HL080711; United States / NCI NIH HHS / CA / U54 CA119338-03; United States / NCI NIH HHS / CA / R01 CA108468; United States / NHLBI NIH HHS / HL / U01 HL080711-03; United States / NCI NIH HHS / CA / CA108468-04; United States / NIGMS NIH HHS / GM / GM072069-03; United States / NCI NIH HHS / CA / R01 CA108468-04; United States / NIGMS NIH HHS / GM / P20 GM072069-03; United States / NCI NIH HHS / CA / U54CA119338; United States / NEI NIH HHS / EY / PN2 EY018244-02; United States / NIGMS NIH HHS / GM / P20 GM072069; United States / NHLBI NIH HHS / HL / HL080711-03; United States / NHLBI NIH HHS / HL / U01HL080711; United States / NCI NIH HHS / CA / U54 CA119338; United States / NEI NIH HHS / EY / EY018244-02; United States / NCI NIH HHS / CA / CA119338-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biocompatible Materials
  • [Number-of-references] 174
  • [Other-IDs] NLM/ NIHMS62165; NLM/ PMC2649798
  •  go-up   go-down


6. Bratasz A, Selvendiran K, Wasowicz T, Bobko A, Khramtsov VV, Ignarro LJ, Kuppusamy P: NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols. J Transl Med; 2008 Feb 26;6:9
Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols.
  • The high mortality rate is associated with lack of early diagnosis and development of drug resistance.
  • The antitumor efficacy and mechanism of NCX-4040, a nitric oxide-releasing aspirin derivative, against ovarian cancer is studied.
  • CONCLUSION: The results suggested that NCX-4040 could resensitize drug-resistant ovarian cancer cells to cisplatin possibly by depletion of cellular thiols.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Oct 1;89(7):1440-7 [11013356.001]
  • [Cites] Mutat Res. 2001 Jul 1;478(1-2):23-43 [11406167.001]
  • [Cites] Gynecol Oncol. 2001 Jul;82(1):172-6 [11426981.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2001;67:93-130 [11525387.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):307-12 [11782393.001]
  • [Cites] Gynecol Oncol. 2002 May;85(2):298-304 [11972391.001]
  • [Cites] Lancet Oncol. 2002 Sep;3(9):529-36 [12217790.001]
  • [Cites] Lancet Oncol. 2002 Sep;3(9):537-45 [12217791.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):312-8 [12543781.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):502-16 [12835670.001]
  • [Cites] Br J Cancer. 2003 Dec;89 Suppl 3:S16-22 [14661042.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):97-105 [14964307.001]
  • [Cites] Magn Reson Med. 2004 Sep;52(3):650-7 [15334586.001]
  • [Cites] Chem Biol Interact. 1987 Mar;61(3):241-8 [3568194.001]
  • [Cites] Cancer Res. 1988 Jan 1;48(1):117-21 [3334986.001]
  • [Cites] Biochem Pharmacol. 1988 Aug 15;37(16):3199-201 [3401252.001]
  • [Cites] Anal Biochem. 1989 Oct;182(1):58-63 [2557778.001]
  • [Cites] Cancer Commun. 1990;2(2):93-100 [2372473.001]
  • [Cites] Trends Biochem Sci. 1992 Nov;17(11):463-8 [1455517.001]
  • [Cites] Cancer. 1993 Jan 15;71(2 Suppl):644-9 [8420689.001]
  • [Cites] Cancer Res. 1993 May 1;53(9):2066-70 [8097674.001]
  • [Cites] Cell. 1993 Oct 22;75(2):241-51 [7503812.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Sep 30;195(3):1191-8 [8216248.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3680-4 [8170969.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] Eur J Biochem. 1995 Dec 1;234(2):472-8 [8536691.001]
  • [Cites] Magn Reson Med. 1996 Aug;36(2):212-8 [8843374.001]
  • [Cites] J Biochem Biophys Methods. 1997 Sep 25;35(2):115-28 [9350517.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1562-8 [9537265.001]
  • [Cites] Chem Biol Interact. 1998 Apr 24;111-112:187-98 [9679554.001]
  • [Cites] Clin Cancer Res. 1996 Nov;2(11):1859-65 [9816141.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Mar;312(3):989-97 [15528452.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Mar;312(3):978-88 [15528453.001]
  • [Cites] Mol Cancer Ther. 2005 Apr;4(4):650-8 [15827339.001]
  • [Cites] Cancer Cell. 2005 Jun;7(6):575-89 [15950906.001]
  • [Cites] Apoptosis. 2005 Oct;10(5):1095-103 [16151642.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3914-9 [16497833.001]
  • [Cites] Mol Cancer Ther. 2006 Apr;5(4):919-26 [16648562.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4826-34 [16651438.001]
  • [Cites] Apoptosis. 2006 Aug;11(8):1321-30 [16699954.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5055-63 [16951221.001]
  • [Cites] Biochem Pharmacol. 2006 Oct 16;72(8):941-8 [16934227.001]
  • [Cites] Stem Cells. 2007 Jan;25(1):88-97 [16960136.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):112-21 [17237271.001]
  • [Cites] Cancer Treat Rev. 2007 Feb;33(1):9-23 [17084534.001]
  • [Cites] Blood. 2007 Mar 15;109(6):2293-302 [17164350.001]
  • [Cites] Hear Res. 2007 Apr;226(1-2):157-67 [17113254.001]
  • [Cites] J Med Chem. 2007 May 17;50(10):2424-31 [17441704.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jul 13;358(4):1096-101 [17512900.001]
  • [Cites] Nat Rev Cancer. 2007 Aug;7(8):573-84 [17625587.001]
  • [Cites] Am J Med Sci. 2007 Aug;334(2):115-24 [17700201.001]
  • [Cites] Chem Res Toxicol. 2007 Dec;20(12):1903-12 [17975886.001]
  • [Cites] J Transl Med. 2007;5:52 [17971198.001]
  • [Cites] Cell Cycle. 2008 Jan 1;7(1):81-8 [18196976.001]
  • [Cites] Trends Pharmacol Sci. 1999 Aug;20(8):319-23 [10431210.001]
  • [Cites] J Inorg Biochem. 1999 Oct;77(1-2):105-10 [10626361.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4097-104 [10632346.001]
  • (PMID = 18302761.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / K01 EB003519; United States / NCI NIH HHS / CA / R01 CA102264; United States / NCI NIH HHS / CA / CA102264; United States / NIBIB NIH HHS / EB / K01 EB03519
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / NCX 4040; 0 / Nitro Compounds; 0 / Sulfhydryl Compounds; 175033-36-0 / nitroaspirin; Q20Q21Q62J / Cisplatin; R16CO5Y76E / Aspirin
  • [Other-IDs] NLM/ PMC2267444
  •  go-up   go-down


7. Qian W, Zhukov T, Song D, Tockman MS: Computerized analysis of cellular features and biomarkers for cytologic diagnosis of early lung cancer. Anal Quant Cytol Histol; 2007 Apr;29(2):103-11
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computerized analysis of cellular features and biomarkers for cytologic diagnosis of early lung cancer.
  • OBJECTIVE: To present a set of novel computerized analysis algorithms to construct a computer-aided cytologic diagnosis (CACD) system to differentiate lung cancer biomarkers and identify cancer cells in the tissue-based specimen images.
  • STUDY DESIGN: Molecular methods, including application of cancer-specific markers, may prove to be complementary to cytology diagnosis, especially when they are combined with CACD system for biomarker assessment.
  • We trained a novel CACD system to recognize expression of the cancer biomarkers histone H2AX in lung cancer cells and then tested the accuracy of this system to distinguish resected lung cancer from preneoplastic and normal tissues.
  • The major characteristics of CACD algorithms is to adapt detection parameters according to cellular image contents.
  • CONCLUSION: The presented algorithms and CACD system for cellular feature enhancement, segmentation and classification are very important in distinguishing benign and malignant lesions.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484274.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


8. Wlodkowic D, Cooper JM: Microfabricated analytical systems for integrated cancer cytomics. Anal Bioanal Chem; 2010 Sep;398(1):193-209
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microfabricated analytical systems for integrated cancer cytomics.
  • Tracking and understanding cell-to-cell variability is fundamental for systems biology, cytomics and computational modelling that aids e.g. anti-cancer drug discovery.
  • Limitations of conventional cell-based techniques, such as flow cytometry and single cell imaging, however, make the high-throughput dynamic analysis on cellular and subcellular processes tedious and exceedingly expensive.
  • In addition, by confining the dimensions of the microfluidic structure, it is possible to facilitate the precise sequential delivery of drugs and/or functional probes into the cellular systems.
  • [MeSH-major] Microarray Analysis / methods. Microfluidic Analytical Techniques / methods. Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20419489.001).
  • [ISSN] 1618-2650
  • [Journal-full-title] Analytical and bioanalytical chemistry
  • [ISO-abbreviation] Anal Bioanal Chem
  • [Language] eng
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  •  go-up   go-down


9. He H, Xie C, Ren J: Nonbleaching fluorescence of gold nanoparticles and its applications in cancer cell imaging. Anal Chem; 2008 Aug 1;80(15):5951-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonbleaching fluorescence of gold nanoparticles and its applications in cancer cell imaging.
  • On the basis of this excellent antiphotobleaching of GNPs and easy photobleaching of cellular autofluorescence, we developed a new method for imaging of cells using GNPs as fluorescent probes.
  • The principle of this method is that after cells stained with GNPs or GNPs bioconjugates are illuminated by strong light, the cellular autofluorescence are photobleached and the fluorescence of GNPs on cell membrane or inside cells can be collected for cell imaging.
  • On the basis of this principle, we imaged living HeLa cells using GNPs as fluorescent probes and obtained good cell images by photobleaching of cellular autofluorescence.
  • Furthermore, anti-EGFR/GNPs were successfully used as targeted probes for fluorescence imaging of cancer cells.
  • Our cellular imaging method described has potential applications in cancer diagnostics, studies, and immunoassays.
  • [MeSH-major] Diagnostic Imaging / methods. Fluorescence. Metal Nanoparticles. Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18590338.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7440-57-5 / Gold
  •  go-up   go-down


10. Huang YF, Chang HT, Tan W: Cancer cell targeting using multiple aptamers conjugated on nanorods. Anal Chem; 2008 Feb 1;80(3):567-72
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer cell targeting using multiple aptamers conjugated on nanorods.
  • Molecular recognition toward specific cells is a key issue for effective disease, such as cancer, diagnosis and therapy.
  • Although many molecular probes such as aptamers and antibodies can recognize the unique molecular signatures of cancer cells, some of these probes only have relatively weak binding affinities.
  • Here, we use Au-Ag nanorods (NRs) as a nanoplatform for multivalent binding by multiple aptamers on the rod to increase both the signal and binding strengths of these aptamers in cancer cell recognition.
  • The molecular assembly of aptamers on the NR surfaces also significantly improves the binding affinity with cancer cells through simultaneous multivalent interactions with the cell membrane receptors.
  • Therefore, the molecular assembly of aptamers clearly shows potential applications for the elucidation of cells with low density of binding sites, or with relatively weak binding probes, and can thus greatly improve our ability to perform cellular imaging and targeting.
  • This is an excellent example of using nanomaterials to develop advanced molecular binders with greatly improved properties for cellular studies.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SILVER, ELEMENTAL .
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166023.001).
  • [ISSN] 0003-2700
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aptamers, Nucleotide; 0 / Fluorescent Dyes; 3M4G523W1G / Silver; 7440-57-5 / Gold
  •  go-up   go-down


11. Ozekes S, Osman O, Ucan ON: Nodule detection in a lung region that's segmented with using genetic cellular neural networks and 3D template matching with fuzzy rule based thresholding. Korean J Radiol; 2008 Jan-Feb;9(1):1-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodule detection in a lung region that's segmented with using genetic cellular neural networks and 3D template matching with fuzzy rule based thresholding.
  • First, to reduce the number of region of interests (ROIs) and the computation time, the lung regions of the CTs were segmented using Genetic Cellular Neural Networks (G-CNN).
  • RESULTS: The computer aided diagnosis (CAD) system achieved 100% sensitivity with 13.375 FPs per case when the nodule thickness was greater than or equal to 5.625 mm.
  • [MeSH-major] Diagnosis, Computer-Assisted. Lung Neoplasms / radiography. Neural Networks (Computer). Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Jun;20(6):490-8 [11437109.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Dec;20(12):1242-50 [11811824.001]
  • [Cites] Med Image Anal. 2003 Sep;7(3):265-81 [12946468.001]
  • [Cites] Acad Radiol. 2003 Nov;10(11):1224-36 [14626297.001]
  • [Cites] AJR Am J Roentgenol. 2004 Feb;182(2):505-10 [14736690.001]
  • [Cites] Radiology. 2004 Sep;232(3):739-48 [15333795.001]
  • [Cites] Acad Radiol. 2004 Sep;11(9):1011-21 [15350582.001]
  • [Cites] Med Phys. 1980 Jul-Aug;7(4):283-90 [6993911.001]
  • [Cites] Invest Radiol. 1994 Apr;29(4):459-65 [8034453.001]
  • [Cites] Med Phys. 1997 Sep;24(9):1395-403 [9304567.001]
  • [Cites] IEEE Trans Med Imaging. 1997 Dec;16(6):828-39 [9533583.001]
  • [Cites] IEEE Trans Med Imaging. 1998 Dec;17(6):872-80 [10048844.001]
  • [Cites] Radiographics. 1999 Sep-Oct;19(5):1303-11 [10489181.001]
  • [Cites] Korean J Radiol. 2005 Oct-Dec;6(4):221-8 [16374079.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Jul;20(7):595-604 [11465466.001]
  • (PMID = 18253070.001).
  • [ISSN] 1229-6929
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2627180
  •  go-up   go-down


12. Kuk C, Kulasingam V, Gunawardana CG, Smith CR, Batruch I, Diamandis EP: Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers. Mol Cell Proteomics; 2009 Apr;8(4):661-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.
  • Current ovarian cancer biomarkers are inadequate because of their relatively low diagnostic sensitivity and specificity.
  • There is a need to discover and validate novel ovarian cancer biomarkers that are suitable for early diagnosis, monitoring, and prediction of therapeutic response.
  • We performed an in-depth proteomics analysis of ovarian cancer ascites fluid.
  • Filtering criteria were used to select potential ovarian cancer biomarker candidates.
  • Among these were 25 proteins previously identified as ovarian cancer biomarkers.
  • Our proteomics approach for discovering novel ovarian cancer biomarkers appears to be highly efficient because it was able to identify 25 known biomarkers and 52 new candidate biomarkers that warrant further validation.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Proteome Res. 2008 Jan;7(1):339-51 [18076136.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):402-8 [18061248.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1065-72 [18258665.001]
  • [Cites] Cell Biochem Biophys. 2007;49(3):182-95 [17952643.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1B):569-72 [10769727.001]
  • [Cites] Oncologist. 2000;5 Suppl 1:45-50 [10804091.001]
  • [Cites] Clin Biochem. 2000 Jul;33(5):369-75 [11018688.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3903-6 [11268474.001]
  • [Cites] Oncogene. 2001 Nov 1;20(50):7293-300 [11704858.001]
  • [Cites] Ann Oncol. 2001 Oct;12(10):1353-7 [11762804.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1917-24 [12414537.001]
  • [Cites] Mol Cell Proteomics. 2002 Nov;1(11):845-67 [12488461.001]
  • [Cites] Cancer Res. 2003 Feb 15;63(4):807-11 [12591730.001]
  • [Cites] Tumour Biol. 2002 Sep-Oct;23(5):303-14 [12595747.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1035-43 [12637468.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2771-4 [12782581.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3695-700 [12839961.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Oct;7(4):433-40 [12882527.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] Clin Chem. 2004 Apr;50(4):709-16 [14764643.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):311-26 [14718574.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3291-300 [15161682.001]
  • [Cites] J Am Coll Surg. 2004 Jun;198(6):999-1011 [15194082.001]
  • [Cites] Gan To Kagaku Ryoho. 2004 Jul;31(7):1003-7 [15272576.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3b):1981-5 [15274388.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5882-90 [15313933.001]
  • [Cites] Neoplasma. 1979;26(6):737-43 [44348.001]
  • [Cites] Tokai J Exp Clin Med. 1982 May;7(3):325-9 [6896935.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1985 Jun;19(6):354-6 [4018373.001]
  • [Cites] Hum Reprod. 1989 Jan;4(1):1-12 [2651469.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] PLoS One. 2008;3(6):e2425 [18560578.001]
  • [Cites] J Transl Med. 2008;6:41 [18652693.001]
  • [Cites] Cancer Treat Rev. 1995 May;21(3):215-45 [7656266.001]
  • [Cites] Anticancer Res. 1995 Nov-Dec;15(6B):2799-804 [8669868.001]
  • [Cites] Biochem Pharmacol. 1997 Sep 1;54(5):541-4 [9337069.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1843-9 [9581823.001]
  • [Cites] J Biomol Tech. 2004 Dec;15(4):238-48 [15585820.001]
  • [Cites] J Proteome Res. 2005 May-Jun;4(3):837-45 [15952730.001]
  • [Cites] Anticancer Res. 2005 Jul-Aug;25(4):2885-9 [16080542.001]
  • [Cites] Proteomics. 2005 Aug;5(13):3292-303 [16052620.001]
  • [Cites] Proteomics. 2005 Aug;5(13):3304-13 [16052628.001]
  • [Cites] Proteomics. 2005 Oct;5(15):4034-45 [16152657.001]
  • [Cites] Gynecol Oncol. 2005 Nov;99(2):267-77 [16061277.001]
  • [Cites] Diagn Cytopathol. 2005 Nov;33(5):316-9 [16240401.001]
  • [Cites] BMC Cancer. 2005;5:133 [16225703.001]
  • [Cites] Proteomics. 2005 Nov;5(17):4625-36 [16220531.001]
  • [Cites] Proteomics. 2005 Nov;5(17):4589-96 [16237736.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):656-63 [16112717.001]
  • [Cites] Obstet Gynecol. 2006 Jun;107(6):1399-410 [16738170.001]
  • [Cites] Genome Biol. 2006;7(5):R40 [16709260.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):458-66 [17255266.001]
  • [Cites] Gynecol Oncol. 2007 Feb;104(2):435-42 [17023034.001]
  • [Cites] Genome Biol. 2006;7(8):R72 [16901338.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2426-34 [17294443.001]
  • [Cites] J Proteome Res. 2007 May;6(5):1728-34 [17397210.001]
  • [Cites] J Proteome Res. 2007 Jul;6(7):2859-65 [17567164.001]
  • [Cites] Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4422-8 [17671125.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4C):2753-8 [17695443.001]
  • [Cites] Mol Cell Proteomics. 2007 Aug;6(8):1406-15 [17495049.001]
  • [Cites] J Cell Biochem. 1990 May;43(1):43-57 [2189881.001]
  • [Cites] J Clin Invest. 1993 Nov;92(5):2160-7 [8227331.001]
  • [Cites] Tumour Biol. 1993;14(6):360-8 [8265982.001]
  • [Cites] Mol Cell Proteomics. 2007 Nov;6(11):1997-2011 [17656355.001]
  • [Cites] J Proteome Res. 2007 Dec;6(12):4549-55 [17970587.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7370-9 [18094419.001]
  • (PMID = 19047685.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Proteome; EC 3.4.21.- / KLK6 protein, human; EC 3.4.21.- / Kallikreins
  • [Other-IDs] NLM/ PMC2667349
  •  go-up   go-down


13. Jiang S, Gnanasammandhan MK, Zhang Y: Optical imaging-guided cancer therapy with fluorescent nanoparticles. J R Soc Interface; 2010 Jan 6;7(42):3-18
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optical imaging-guided cancer therapy with fluorescent nanoparticles.
  • The diagnosis and treatment of cancer have been greatly improved with the recent developments in nanotechnology.
  • One of the promising nanoscale tools for cancer diagnosis is fluorescent nanoparticles (NPs), such as organic dye-doped NPs, quantum dots and upconversion NPs that enable highly sensitive optical imaging of cancer at cellular and animal level.
  • Furthermore, the emerging development of novel multi-functional NPs, which can be conjugated with several functional molecules simultaneously including targeting moieties, therapeutic agents and imaging probes, provides new potentials for clinical therapies and diagnostics and undoubtedly will play a critical role in cancer therapy.
  • In this article, we review the types and characteristics of fluorescent NPs, in vitro and in vivo imaging of cancer using fluorescent NPs and multi-functional NPs for imaging-guided cancer therapy.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2004 Jan 30;558(1-3):63-8 [14759517.001]
  • [Cites] Nat Med. 2004 Mar;10(3):255-61 [14981512.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1821-7 [14996745.001]
  • [Cites] Science. 2004 Mar 19;303(5665):1818-22 [15031496.001]
  • [Cites] Gene Ther. 2004 Aug;11(15):1175-87 [15141158.001]
  • [Cites] Nat Biotechnol. 2004 Aug;22(8):969-76 [15258594.001]
  • [Cites] Adv Drug Deliv Rev. 2004 Sep 22;56(11):1649-59 [15350294.001]
  • [Cites] Anal Chem. 2004 Sep 15;76(18):5302-12 [15362886.001]
  • [Cites] Microbiol Immunol. 2004;48(9):669-75 [15383704.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] J Natl Cancer Inst. 1990 Jan 3;82(1):4-6 [1688381.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Jun 15;57(8):1087-108 [15908041.001]
  • [Cites] Nat Biotechnol. 2005 Jun;23(6):709-17 [15908939.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6910-8 [16061675.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12177-82 [16091473.001]
  • [Cites] Nat Methods. 2004 Oct;1(1):73-8 [16138413.001]
  • [Cites] Angew Chem Int Ed Engl. 2005 Sep 19;44(37):6054-7 [16118828.001]
  • [Cites] Technol Cancer Res Treat. 2005 Dec;4(6):593-602 [16292879.001]
  • [Cites] FASEB J. 2005 Dec;19(14):2014-6 [16230334.001]
  • [Cites] J Am Chem Soc. 2007 Oct 24;129(42):12739-45 [17892287.001]
  • [Cites] J Nucl Med. 2007 Nov;48(11):1862-70 [17942800.001]
  • [Cites] Biomacromolecules. 2007 Nov;8(11):3422-8 [17958440.001]
  • [Cites] Mol Cancer Ther. 2007 Nov;6(11):3019-27 [18025286.001]
  • [Cites] J Am Chem Soc. 2007 Nov 28;129(47):14759-66 [17983227.001]
  • [Cites] Nanomedicine. 2007 Dec;3(4):266-72 [17988954.001]
  • [Cites] Biomaterials. 2008 Mar;29(7):937-43 [18061257.001]
  • [Cites] Chembiochem. 2008 Jan 4;9(1):53-7 [17999392.001]
  • [Cites] Bioconjug Chem. 2008 Jan;19(1):109-17 [18163535.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1310-6 [18316549.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):97-110 [18227410.001]
  • [Cites] J Control Release. 2008 Apr 7;127(1):41-9 [18234388.001]
  • [Cites] Nanomedicine (Lond). 2008 Feb;3(1):73-82 [18393642.001]
  • [Cites] Bioconjug Chem. 2008 Jun;19(6):1170-8 [18491928.001]
  • [Cites] J Am Chem Soc. 2008 Jul 16;130(28):9006-12 [18570415.001]
  • [Cites] Trends Biotechnol. 2008 Aug;26(8):425-33 [18514941.001]
  • [Cites] Anal Biochem. 2001 Jan 15;288(2):176-87 [11152588.001]
  • [Cites] J Biol Chem. 1992 Jun 5;267(16):10931-4 [1375931.001]
  • [Cites] Abdom Imaging. 1995 Jan-Feb;20(1):2-8 [7894290.001]
  • [Cites] Microvasc Res. 1996 May;51(3):327-46 [8992232.001]
  • [Cites] Br J Cancer. 1996 Dec;74(11):1749-56 [8956788.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):806-11 [9486653.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4607-12 [9539785.001]
  • [Cites] Anal Biochem. 1999 Feb 1;267(1):30-6 [9918652.001]
  • [Cites] Semin Cancer Biol. 1999 Apr;9(2):125-38 [10202134.001]
  • [Cites] Nature. 2004 Nov 11;432(7014):173-8 [15538359.001]
  • [Cites] Int J Pharm. 2005 Jan 20;288(2):361-8 [15620876.001]
  • [Cites] J Drug Target. 2004;12(7):461-71 [15621671.001]
  • [Cites] J Drug Target. 2004;12(8):477-89 [15621674.001]
  • [Cites] Gene Ther. 2005 Mar;12(5):461-6 [15616603.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):161-71 [15738981.001]
  • [Cites] J Gene Med. 2005 Feb;7(2):198-207 [15515135.001]
  • [Cites] Bioconjug Chem. 2008 Dec;19(12):2321-31 [18937508.001]
  • [Cites] Nano Lett. 2005 Jan;5(1):37-43 [15792409.001]
  • [Cites] J Am Chem Soc. 2005 Apr 13;127(14):4990-1 [15810812.001]
  • [Cites] Chem Commun (Camb). 2006 Jun 28;(24):2557-9 [16779476.001]
  • [Cites] Anal Chem. 2006 Jul 1;78(13):4690-6 [16808483.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6732-40 [16818648.001]
  • [Cites] J Clin Oncol. 2006 Jul 10;24(20):3299-308 [16829654.001]
  • [Cites] Nat Biotechnol. 2006 Aug;24(8):1005-15 [16823371.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1181-91 [16778828.001]
  • [Cites] Mol Cancer Ther. 2006 Aug;5(8):1909-17 [16928810.001]
  • [Cites] Mol Ther. 2006 Oct;14(4):476-84 [16829204.001]
  • [Cites] Biomaterials. 2007 Feb;28(5):869-76 [17055572.001]
  • [Cites] Nat Chem Biol. 2006 Dec;2(12):711-9 [17108989.001]
  • [Cites] Angew Chem Int Ed Engl. 2006 Nov 27;45(46):7732-5 [17089426.001]
  • [Cites] Adv Drug Deliv Rev. 2006 Dec 1;58(14):1532-55 [17092599.001]
  • [Cites] J Control Release. 2006 Dec 1;116(3):330-6 [17118476.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jan;8(1):23-36 [17183358.001]
  • [Cites] Clin Chem. 2007 Jan;53(1):145-6 [17202501.001]
  • [Cites] J Biomed Mater Res B Appl Biomater. 2006 Jan;76(1):161-8 [16208637.001]
  • [Cites] J Am Chem Soc. 2006 Mar 1;128(8):2526-7 [16492023.001]
  • [Cites] J Nanosci Nanotechnol. 2002 Jun-Aug;2(3-4):405-9 [12908270.001]
  • [Cites] J Nucl Med. 2003 Dec;44(12):1962-9 [14660722.001]
  • [Cites] Nat Biotechnol. 2004 Jan;22(1):93-7 [14661026.001]
  • [Cites] Nat Biotechnol. 2004 Feb;22(2):198-203 [14704683.001]
  • [Cites] Nat Biotechnol. 2001 Mar;19(3):273-6 [11231563.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4420-5 [11287650.001]
  • [Cites] Nature. 2001 May 24;411(6836):494-8 [11373684.001]
  • [Cites] J Am Chem Soc. 2001 May 2;123(17):4103-4 [11457171.001]
  • [Cites] Clin Chem. 2001 Oct;47(10):1885-93 [11568115.001]
  • [Cites] Anal Chem. 2001 Oct 15;73(20):4988-93 [11681477.001]
  • [Cites] Nature. 2002 Jul 4;418(6893):38-9 [12097900.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):244-51 [12110901.001]
  • [Cites] Cell. 2002 Sep 6;110(5):563-74 [12230974.001]
  • [Cites] Science. 2002 Nov 29;298(5599):1759-62 [12459582.001]
  • [Cites] Nat Biotechnol. 2003 Jan;21(1):41-6 [12459735.001]
  • [Cites] Nat Biotechnol. 2003 Jan;21(1):47-51 [12459736.001]
  • [Cites] Chem Rev. 2003 Feb;103(2):577-644 [12580643.001]
  • [Cites] Genes Dev. 2003 Mar 1;17(5):545-80 [12629038.001]
  • [Cites] J Am Chem Soc. 2003 Apr 16;125(15):4451-9 [12683815.001]
  • [Cites] Nat Rev Drug Discov. 2003 May;2(5):347-60 [12750738.001]
  • [Cites] J Am Chem Soc. 2008 Dec 31;130(52):17648-9 [19055348.001]
  • [Cites] Int J Pharm. 2009 Jan 21;366(1-2):201-10 [18835580.001]
  • [Cites] J Gene Med. 2009 Jan;11(1):38-45 [19021130.001]
  • [Cites] Cancer Biomark. 2008;4(6):307-19 [19126959.001]
  • [Cites] Opt Express. 2009 Jan 5;17(1):80-6 [19129875.001]
  • [Cites] Nature. 2009 Jan 22;457(7228):426-33 [19158789.001]
  • [Cites] Angew Chem Int Ed Engl. 2009;48(5):872-97 [19142939.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):1182-9 [19141648.001]
  • [Cites] Angew Chem Int Ed Engl. 2009;48(8):1378-98 [19153977.001]
  • [Cites] Nanotechnology. 2009 Jan 7;20(1):015102 [19417242.001]
  • [Cites] Nanotechnology. 2009 Apr 15;20(15):155101 [19420539.001]
  • [Cites] Bioconjug Chem. 2009 Mar 18;20(3):511-7 [19193062.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2796-802 [16385568.001]
  • [Cites] Nano Lett. 2006 Apr;6(4):669-76 [16608262.001]
  • [Cites] Expert Rev Mol Diagn. 2006 May;6(3):307-18 [16706735.001]
  • [Cites] Science. 2006 May 26;312(5777):1168-71 [16728630.001]
  • [Cites] Biomaterials. 2008 Oct;29(30):4122-8 [18675453.001]
  • [Cites] Nano Lett. 2008 Sep;8(9):2599-606 [18386933.001]
  • [Cites] Nano Lett. 2008 Sep;8(9):2851-7 [18712930.001]
  • [Cites] Trends Biotechnol. 2008 Oct;26(10):552-8 [18722682.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1857-67 [18491091.001]
  • [Cites] Biomaterials. 2009 Jan;30(2):242-53 [18838158.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8843-51 [18974128.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):9078-86 [18974154.001]
  • [Cites] Small. 2008 Nov;4(11):2043-50 [18949788.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Dec 14;60(15):1615-26 [18840489.001]
  • [Cites] Angew Chem Int Ed Engl. 2008;47(44):8438-41 [18726979.001]
  • [Cites] Opt Express. 2008 Nov 24;16(24):19568-78 [19030044.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2235-44 [18566815.001]
  • [Cites] Anal Biochem. 2000 Apr 10;280(1):128-36 [10805530.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8495-500 [10880576.001]
  • [Cites] Biomaterials. 2007 Mar;28(8):1565-71 [17161865.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):932-6 [17215365.001]
  • [Cites] Curr Opin Biotechnol. 2007 Feb;18(1):17-25 [17234399.001]
  • [Cites] Nat Med. 2007 Mar;13(3):372-7 [17322898.001]
  • [Cites] Angew Chem Int Ed Engl. 2007;46(12):2023-7 [17290476.001]
  • [Cites] Int J Cancer. 2007 Jun 15;120(12):2527-37 [17390371.001]
  • [Cites] Angew Chem Int Ed Engl. 2007;46(14):2448-52 [17318931.001]
  • [Cites] J Am Chem Soc. 2007 May 9;129(18):5798-9 [17428054.001]
  • [Cites] Spectrochim Acta A Mol Biomol Spectrosc. 2007 Jun;67(2):517-21 [16965933.001]
  • [Cites] Nat Protoc. 2007;2(5):1152-65 [17546006.001]
  • [Cites] J Phys Chem B. 2007 Jun 28;111(25):6969-72 [17552555.001]
  • [Cites] Anal Chim Acta. 2007 Jul 16;596(1):106-15 [17616247.001]
  • [Cites] Small. 2007 Aug;3(8):1341-6 [17566138.001]
  • [Cites] Small. 2007 Sep;3(9):1560-5 [17705315.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15549-54 [17875985.001]
  • [Cites] Nano Lett. 2007 Oct;7(10):3065-70 [17854227.001]
  • [Cites] J Mol Med (Berl). 2005 May;83(5):377-85 [15688234.001]
  • (PMID = 19759055.001).
  • [ISSN] 1742-5662
  • [Journal-full-title] Journal of the Royal Society, Interface
  • [ISO-abbreviation] J R Soc Interface
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Contrast Media
  • [Number-of-references] 245
  • [Other-IDs] NLM/ PMC2839386
  •  go-up   go-down


14. Godin B, Sakamoto JH, Serda RE, Grattoni A, Bouamrani A, Ferrari M: Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci; 2010 May;31(5):199-205

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases.
  • It therefore bridges the gap between molecular and cellular interactions, and has the potential to revolutionize medicine.
  • This will occur through improvement of the diagnosis and therapy of cardiovascular disorders as atherosclerosis, restenosis and myocardial infarction.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Ltd.
  • [Cites] Biomaterials. 2005 Feb;26(4):451-61 [15275819.001]
  • [Cites] Circulation. 2004 Sep 14;110(11):1463-6 [15238457.001]
  • [Cites] Nanomedicine (Lond). 2007 Dec;2(6):831-46 [18095849.001]
  • [Cites] Nano Lett. 2008 Jan;8(1):350-61 [18076201.001]
  • [Cites] Circulation. 2008 Jan 22;117(3):379-87 [18158358.001]
  • [Cites] Basic Res Cardiol. 2008 Mar;103(2):122-30 [18324368.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2008 May;28(5):820-6 [18292395.001]
  • [Cites] Biomed Mater. 2006 Dec;1(4):L11-5 [18458401.001]
  • [Cites] Int J Nanomedicine. 2008;3(1):75-82 [18488418.001]
  • [Cites] J Am Chem Soc. 2008 Jul 23;130(29):9186-7 [18572935.001]
  • [Cites] Nat Nanotechnol. 2006 Oct;1(1):8-10 [18654128.001]
  • [Cites] Nat Nanotechnol. 2007 Dec;2(12):751-60 [18654426.001]
  • [Cites] Nat Nanotechnol. 2008 Mar;3(3):131-2 [18654480.001]
  • [Cites] Contrast Media Mol Imaging. 2008 Nov-Dec;3(6):233-42 [19072768.001]
  • [Cites] Angew Chem Int Ed Engl. 2009;48(5):872-97 [19142939.001]
  • [Cites] Adv Exp Med Biol. 2009;645:101-7 [19227457.001]
  • [Cites] JAMA. 2005 Oct 12;294(14):1799-809 [16219884.001]
  • [Cites] AJR Am J Roentgenol. 2006 Feb;186(2):300-7 [16423931.001]
  • [Cites] Catheter Cardiovasc Interv. 2006 May;67(5):698-702 [16575925.001]
  • [Cites] J Proteome Res. 2006 May;5(5):1261-6 [16674117.001]
  • [Cites] Circulation. 2006 May 16;113(19):2335-62 [16702488.001]
  • [Cites] J Cardiovasc Magn Reson. 2006;8(3):535-41 [16755843.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):2103-9 [16825592.001]
  • [Cites] Adv Drug Deliv Rev. 2006 Dec 1;58(14):1471-504 [17116343.001]
  • [Cites] J Vasc Surg. 2006 Dec;44(6):1363-8 [17145446.001]
  • [Cites] Anal Chem. 2006 Dec 15;78(24):8175-82 [17165805.001]
  • [Cites] N Engl J Med. 2006 Dec 21;355(25):2631-9 [17182988.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):961-6 [17215360.001]
  • [Cites] N Engl J Med. 2007 Mar 8;356(10):1020-9 [17296821.001]
  • [Cites] N Engl J Med. 2007 Mar 8;356(10):1009-19 [17296822.001]
  • [Cites] N Engl J Med. 2007 Mar 8;356(10):1030-9 [17296823.001]
  • [Cites] N Engl J Med. 2007 Mar 8;356(10):998-1008 [17296824.001]
  • [Cites] Nat Med. 2007 May;13(5):636-41 [17417649.001]
  • [Cites] J Am Chem Soc. 2007 Jun 20;129(24):7661-5 [17530850.001]
  • [Cites] Nanomedicine (Lond). 2006 Oct;1(3):321-9 [17716162.001]
  • [Cites] Nanomedicine (Lond). 2007 Aug;2(4):533-43 [17716136.001]
  • [Cites] Int J Nanomedicine. 2007;2(2):143-61 [17722543.001]
  • [Cites] Conf Proc IEEE Eng Med Biol Soc. 2007;2007:115-8 [18001902.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):667-76 [10712389.001]
  • [Cites] Circulation. 2000 Sep 12;102(11):1216-20 [10982533.001]
  • [Cites] Science. 2001 Aug 17;293(5533):1289-92 [11509722.001]
  • [Cites] Biomaterials. 2002 Feb;23(3):691-8 [11771689.001]
  • [Cites] Am J Med. 2002 May;112(7):556-65 [12015248.001]
  • [Cites] Circulation. 2002 Jul 30;106(5):599-605 [12147543.001]
  • [Cites] Bioconjug Chem. 2009 Feb;20(2):397-401 [19138113.001]
  • [Cites] Nanomedicine (Lond). 2009 Apr;4(3):331-9 [19331540.001]
  • [Cites] Nat Nanotechnol. 2009 Apr;4(4):259-64 [19350038.001]
  • [Cites] JACC Cardiovasc Imaging. 2008 Sep;1(5):624-34 [19356492.001]
  • [Cites] Angew Chem Int Ed Engl. 2009;48(23):4170-3 [19418503.001]
  • [Cites] Int J Cardiol. 2009 Jun 26;135(2):245-8 [18590936.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2009 Jul;29(7):1017-24 [19359659.001]
  • [Cites] Chem Commun (Camb). 2009 Jun 14;(22):3234-6 [19587924.001]
  • [Cites] Clin Chem. 2009 Aug;55(8):1530-8 [19556448.001]
  • [Cites] Am Heart J. 2009 Sep;158(3):386-91 [19699861.001]
  • [Cites] Ann Biomed Eng. 2009 Oct;37(10):1922-33 [19184435.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16145-50 [19805271.001]
  • [Cites] J Am Chem Soc. 2009 Oct 28;131(42):15522-7 [19795893.001]
  • [Cites] Nanoscale. 2009 Nov;1(2):250-9 [20644846.001]
  • [Cites] Nat Chem. 2009 Sep;1(6):473-81 [21378915.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):9783-8 [12119412.001]
  • [Cites] Pharm Res. 2004 Sep;21(9):1656-61 [15497693.001]
  • [Cites] J Reprod Med. 1992 Jan;37(1):19-26 [1548634.001]
  • [Cites] Circulation. 1996 Sep 15;94(6):1247-54 [8822976.001]
  • [Cites] Arch Mal Coeur Vaiss. 1997 Aug;90(8):1127-30 [9404421.001]
  • [Cites] J Acoust Soc Am. 1998 Dec;104(6):3665-72 [9857523.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1999 Mar;19(3):493-8 [10073948.001]
  • [Cites] Science. 2005 Jan 28;307(5709):538-44 [15681376.001]
  • [Cites] Physiol Meas. 2004 Dec;25(6):N21-6 [15712731.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):161-71 [15738981.001]
  • [Cites] Magn Reson Med. 2005 May;53(5):999-1005 [15844142.001]
  • [Cites] Trends Cardiovasc Med. 2005 Aug;15(6):207-11 [16182130.001]
  • [Cites] Acad Radiol. 2003 May;10(5):475-83 [12755534.001]
  • [Cites] Circulation. 2003 May 20;107(19):2453-8 [12719280.001]
  • [Cites] Circulation. 2003 Jun 3;107(21):2677-83 [12742981.001]
  • [Cites] Catheter Cardiovasc Interv. 2003 Nov;60(3):399-407 [14571494.001]
  • [Cites] Circulation. 2003 Nov 4;108(18):2270-4 [14557370.001]
  • [Cites] Technol Cancer Res Treat. 2004 Feb;3(1):33-40 [14750891.001]
  • [Cites] N Engl J Med. 2004 Feb 12;350(7):655-63 [14960742.001]
  • [Cites] Magn Reson Med. 2004 Mar;51(3):480-6 [15004788.001]
  • [Cites] N Engl J Med. 2004 Apr 1;350(14):1387-97 [15070788.001]
  • (PMID = 20172613.001).
  • [ISSN] 1873-3735
  • [Journal-full-title] Trends in pharmacological sciences
  • [ISO-abbreviation] Trends Pharmacol. Sci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA128797-03; United States / NCI NIH HHS / CA / U54 CA143837-01; United States / NCI NIH HHS / CA / R01CA128797; United States / NCI NIH HHS / CA / CA128797-03; United States / NCI NIH HHS / CA / R33 CA122864-03; United States / NCI NIH HHS / CA / U54 CA143837; United States / NCI NIH HHS / CA / U54CA143837; United States / NCI NIH HHS / CA / CA122864-03; United States / NCI NIH HHS / CA / R01 CA128797; United States / NCI NIH HHS / CA / R33 CA122864
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] England
  • [Number-of-references] 86
  • [Other-IDs] NLM/ NIHMS176187; NLM/ PMC2862836
  •  go-up   go-down


15. Lu W, Singh AK, Khan SA, Senapati D, Yu H, Ray PC: Gold nano-popcorn-based targeted diagnosis, nanotherapy treatment, and in situ monitoring of photothermal therapy response of prostate cancer cells using surface-enhanced Raman spectroscopy. J Am Chem Soc; 2010 Dec 29;132(51):18103-14
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gold nano-popcorn-based targeted diagnosis, nanotherapy treatment, and in situ monitoring of photothermal therapy response of prostate cancer cells using surface-enhanced Raman spectroscopy.
  • Prostate cancer is the second leading cause of cancer-related death among the American male population, and the cost of treating prostate cancer patients is about $10 billion/year in the United States.
  • Current treatments are mostly ineffective against advanced-stage prostate cancer and are often associated with severe side effects.
  • Our experimental data show that, in the presence of LNCaP human prostate cancer cells, multifunctional popcorn-shaped gold nanoparticles form several hot spots and provide a significant enhancement of the Raman signal intensity by several orders of magnitude (2.5 × 10(9)).
  • As a result, it can recognize human prostate cancer cells at the 50-cells level.
  • Our results indicate that the localized heating that occurs during near-infrared irradiation can cause irreparable cellular damage to the prostate cancer cells.
  • Ultimately, this nanotechnology-driven assay could have enormous potential applications in rapid, on-site targeted sensing, nanotherapy treatment, and monitoring of the nanotherapy process, which are critical to providing effective treatment of cancer.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Chem. 2008 Feb 1;80(3):567-72 [18166023.001]
  • [Cites] ACS Nano. 2010 Nov 23;4(11):6395-403 [20958080.001]
  • [Cites] Nat Rev Cancer. 2008 Apr;8(4):268-78 [18337732.001]
  • [Cites] J Am Chem Soc. 2008 Apr 23;130(16):5523-9 [18373341.001]
  • [Cites] Bioconjug Chem. 2008 Jun;19(6):1309-12 [18512972.001]
  • [Cites] Nat Nanotechnol. 2007 Dec;2(12):751-60 [18654426.001]
  • [Cites] J Proteome Res. 2008 Aug;7(8):3329-38 [18578523.001]
  • [Cites] J Phys Chem B. 2008 Sep 11;112(36):11198-201 [18702540.001]
  • [Cites] J Am Chem Soc. 2008 Nov 12;130(45):14934-5 [18937463.001]
  • [Cites] Mod Pathol. 2008 Dec;21(12):1421-7 [18839017.001]
  • [Cites] Acc Chem Res. 2008 Dec;41(12):1842-51 [19053240.001]
  • [Cites] J Am Chem Soc. 2008 Dec 24;130(51):17214-5 [19053187.001]
  • [Cites] Chemistry. 2009;15(2):342-51 [19035615.001]
  • [Cites] J Am Chem Soc. 2009 Jan 14;131(1):162-9 [19063599.001]
  • [Cites] ACS Nano. 2007 Oct;1(3):208-14 [19206651.001]
  • [Cites] ACS Nano. 2008 Nov 25;2(11):2306-14 [19206397.001]
  • [Cites] ACS Nano. 2009 Jan 27;3(1):80-6 [19206252.001]
  • [Cites] Acc Chem Res. 2008 Dec;41(12):1578-86 [18447366.001]
  • [Cites] Acc Chem Res. 2008 Dec;41(12):1630-40 [18698851.001]
  • [Cites] Nano Lett. 2009 Mar;9(3):1139-46 [19193041.001]
  • [Cites] J Am Chem Soc. 2009 Apr 29;131(16):5728-9 [19351115.001]
  • [Cites] J Am Chem Soc. 2009 Jun 17;131(23):7937-9 [19507897.001]
  • [Cites] Chem Rev. 2009 Jul;109(7):3200-8 [19522504.001]
  • [Cites] Chem Rev. 2009 Jul;109(7):2859-61 [19583428.001]
  • [Cites] ACS Nano. 2009 Sep 22;3(9):2834-40 [19691350.001]
  • [Cites] J Am Chem Soc. 2009 Sep 30;131(38):13639-45 [19772360.001]
  • [Cites] J Am Chem Soc. 2009 Dec 2;131(47):17328-34 [19929020.001]
  • [Cites] J Am Chem Soc. 2010 Feb 17;132(6):1929-38 [20092330.001]
  • [Cites] ACS Nano. 2010 Mar 23;4(3):1739-49 [20155973.001]
  • [Cites] J Am Chem Soc. 2010 Apr 7;132(13):4678-84 [20225865.001]
  • [Cites] Nat Rev Clin Oncol. 2010 May;7(5):266-76 [20351700.001]
  • [Cites] Chem Rev. 2010 May 12;110(5):3196-211 [20170129.001]
  • [Cites] Chem Rev. 2010 May 12;110(5):3146-95 [20225900.001]
  • [Cites] Angew Chem Int Ed Engl. 2010 May 17;49(22):3777-81 [20391446.001]
  • [Cites] Chemistry. 2010 May 17;16(19):5600-6 [20397252.001]
  • [Cites] Nat Rev Cancer. 2005 Mar;5(3):161-71 [15738981.001]
  • [Cites] J Am Chem Soc. 2005 Mar 9;127(9):3115-9 [15740151.001]
  • [Cites] Nat Rev Cancer. 2006 Jan;6(1):63-74 [16372017.001]
  • [Cites] J Am Chem Soc. 2006 Feb 15;128(6):2115-20 [16464114.001]
  • [Cites] J Am Chem Soc. 2006 Feb 22;128(7):2426-33 [16478198.001]
  • [Cites] J Am Chem Soc. 2006 Jul 5;128(26):8378-9 [16802785.001]
  • [Cites] Cancer Lett. 2006 Jul 28;239(1):36-45 [16202512.001]
  • [Cites] J Am Chem Soc. 2007 Nov 28;129(47):14572-3 [17985912.001]
  • [Cites] Nano Lett. 2008 Jan;8(1):214-20 [18052230.001]
  • [Cites] J Am Chem Soc. 2008 Mar 5;130(9):2780-2 [18257576.001]
  • (PMID = 21128627.001).
  • [ISSN] 1520-5126
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM008047-35; United States / NIGMS NIH HHS / GM / S06 GM008047; United States / NIGMS NIH HHS / GM / S06 GM008047-35; United States / NIGMS NIH HHS / GM / S06GM008047
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 7440-57-5 / Gold
  • [Other-IDs] NLM/ NIHMS256741; NLM/ PMC3074586
  •  go-up   go-down


16. Nemeth E: Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Adv Hematol; 2010;2010:750643
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias.
  • Hepcidin acts by causing the degradation of its receptor, the cellular iron exporter ferroportin.
  • The diagnosis of different forms of anemia will be facilitated by improved hepcidin assays, and the treatment will be enhanced by the development of hepcidin agonists and antagonists.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2007 Jul;117(7):1926-32 [17557118.001]
  • [Cites] J Clin Invest. 2007 Jul;117(7):1933-9 [17607365.001]
  • [Cites] Haematologica. 2007 May;92(5):583-8 [17488680.001]
  • [Cites] Blood. 2007 May 1;109(9):4038-44 [17218383.001]
  • [Cites] Clin Chem. 2007 Apr;53(4):620-8 [17272487.001]
  • [Cites] Mol Biol Cell. 2007 Mar;18(3):743-54 [17182845.001]
  • [Cites] Blood. 2007 Jan 1;109(1):353-8 [16946298.001]
  • [Cites] Physiol Res. 2006;55(6):667-74 [16497104.001]
  • [Cites] Inflamm Bowel Dis. 2006 Dec;12(12):1101-6 [17119383.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jan;48(1):57-63 [16220548.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3730-5 [16882706.001]
  • [Cites] J Biol Chem. 2006 Sep 29;281(39):28494-8 [16893896.001]
  • [Cites] Am J Gastroenterol. 2006 Sep;101(9):2160-2 [16817847.001]
  • [Cites] Haematologica. 2006 Jun;91(6):727-32 [16769573.001]
  • [Cites] Nat Genet. 2006 May;38(5):531-9 [16604073.001]
  • [Cites] Blood. 2006 May 1;107(9):3727-32 [16391018.001]
  • [Cites] Pediatr Blood Cancer. 2006 May 1;46(5):554-7 [16261603.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2627-32 [15998837.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2884-9 [15998830.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2196-9 [15933050.001]
  • [Cites] J Clin Invest. 2005 Aug;115(8):2180-6 [16075058.001]
  • [Cites] Cell Metab. 2005 Mar;1(3):191-200 [16054062.001]
  • [Cites] Blood. 2005 Feb 15;105(4):1797-802 [15479721.001]
  • [Cites] Science. 2004 Dec 17;306(5704):2090-3 [15514116.001]
  • [Cites] Semin Hematol. 1966 Oct;3(4):351-75 [5341723.001]
  • [Cites] J Clin Invest. 2004 May;113(9):1271-6 [15124018.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2461-3 [12433676.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):21-2 [12469120.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3776-81 [12393428.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):7806-10 [11113131.001]
  • [Cites] J Biol Chem. 2000 Jun 30;275(26):19906-12 [10747949.001]
  • [Cites] Mol Cell. 2000 Feb;5(2):299-309 [10882071.001]
  • [Cites] Nature. 2000 Feb 17;403(6771):776-81 [10693807.001]
  • [Cites] Nat Genet. 2009 Nov;41(11):1173-5 [19820699.001]
  • [Cites] Nat Genet. 2009 Nov;41(11):1170-2 [19820698.001]
  • [Cites] Br J Biomed Sci. 2009;66(3):150-7 [19839227.001]
  • [Cites] Clin J Am Soc Nephrol. 2009 Aug;4(8):1384-7 [19556376.001]
  • [Cites] Blood. 2009 Jul 2;114(1):181-6 [19414861.001]
  • [Cites] Clin J Am Soc Nephrol. 2009 Jun;4(6):1051-6 [19406957.001]
  • [Cites] Haematologica. 2009 Jun;94(6):765-72 [19454495.001]
  • [Cites] J Pharmacol Toxicol Methods. 2009 May-Jun;59(3):171-80 [19258043.001]
  • [Cites] Rapid Commun Mass Spectrom. 2009 Jun;23(11):1531-42 [19399775.001]
  • [Cites] J Hepatol. 2009 Jun;50(6):1219-25 [19398238.001]
  • [Cites] Cell Metab. 2009 May;9(5):461-73 [19416716.001]
  • [Cites] Anal Biochem. 2009 Jun 15;389(2):124-9 [19341701.001]
  • [Cites] Kidney Int. 2009 May;75(9):976-81 [19212416.001]
  • [Cites] Blood. 2009 Apr 9;113(15):3593-9 [19204324.001]
  • [Cites] Nat Genet. 2009 Apr;41(4):478-81 [19252488.001]
  • [Cites] Nat Genet. 2009 Apr;41(4):482-7 [19252486.001]
  • [Cites] J Am Diet Assoc. 2009 Feb;109(2):297-302 [19167957.001]
  • [Cites] Adv Chronic Kidney Dis. 2009 Mar;16(2):94-100 [19233068.001]
  • [Cites] Adv Chronic Kidney Dis. 2009 Mar;16(2):76-82 [19233066.001]
  • [Cites] J Hepatol. 2009 Feb;50(2):394-401 [19070914.001]
  • [Cites] Am J Clin Nutr. 2009 Feb;89(2):533-8 [19073788.001]
  • [Cites] Cell Metab. 2008 Dec;8(6):502-11 [18976966.001]
  • [Cites] Blood. 2008 Nov 15;112(10):4292-7 [18689548.001]
  • [Cites] Haematologica. 2008 Oct;93(10):1473-9 [18603562.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1503-9 [18539898.001]
  • [Cites] J Biol Chem. 2008 Jun 20;283(25):17494-502 [18445598.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3262-7 [18519751.001]
  • [Cites] Nat Genet. 2008 May;40(5):569-71 [18408718.001]
  • [Cites] Blood. 2008 May 15;111(10):5195-204 [18326817.001]
  • [Cites] Blood. 2007 Dec 1;110(12):4096-100 [17724144.001]
  • [Cites] Haematologica. 2007 Jun;92(6):857-8 [17550864.001]
  • (PMID = 20066043.001).
  • [ISSN] 1687-9112
  • [Journal-full-title] Advances in hematology
  • [ISO-abbreviation] Adv Hematol
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK082717
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2798567
  •  go-up   go-down


17. Zhang JY, Looi KS, Tan EM: Identification of tumor-associated antigens as diagnostic and predictive biomarkers in cancer. Methods Mol Biol; 2009;520:1-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of tumor-associated antigens as diagnostic and predictive biomarkers in cancer.
  • Many studies demonstrated that cancer sera contain antibodies which react with autologous cellular antigens generally known as tumor-associated antigens (TAAs).
  • In our laboratories, the approach used in the identification of TAAs has involved initially examining the sera of cancer patients using extracts of tissue culture cells as source of antigens in Western blotting and by indirect immunofluorescence on whole cells.
  • In extension of these studies, we evaluate the sensitivity and specificity of different antigen-antibody systems as markers in cancer in order to develop "tumor-associated antigen array" systems for cancer diagnosis, cancer prediction, and for following the response of patients to treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1777-88 [10766157.001]
  • [Cites] J Proteome Res. 2005 Jul-Aug;4(4):1123-33 [16083262.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):945-53 [11549587.001]
  • [Cites] J Clin Invest. 2001 Nov;108(10):1411-5 [11714730.001]
  • [Cites] Mol Cell Proteomics. 2002 Mar;1(3):197-203 [12096119.001]
  • [Cites] Oncogene. 2002 Jul 25;21(32):5006-15 [12118381.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):136-43 [12582023.001]
  • [Cites] Technol Cancer Res Treat. 2002 Aug;1(4):257-62 [12625784.001]
  • [Cites] Int J Cancer. 1982 Oct 15;30(4):403-8 [6292117.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Apr;82(7):2115-9 [3856888.001]
  • [Cites] Cancer Res. 1992 Aug 1;52(15):4168-74 [1322237.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):26-35 [8380118.001]
  • [Cites] J Clin Invest. 1993 Nov;92(5):2419-26 [8227358.001]
  • [Cites] J Cell Sci. 1993 Dec;106 ( Pt 4):1045-56 [7907337.001]
  • [Cites] Exp Cell Res. 1994 Jun;212(2):255-61 [7910562.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3 [8524854.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] Nat Med. 1997 Aug;3(8):917-21 [9256286.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3363-7 [9363867.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1163-7 [9547328.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1349-54 [9547346.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):5-7 [9874760.001]
  • [Cites] J Exp Med. 1999 Apr 5;189(7):1101-10 [10190901.001]
  • [Cites] Prostate. 2005 Jan 1;62(1):14-26 [15389814.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2756-9 [10850408.001]
  • (PMID = 19381943.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA056956; United States / NIGMS NIH HHS / GM / 2S06GM008012-37; United States / NCRR NIH HHS / RR / 5G12RR08124; United States / NIGMS NIH HHS / GM / S06 GM008012-390010; United States / NCRR NIH HHS / RR / G12 RR008124; United States / NIGMS NIH HHS / GM / S06 GM008012; United States / NCI NIH HHS / CA / CA56956; United States / NIGMS NIH HHS / GM / GM008012-390010
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS183653; NLM/ PMC2839120
  •  go-up   go-down


18. Hellström M, Lexander H, Franzén B, Egevad L: Proteomics in prostate cancer research. Anal Quant Cytol Histol; 2007 Feb;29(1):32-40
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomics in prostate cancer research.
  • The incidence of early prostate cancer (PCa) among middle-aged men has increased rapidly.
  • Although labor-intensive and time-consuming, 2-DE is presently the most powerful method for analysis of cellular protein phenotype and may potentially reveal gene regulations that cannot be detected on a genetic level.

  • Genetic Alliance. consumer health - Prostate cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17375872.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 80
  •  go-up   go-down


19. Sieren JC, Weydert J, Bell A, De Young B, Smith AR, Thiesse J, Namati E, McLennan G: An automated segmentation approach for highlighting the histological complexity of human lung cancer. Ann Biomed Eng; 2010 Dec;38(12):3581-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An automated segmentation approach for highlighting the histological complexity of human lung cancer.
  • Lung cancer nodules, particularly adenocarcinoma, contain a complex intermixing of cellular tissue types: incorporating cancer cells, fibroblastic stromal tissue, and inactive fibrosis.
  • Quantitative proportions and distributions of the various tissue types may be insightful for understanding lung cancer growth, classification, and prognostic factors.
  • However, current methods of histological assessment are qualitative and provide limited opportunity to systematically evaluate the relevance of lung nodule cellular heterogeneity.
  • In this study we present both a manual and an automatic method for segmentation of tissue types in histological sections of resected human lung cancer nodules.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Quant Cytol Histol. 2003 Dec;25(6):321-31 [14714298.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):937-51 [12826886.001]
  • [Cites] Biotech Histochem. 1992 Sep;67(5):253-5 [1284404.001]
  • [Cites] N Engl J Med. 1993 Dec 16;329(25):1862-72 [8305063.001]
  • [Cites] Cancer. 1997 Jun 25;81(3):172-9 [9196016.001]
  • [Cites] Ann Intern Med. 1997 Dec 1;127(11):981-5 [9412303.001]
  • [Cites] J Clin Oncol. 2005 May 10;23(14):3279-87 [15886315.001]
  • [Cites] Nat Clin Pract Nephrol. 2005 Nov;1(1):44-54 [16932363.001]
  • [Cites] Pathol Int. 2006 Sep;56(9):494-502 [16930329.001]
  • [Cites] Ann Thorac Surg. 2007 Jan;83(1):209-14 [17184664.001]
  • [Cites] Diabetes. 2007 Jul;56(7):1825-33 [17456853.001]
  • [Cites] BMC Med Imaging. 2007;7:7 [17822559.001]
  • [Cites] Anat Rec (Hoboken). 2007 Nov;290(11):1377-87 [17853414.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Apr;135(4):830-6 [18374763.001]
  • [Cites] Int J Clin Exp Pathol. 2009;3(1):98-105 [19918333.001]
  • [Cites] Acad Radiol. 2010 Feb;17(2):169-80 [19926496.001]
  • [Cites] Comput Med Imaging Graph. 2010 Sep;34(6):453-61 [20060681.001]
  • [Cites] Science. 2000 Feb 18;287(5456):1253-8 [10678830.001]
  • [Cites] Ann Thorac Surg. 2000 Mar;69(3):893-7 [10750779.001]
  • [Cites] Eur Respir J. 2001 Dec;18(6):1059-68 [11829087.001]
  • [Cites] Cancer. 2002 Dec 15;95(12):2546-54 [12467069.001]
  • [Cites] Kidney Int. 2003 Jul;64(1):350-5 [12787428.001]
  • [Cites] Cell. 1982 Nov;31(1):11-24 [6186379.001]
  • (PMID = 20571856.001).
  • [ISSN] 1573-9686
  • [Journal-full-title] Annals of biomedical engineering
  • [ISO-abbreviation] Ann Biomed Eng
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA129022-03; United States / NCI NIH HHS / CA / R01 CA129022; United States / NCI NIH HHS / CA / R01 CA129022-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS251946; NLM/ PMC2996273
  •  go-up   go-down


20. Iorio E, Ricci A, Bagnoli M, Pisanu ME, Castellano G, Di Vito M, Venturini E, Glunde K, Bhujwalla ZM, Mezzanzanica D, Canevari S, Podo F: Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells. Cancer Res; 2010 Mar 1;70(5):2126-35
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells.
  • Altered phosphatidylcholine (PC) metabolism in epithelial ovarian cancer (EOC) could provide choline-based imaging approaches as powerful tools to improve diagnosis and identify new therapeutic targets.
  • PC-plc inhibition by tricyclodecan-9-yl-potassium xanthate (D609) in OVCAR3 and SKOV3 cancer cells induced a 30% to 40% reduction of PCho content and blocked cell proliferation.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] NMR Biomed. 1999 Nov;12(7):413-39 [10654290.001]
  • [Cites] Cancer Res. 2007 Dec 1;67(23):11284-90 [18056454.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3599-603 [11325827.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):1966-70 [11929812.001]
  • [Cites] Oncogene. 2002 Jun 20;21(27):4317-22 [12082619.001]
  • [Cites] Methods Mol Biol. 2003;218:155-76 [12616720.001]
  • [Cites] J Nucl Med. 2003 Jul;44(7):1051-6 [12843219.001]
  • [Cites] J Cell Biochem. 2003 Oct 15;90(3):525-33 [14523987.001]
  • [Cites] J Lipid Res. 2003 Oct;44(10):1963-75 [12837850.001]
  • [Cites] Prog Lipid Res. 2004 May;43(3):266-81 [15003397.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4270-6 [15205341.001]
  • [Cites] Radiology. 2004 Aug;232(2):599-605 [15286325.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5202-14 [15297424.001]
  • [Cites] Exp Cell Res. 2004 Oct 1;299(2):370-82 [15350536.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6732-9 [15374991.001]
  • [Cites] Nucl Med Biol. 2004 Oct;31(7):859-65 [15464387.001]
  • [Cites] NMR Biomed. 1992 Sep-Oct;5(5):303-24 [1333263.001]
  • [Cites] EMBO J. 1995 Dec 1;14(23):5859-68 [8846779.001]
  • [Cites] Anticancer Res. 1996 May-Jun;16(3B):1399-412 [8694508.001]
  • [Cites] J Biol Chem. 1997 Apr 25;272(17):11011-6 [9110992.001]
  • [Cites] Anal Biochem. 1997 Aug 15;251(1):45-9 [9300081.001]
  • [Cites] Anal Biochem. 1997 Oct 1;252(1):1-9 [9324933.001]
  • [Cites] Int J Cancer. 1997 Sep 26;73(1):143-50 [9334822.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):11026-31 [18667693.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6541-9 [18701477.001]
  • [Cites] NMR Biomed. 2009 Jan;22(1):114-27 [19016452.001]
  • [Cites] Arch Biochem Biophys. 2009 Mar 1;483(1):90-8 [19135976.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3464-71 [19336572.001]
  • [Cites] Neoplasia. 2009 May;11(5):477-84 [19412432.001]
  • [Cites] Oncogene. 2009 Jul 2;28(26):2425-35 [19448670.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):80-4 [9892190.001]
  • [Cites] Mol Imaging. 2004 Oct;3(4):319-23 [15802048.001]
  • [Cites] Annu Rev Biomed Eng. 2005;7:287-326 [16004573.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9369-76 [16230400.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11034-43 [16322253.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):427-34 [16397258.001]
  • [Cites] Biochem J. 2006 Feb 15;394(Pt 1):299-308 [16255717.001]
  • [Cites] Radiology. 2006 Mar;238(3):958-69 [16424238.001]
  • [Cites] Curr Med Chem. 2006;13(10):1169-86 [16719778.001]
  • [Cites] Mol Pharm. 2006 Sep-Oct;3(5):496-506 [17009848.001]
  • [Cites] Pharmacogenomics. 2006 Oct;7(7):1109-23 [17054420.001]
  • [Cites] Mol Imaging. 2006 Oct-Dec;5(4):498-509 [17150162.001]
  • [Cites] Int J Cancer. 2007 Apr 15;120(8):1721-30 [17236204.001]
  • [Cites] J Cell Biochem. 2007 Oct 1;102(2):421-8 [17393430.001]
  • [Cites] Lancet Oncol. 2007 Oct;8(10):889-97 [17851129.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2482-91 [10873103.001]
  • (PMID = 20179205.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA103175-05; United States / NCI NIH HHS / CA / P50 CA103175; United States / NCI NIH HHS / CA / P50 CA103175-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Transport Proteins; 0 / Phosphatidylcholines; 0 / choline transporter; EC 2.7.1.32 / Choline Kinase; EC 3.1.4.- / Phosphoric Diester Hydrolases; EC 3.1.4.- / Type C Phospholipases; EC 3.1.4.2 / glycerophosphocholine phosphodiesterase; EC 3.1.4.3 / phosphatidylcholine-specific phospholipase C; EC 3.1.4.4 / Phospholipase D
  • [Other-IDs] NLM/ NIHMS167358; NLM/ PMC2831129
  •  go-up   go-down


21. Song JW, Cavnar SP, Walker AC, Luker KE, Gupta M, Tung YC, Luker GD, Takayama S: Microfluidic endothelium for studying the intravascular adhesion of metastatic breast cancer cells. PLoS One; 2009 Jun 01;4(6):e5756
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microfluidic endothelium for studying the intravascular adhesion of metastatic breast cancer cells.
  • BACKGROUND: The ability to properly model intravascular steps in metastasis is essential in identifying key physical, cellular, and molecular determinants that can be targeted therapeutically to prevent metastatic disease.
  • METHODOLOGY/PRINCIPAL FINDINGS: We present a microfluidic vasculature system to model interactions between circulating breast cancer cells with microvascular endothelium at potential sites of metastasis.
  • CONCLUSIONS/SIGNIFICANCE: When added from the basal side, CXCL12 acts through receptor CXCR4 on endothelium to promote adhesion of circulating breast cancer cells, independent of CXCL12 receptors CXCR4 or CXCR7 on tumor cells.

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Metastasis Rev. 2007 Dec;26(3-4):401-20 [17717637.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):18886-91 [18006663.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Dec;293(6):C1824-33 [17913848.001]
  • [Cites] Sci Am. 1994 Jul;271(1):58-65 [8066425.001]
  • [Cites] Annu Rev Physiol. 1995;57:827-72 [7778885.001]
  • [Cites] Diabetologia. 1995 Apr;38(4):474-80 [7796989.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1529-37 [9362419.001]
  • [Cites] J Biol Chem. 1998 Feb 13;273(7):4282-7 [9461627.001]
  • [Cites] Nature. 1998 Apr 9;392(6676):565-8 [9560152.001]
  • [Cites] Biophys J. 1998 Aug;75(2):721-33 [9675174.001]
  • [Cites] Front Biosci. 2005 Jan 1;10:379-84 [15574376.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):465-72 [15695388.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):969-73 [15959517.001]
  • [Cites] Anal Chem. 2005 Jul 1;77(13):3993-9 [15987102.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):591-602 [16056258.001]
  • [Cites] Anal Chem. 2005 Sep 1;77(17):5453-9 [16131052.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):610-21 [16467548.001]
  • [Cites] Adv Drug Deliv Rev. 1998 Aug 3;33(1-2):141-64 [10837657.001]
  • [Cites] J Exp Med. 2000 Aug 21;192(4):495-506 [10952719.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4478-85 [11296290.001]
  • [Cites] Nat Immunol. 2001 Jun;2(6):515-22 [11376338.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6540-7 [11522652.001]
  • [Cites] Physiol Genomics. 2001 Oct 10;7(1):55-63 [11595792.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):89-96 [12027580.001]
  • [Cites] FEBS Lett. 2002 Sep 11;527(1-3):255-62 [12220670.001]
  • [Cites] Biorheology. 2003;40(1-3):41-5 [12454385.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):860-7 [12490959.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7328-34 [12499276.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):257-62 [12414810.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2667-74 [12468429.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Jun 15;167(12):1676-86 [12626353.001]
  • [Cites] Nat Med. 2003 Jul;9(7):969-73 [12819780.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6751-7 [14583470.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):13081-6 [14569029.001]
  • [Cites] Trends Pharmacol Sci. 2003 Dec;24(12):640-7 [14654305.001]
  • [Cites] J Exp Med. 2004 Oct 4;200(7):935-9 [15466624.001]
  • [Cites] In Vitro. 1978 Nov;14(11):911-5 [730202.001]
  • [Cites] Endocr Rev. 1988 Feb;9(1):57-66 [3286235.001]
  • [Cites] Am J Physiol. 1990 Mar;258(3 Pt 2):H647-54 [2316679.001]
  • [Cites] Immunol Lett. 1990 Sep;25(4):331-40 [2249877.001]
  • [Cites] J Clin Invest. 1993 Jun;91(6):2609-19 [7685772.001]
  • [Cites] Cancer Lett. 2006 Jul 8;238(1):30-41 [16046252.001]
  • [Cites] Nat Med. 2006 Aug;12(8):895-904 [16892035.001]
  • [Cites] J Exp Med. 2006 Sep 4;203(9):2201-13 [16940167.001]
  • [Cites] Cancer Metastasis Rev. 2006 Dec;25(4):573-87 [17165132.001]
  • [Cites] Anal Chem. 2007 Feb 1;79(3):1126-34 [17263345.001]
  • [Cites] Anal Chem. 2007 May 1;79(9):3504-8 [17388566.001]
  • [Cites] Virology. 2007 Jun 20;363(1):48-58 [17331554.001]
  • [Cites] Annu Rev Biomed Eng. 2007;9:121-67 [17373886.001]
  • [Cites] J Exp Med. 2008 Feb 18;205(2):479-90 [18268039.001]
  • [Cites] Nat Immunol. 2008 Sep;9(9):949-52 [18711431.001]
  • [Cites] Hepatology. 2008 Oct;48(4):1262-72 [18697212.001]
  • [Cites] Blood. 2009 Aug 13;114(7):1331-9 [19141863.001]
  • (PMID = 19484126.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL084370-04; United States / NCI NIH HHS / CA / R01 CA136829; United States / NCI NIH HHS / CA / 1 R01 CA136829; United States / NHLBI NIH HHS / HL / HL084370; United States / NHLBI NIH HHS / HL / R01 HL084370-04; United States / NHLBI NIH HHS / HL / R01 HL084370; United States / NCI NIH HHS / CA / R01 CA136553; United States / NCI NIH HHS / CA / 1 R01 CA136553; United States / NCI NIH HHS / CA / P50 CA093990
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / CXCR4 protein, human; 0 / CXCR7 protein, human; 0 / Chemokine CXCL12; 0 / Receptors, CXCR; 0 / Receptors, CXCR4; EC 1.13.12.- / Luciferases
  • [Other-IDs] NLM/ PMC2684591
  •  go-up   go-down


22. Takano S, Sogawa K, Yoshitomi H, Shida T, Mogushi K, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Ishihara T, Tanaka H, Yokosuka O, Nomura F, Miyazaki M: Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer. Br J Cancer; 2010 Jul 13;103(2):223-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer.
  • BACKGROUND: Intracellular phosphoprotein activation significantly regulates cancer progression.
  • We investigated the serum phosphoprotein profile involved in pancreatic cancer (PaCa) by a novel approach that comprehensively measured serum phosphoproteins levels, and clinically applied this method to the detection of PaCa.
  • METHODS: We analysed the serum phosphoproteins that comprised cancer cellular signal pathways by comparing sera from PaCa patients and benign controls including healthy volunteers (HVs) and pancreatitis patients.
  • For the combination of these serum levels, the area under the receiver-operator characteristics curves was showing significant ability to distinguish between the two populations in independent validation set, and between cancer and non-cancer populations in another validation set.
  • [MeSH-major] Biomarkers, Tumor / blood. Pancreatic Neoplasms / diagnosis. Phosphoproteins / blood. Signal Transduction

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2006 Jan;116(1):26-30 [16395400.001]
  • [Cites] Clin Chem. 2005 Oct;51(10):1933-45 [16099937.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):144-51 [16397036.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):252-8 [16344318.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3360-4 [16585153.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5313-27 [17060676.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1388-94 [18311901.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2841-9 [18413752.001]
  • [Cites] Oncogene. 2008 May 1;27(20):2810-22 [18037960.001]
  • [Cites] J Theor Biol. 2008 Aug 7;253(3):616-22 [18513748.001]
  • [Cites] J Proteome Res. 2008 Sep;7(9):4164-72 [18642943.001]
  • [Cites] Anal Chem. 2009 Jan 1;81(1):94-104 [19117447.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):91-9 [11786403.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):311-26 [14718574.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5882-90 [15313933.001]
  • [Cites] J Clin Chem Clin Biochem. 1987 May;25(5):337-42 [3612033.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4456-62 [15483017.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1110-8 [15709178.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3614-21 [15908672.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4524-31 [16002843.001]
  • [Cites] J Clin Invest. 2006 Jan;116(1):271-84 [16395409.001]
  • (PMID = 20551957.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Phosphoproteins; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.25 / MAP Kinase Kinase Kinases
  • [Other-IDs] NLM/ PMC2906731
  •  go-up   go-down


23. Zhang J, Fu Y, Mei Y, Jiang F, Lakowicz JR: Fluorescent metal nanoshell probe to detect single miRNA in lung cancer cell. Anal Chem; 2010 Jun 1;82(11):4464-71
Hazardous Substances Data Bank. SILVER, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescent metal nanoshell probe to detect single miRNA in lung cancer cell.
  • In this study, fluorescent metal nanoshells were synthesized as a molecular imaging agent to detect single microRNA (miRNA) molecules in the cells positive to lung cancer.
  • It was shown that with stronger emission intensity and longer lifetime, the conjugated metal nanoshells were isolated distinctly from the cellular autofluorescence on the cell images.
  • The results may reflect a genomic signal change and provide a reference to lung cancer early diagnosis as well as other diseases.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Nucleic Acids Res. 2009 Aug;37(14):e100 [19515934.001]
  • [Cites] Anal Biochem. 2005 Feb 15;337(2):171-94 [15691498.001]
  • [Cites] Chem Rev. 2005 Apr;105(4):1547-62 [15826019.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):189-98 [16530703.001]
  • [Cites] Future Oncol. 2005 Feb;1(1):37-50 [16555974.001]
  • [Cites] Oncogene. 2006 Apr 27;25(18):2628-35 [16369491.001]
  • [Cites] J Phys Chem B. 2006 May 11;110(18):8986-91 [16671705.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):18957-62 [17135348.001]
  • [Cites] Methods. 2007 Oct;43(2):105-9 [17889796.001]
  • [Cites] Chem Rev. 2007 Nov;107(11):4672-97 [17944519.001]
  • [Cites] Nano Lett. 2008 Apr;8(4):1179-86 [18341300.001]
  • [Cites] Chem Rev. 2008 Apr;108(4):1171-224 [18361529.001]
  • [Cites] Acc Chem Res. 2008 Dec;41(12):1842-51 [19053240.001]
  • [Cites] Anal Chem. 2009 Feb 1;81(3):883-9 [19113832.001]
  • [Cites] Acc Chem Res. 2000 Jan;33(1):27-36 [10639073.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Anal Biochem. 2001 Nov 1;298(1):1-24 [11673890.001]
  • [Cites] Science. 2001 Oct 26;294(5543):853-8 [11679670.001]
  • [Cites] J Clin Pathol. 2003 Nov;56(11):805-10 [14600122.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):3753-6 [15172979.001]
  • [Cites] Cancer Detect Prev. 2004;28(4):244-51 [15350627.001]
  • [Cites] Curr Med Chem. 2009;16(9):1047-61 [19275611.001]
  • [Cites] Chem Rev. 2009 May;109(5):1948-98 [19301873.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12085-90 [19597153.001]
  • [Cites] Adv Anat Pathol. 1998 Jul;5(4):205-15 [9859753.001]
  • (PMID = 20433154.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R21 EB009509-01A2; United States / NCI NIH HHS / CA / R21 CA135382; None / None / / R21 HG005090-01; United States / NHGRI NIH HHS / HG / HG002655-02; United States / NHGRI NIH HHS / HG / R01 HG002655; United States / NHGRI NIH HHS / HG / R21 HG005090; United States / NCI NIH HHS / CA / CA-137742; United States / NCI NIH HHS / CA / CA-133956; United States / NCI NIH HHS / CA / R03 CA137742-02; United States / NCI NIH HHS / CA / CA137742-02; United States / NIBIB NIH HHS / EB / R21 EB009509; United States / NCI NIH HHS / CA / R03 CA137742; United States / NHGRI NIH HHS / HG / R01 HG002655-02; United States / NIBIB NIH HHS / EB / R01 EB006521; United States / NHGRI NIH HHS / HG / R21 HG005090-01; United States / NIBIB NIH HHS / EB / R01 EB006521-03S1; None / None / / R01 EB006521-03S1; United States / NIBIB NIH HHS / EB / EB006521; United States / NCI NIH HHS / CA / R03 CA133956-02; United States / NCI NIH HHS / CA / CA-135382; United States / NCI NIH HHS / CA / R21 CA135382-02; United States / NIBIB NIH HHS / EB / EB009509; United States / NHGRI NIH HHS / HG / HG005090; United States / NCI NIH HHS / CA / R03 CA133956; United States / NCI NIH HHS / CA / CA135382-02; United States / NHGRI NIH HHS / HG / HG-002655
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 0 / MicroRNAs; 0 / Nucleic Acid Probes; 0 / Organometallic Compounds; 0 / tris(2,2'-bipyridyl)ruthenium(II); 3M4G523W1G / Silver
  • [Other-IDs] NLM/ NIHMS201387; NLM/ PMC2878973
  •  go-up   go-down


24. Ma B, Meyer CR, Pickles MD, Chenevert TL, Bland PH, Galbán CJ, Rehemtulla A, Turnbull LW, Ross BD: Voxel-by-voxel functional diffusion mapping for early evaluation of breast cancer treatment. Inf Process Med Imaging; 2009;21:276-87
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Voxel-by-voxel functional diffusion mapping for early evaluation of breast cancer treatment.
  • The primary goal of this paper is to extend this voxel-by-voxel analysis to assess therapeutic response in breast cancer.
  • Nonlinear registration (with higher degrees of freedom) between the pre- and post-treatment exams is needed to ensure that the corresponding voxels actually contain similar cellular partial contributions due to soft tissue deformations in the breast and compartmental tumor changes during treatment as well.
  • Comparison of the experimental results with pathology shows that ADC changes can be used to evaluate early response of breast cancer treatment.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Dec 20;92(24):2029-36 [11121466.001]
  • [Cites] J Clin Oncol. 2008 Jul 10;26(20):3387-94 [18541899.001]
  • [Cites] Mol Cancer Ther. 2003 Jun;2(6):581-7 [12813138.001]
  • [Cites] Mol Imaging. 2002 Oct;1(4):336-43 [12926229.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):93-100 [9440728.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2672-85 [9704717.001]
  • [Cites] Med Image Anal. 1997 Apr;1(3):195-206 [9873906.001]
  • [Cites] J Clin Oncol. 1999 Feb;17(2):460-9 [10080586.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 12;102(15):5524-9 [15805192.001]
  • [Cites] Breast Cancer Res Treat. 2005 Aug;92(3):231-8 [16155794.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16759-64 [16267128.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4687-92 [16651420.001]
  • [Cites] Magn Reson Imaging. 2006 Sep;24(7):843-7 [16916701.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):443-50 [17255264.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3524-8 [17440058.001]
  • [Cites] Neoplasia. 2007 Dec;9(12):1003-11 [18084607.001]
  • [Cites] Cancer J. 2001 Sep-Oct;7(5):413-20 [11693900.001]
  • (PMID = 19694270.001).
  • [ISSN] 1011-2499
  • [Journal-full-title] Information processing in medical imaging : proceedings of the ... conference
  • [ISO-abbreviation] Inf Process Med Imaging
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 1P01CA85878; United States / NCI NIH HHS / CA / P01 CA087634; United States / NCI NIH HHS / CA / P50CA93990; United States / NCI NIH HHS / CA / 1P01CA87634; United States / NCI NIH HHS / CA / P01 CA087634-05; United States / NCI NIH HHS / CA / CA085878-079002; United States / NCI NIH HHS / CA / CA087634-05; United States / NCI NIH HHS / CA / P01 CA085878-079002; United States / NCI NIH HHS / CA / P01 CA085878; United States / NCI NIH HHS / CA / P50 CA093990
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS166397; NLM/ PMC2804941
  •  go-up   go-down


25. Wang D, Zhao Z, Caperell-Grant A, Yang G, Mok SC, Liu J, Bigsby RM, Xu Y: S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells. Mol Cancer Ther; 2008 Jul;7(7):1993-2002
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells.
  • Epithelial ovarian cancer (EOC) arises from the epithelial layer covering the surface of ovaries and i.p. metastasis is commonly observed at diagnosis.
  • The cellular preexisting stress fibers are also important determinants for the migratory response to S1P.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem J. 2003 Sep 15;374(Pt 3):715-22 [12803545.001]
  • [Cites] Cancer Cell. 2003 Jul;4(1):67-79 [12892714.001]
  • [Cites] J Biochem. 2004 Jun;135(6):673-81 [15213242.001]
  • [Cites] J Cell Biochem. 2004 Aug 1;92(5):913-22 [15258915.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):952-9 [16956652.001]
  • [Cites] Carcinogenesis. 2007 Jan;28(1):174-82 [16829690.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Apr 27;356(1):239-44 [17349972.001]
  • [Cites] Cell Signal. 2007 Jun;19(6):1328-38 [17307336.001]
  • [Cites] Oncogene. 2007 May 3;26(20):2894-901 [17130843.001]
  • [Cites] FEBS Lett. 2007 Sep 18;581(23):4411-6 [17719584.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):298-309 [17716713.001]
  • [Cites] Mol Endocrinol. 2004 Oct;18(10):2570-82 [15243131.001]
  • [Cites] Exp Cell Res. 1995 Jun;218(2):499-507 [7796885.001]
  • [Cites] Biochem J. 1995 Aug 1;309 ( Pt 3):933-40 [7639713.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2234-42 [15781636.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):870-8 [15919106.001]
  • [Cites] Cell Signal. 2006 Mar;18(3):276-84 [16109477.001]
  • [Cites] Biochim Biophys Acta. 2006 Jan;1761(1):43-51 [16510307.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):225-38 [16530706.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3006-14 [16540649.001]
  • [Cites] Oncogene. 2006 Apr 6;25(15):2234-44 [16301993.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7983-90 [16912173.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5370-5 [10537322.001]
  • [Cites] Ann N Y Acad Sci. 2000 Apr;905:242-59 [10818458.001]
  • [Cites] Cell. 2000 Oct 13;103(2):227-38 [11057896.001]
  • [Cites] Mol Cell Biol. 2000 Dec;20(24):9247-61 [11094076.001]
  • [Cites] Curr Opin Genet Dev. 2001 Feb;11(1):41-7 [11163149.001]
  • [Cites] EMBO J. 2001 Feb 15;20(4):755-66 [11179220.001]
  • [Cites] Anal Biochem. 2001 Mar15;290(2):302-13 [11237333.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):255-88 [11294827.001]
  • [Cites] J Biol Chem. 2001 Apr 13;276(15):11830-7 [11150298.001]
  • [Cites] Cell Mol Life Sci. 2001 Mar;58(3):371-92 [11315186.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):291-300 [11330965.001]
  • [Cites] Mol Cell Endocrinol. 2001 May 25;177(1-2):3-11 [11377814.001]
  • [Cites] J Cell Sci. 2001 Aug;114(Pt 15):2713-22 [11683406.001]
  • [Cites] Mol Biol Cell. 2002 Jan;13(1):336-47 [11809843.001]
  • [Cites] J Biochem. 2002 Jun;131(6):767-71 [12038970.001]
  • [Cites] J Biol Chem. 2002 Jun 7;277(23):20903-10 [11925438.001]
  • [Cites] Biochim Biophys Acta. 2002 May 23;1582(1-3):190-6 [12069828.001]
  • [Cites] CA Cancer J Clin. 2002 Jul-Aug;52(4):216-25 [12139233.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6015-20 [12414621.001]
  • [Cites] J Cell Sci. 2002 Dec 1;115(Pt 23):4399-411 [12414987.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(5):1534-45 [12588974.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 May;4(5):397-407 [12728273.001]
  • [Cites] FASEB J. 2003 Aug;17(11):1570-2 [12824286.001]
  • [Cites] J Biol Chem. 2004 Jan 16;279(3):1885-91 [14559914.001]
  • (PMID = 18645009.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA089228-05; United States / NCI NIH HHS / CA / R01 CA095042-06; United States / NCI NIH HHS / CA / R01 CA089228; United States / NCI NIH HHS / CA / R01 CA095042; United States / NCI NIH HHS / CA / CA095042-06; United States / NCI NIH HHS / CA / CA-89228; United States / NCI NIH HHS / CA / CA089228-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lysophospholipids; 0 / Receptors, Lysosphingolipid; 22002-87-5 / lysophosphatidic acid; 26993-30-6 / sphingosine 1-phosphate; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; NGZ37HRE42 / Sphingosine
  • [Other-IDs] NLM/ NIHMS95397; NLM/ PMC2649755
  •  go-up   go-down


26. Cuschieri K, Wentzensen N: Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev; 2008 Oct;17(10):2536-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia.
  • Human papillomavirus (HPV) infection of the genital tract is very common and normally follows a benign clinical course; however, in an unfortunate minority of infected individuals, it can cause disease that sometimes leads to cancer.
  • HPV oncogene expression and evidence of its deregulation can be monitored through direct detection of viral mRNA transcripts or through detection of the cellular protein p16.
  • Currently, there is promising data indicating that HPV mRNA and p16 might play an important role in future cervical cancer screening scenarios.
  • METHODS: PubMed and OVID were interrogated with search terms "HPV RNA;" "HPV mRNA;" "HPV transcript-detection, testing, and methods;" "p16" AND "cervical cancer;" "p16" AND "CIN;" "p16" AND "histology"; "p16" AND "cytology;" "p16;" and "screening. "
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasm Proteins / genetics. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis. RNA, Messenger / analysis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Mass Screening / methods. Precancerous Conditions / diagnosis. Precancerous Conditions / genetics. Precancerous Conditions / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2006 Nov 1;107(9):2307-13 [17029280.001]
  • [Cites] Int J Cancer. 2007 Jan 15;120(2):351-6 [17066437.001]
  • [Cites] Cancer. 2006 Dec 25;108(6):494-500 [17063495.001]
  • [Cites] Cancer. 2007 Feb 25;111(1):58-66 [17186505.001]
  • [Cites] Cancer. 2007 Feb 25;111(1):1-14 [17219448.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2435-8 [17294450.001]
  • [Cites] J Low Genit Tract Dis. 2007 Apr;11(2):98-104 [17415114.001]
  • [Cites] Cancer. 2007 Apr 25;111(2):83-92 [17334990.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1419-24 [17342094.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2599-605 [17473189.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jul;26(3):223-8 [17581402.001]
  • [Cites] Dis Markers. 2007;23(4):213-27 [17627057.001]
  • [Cites] J Med Virol. 2000 Oct;62(2):251-8 [11002256.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):276-84 [11291057.001]
  • [Cites] Mol Diagn. 2001 Jun;6(2):125-30 [11468697.001]
  • [Cites] Oncogene. 2001 Nov 26;20(54):7874-87 [11753670.001]
  • [Cites] Oncogene. 2001 Nov 26;20(54):7888-98 [11753671.001]
  • [Cites] Acta Cytol. 2002 Jan-Feb;46(1):25-9 [11843554.001]
  • [Cites] Ophthalmology. 2002 Mar;109(3):542-7 [11874759.001]
  • [Cites] J Mol Diagn. 2002 May;4(2):97-102 [11986400.001]
  • [Cites] Cancer. 2002 Apr 15;94(8):2199-210 [12001118.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1948-52 [16103442.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):35-40 [15790434.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):578-84 [16139346.001]
  • [Cites] Cancer. 2005 Dec 25;105(6):461-7 [16116604.001]
  • [Cites] Int J Cancer. 2006 Mar 1;118(5):1254-60 [16161049.001]
  • [Cites] Dis Markers. 2007;23(4):273-81 [17627062.001]
  • [Cites] Dis Markers. 2007;23(4):315-30 [17627065.001]
  • [Cites] Int J Cancer. 2004 Mar 1;108(6):871-6 [14712490.001]
  • [Cites] Lancet. 2007 Sep 8;370(9590):890-907 [17826171.001]
  • [Cites] N Engl J Med. 2007 Oct 18;357(16):1579-88 [17942871.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2787-93 [17722112.001]
  • [Cites] Lancet. 2007 Nov 24;370(9601):1764-72 [17919718.001]
  • [Cites] J Clin Pathol. 2008 Jan;61(1):132-7 [17468293.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Jan;6(1):83-95 [18267061.001]
  • [Cites] Am J Surg Pathol. 2008 Apr;32(4):502-12 [18223479.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1389-99 [12409715.001]
  • [Cites] Diagn Cytopathol. 2002 Dec;27(6):365-70 [12451568.001]
  • [Cites] J Clin Pathol. 2003 Jan;56(1):56-63 [12499437.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):187-93 [12548164.001]
  • [Cites] Anal Quant Cytol Histol. 2003 Feb;25(1):8-11 [12630076.001]
  • [Cites] Cancer. 2003 Apr 25;99(2):89-96 [12704688.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):665-73 [12861062.001]
  • [Cites] EMBO J. 2003 Aug 15;22(16):4212-22 [12912919.001]
  • [Cites] Acta Cytol. 2003 Jul-Aug;47(4):616-23 [12920756.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):201-8 [14529682.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):492-6 [15006929.001]
  • [Cites] J Med Virol. 2004 May;73(1):65-70 [15042650.001]
  • [Cites] Acta Cytol. 2004 Mar-Apr;48(2):173-80 [15098536.001]
  • [Cites] Cancer. 2004 Apr 25;102(2):100-8 [15098254.001]
  • [Cites] Cancer. 2004 Jun 25;102(3):142-9 [15211472.001]
  • [Cites] J Clin Microbiol. 2004 Jul;42(7):3176-84 [15243079.001]
  • [Cites] J Med Virol. 2004 Sep;74(1):107-16 [15258976.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1355-60 [15298958.001]
  • [Cites] Diagn Cytopathol. 2004 Oct;31(4):235-42 [15452898.001]
  • [Cites] Hum Pathol. 1992 Feb;23(2):117-28 [1310950.001]
  • [Cites] J Virol Methods. 1991 Dec;35(3):305-13 [1667790.001]
  • [Cites] Int J Cancer. 1992 Jul 9;51(5):831-4 [1319412.001]
  • [Cites] Gynecol Oncol. 1995 Feb;56(2):239-44 [7896192.001]
  • [Cites] J Virol Methods. 1995 Jul;54(1):75-81 [7559859.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4350-4 [8633069.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1741-8 [9846965.001]
  • [Cites] Virchows Arch. 2004 Dec;445(6):610-5 [15378361.001]
  • [Cites] Virchows Arch. 2004 Dec;445(6):616-20 [15480761.001]
  • [Cites] Acta Cytol. 2004 Nov-Dec;48(6):771-82 [15581161.001]
  • [Cites] Diagn Cytopathol. 2005 Jan;32(1):21-4 [15584047.001]
  • [Cites] J Virol Methods. 2005 Mar;124(1-2):211-5 [15664071.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):267-73 [15492761.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):367-72 [15734959.001]
  • [Cites] Int J Cancer. 2005 May 10;114(6):973-6 [15645423.001]
  • [Cites] J Clin Pathol. 2005 May;58(5):525-34 [15858126.001]
  • [Cites] Zentralbl Gynakol. 2005 Jun;127(3):140-5 [15915391.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):908-15 [15943992.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9 [16030305.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):347-53 [16445657.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):791-6 [16287075.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):384-91 [16415792.001]
  • [Cites] Clin Sci (Lond). 2006 May;110(5):525-41 [16597322.001]
  • [Cites] J Clin Microbiol. 2006 Apr;44(4):1310-7 [16597856.001]
  • [Cites] Cancer. 2006 Apr 25;108(2):119-23 [16411180.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):1102-7 [16570279.001]
  • [Cites] Br J Dermatol. 2006 Jul;155(1):129-36 [16792764.001]
  • [Cites] J Clin Pathol. 2006 Aug;59(8):827-30 [16467166.001]
  • [Cites] J Virol Methods. 2006 Oct;137(1):58-62 [16828171.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):62-6 [16494930.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):18-20 [16919709.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1017-28 [16679355.001]
  • (PMID = 18842994.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA CP010124-14
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / P16 protein, human; 0 / RNA, Messenger
  • [Number-of-references] 89
  • [Other-IDs] NLM/ NIHMS212843; NLM/ PMC2900792
  •  go-up   go-down


27. Ma Y, Peng J, Liu W, Zhang P, Huang L, Gao B, Shen T, Zhou Y, Chen H, Chu Z, Zhang M, Qin H: Proteomics identification of desmin as a potential oncofetal diagnostic and prognostic biomarker in colorectal cancer. Mol Cell Proteomics; 2009 Aug;8(8):1878-90
MedlinePlus Health Information. consumer health - Fetal Health and Development.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomics identification of desmin as a potential oncofetal diagnostic and prognostic biomarker in colorectal cancer.
  • Colorectal cancer (CRC) is the third most common cancer worldwide and has poor prognosis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colorectal Neoplasms / diagnosis. Desmin / analysis. Fetal Diseases / diagnosis. Proteomics / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Proteomics. 2008 Oct;7(10):1810-23 [18421009.001]
  • [Cites] J Biol Chem. 2008 Sep 26;283(39):26428-35 [18660501.001]
  • [Cites] Stat Med. 2004 Nov 15;23(21):3319-31 [15490426.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Semin Reprod Endocrinol. 1999;17(3):275-90 [10797946.001]
  • [Cites] Biochim Biophys Acta. 2000 Jul 14;1480(1-2):41-56 [11004554.001]
  • [Cites] N Engl J Med. 2000 Nov 30;343(22):1641-3 [11096175.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1865-78 [11251019.001]
  • [Cites] Clin Chem. 2001 Apr;47(4):624-30 [11274010.001]
  • [Cites] Proteomics. 2002 Jan;2(1):3-10 [11788986.001]
  • [Cites] Nat Rev Drug Discov. 2002 Sep;1(9):683-95 [12209149.001]
  • [Cites] Biochim Biophys Acta. 2002 Dec 19;1573(3):241-6 [12417406.001]
  • [Cites] Nat Rev Cancer. 2002 Dec;2(12):897-909 [12459728.001]
  • [Cites] Cancer Cell. 2003 Jan;3(1):9-15 [12559171.001]
  • [Cites] JAMA. 2003 Mar 12;289(10):1288-96 [12633191.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):193-7 [12634792.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):208-15 [12634794.001]
  • [Cites] Brain. 2004 Apr;127(Pt 4):723-34 [14724127.001]
  • [Cites] Biophys J. 2004 May;86(5):2993-3008 [15111414.001]
  • [Cites] Exp Biol Med (Maywood). 2004 Jun;229(6):439-63 [15169963.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5232-6 [15289328.001]
  • [Cites] J Struct Biol. 2004 Nov;148(2):137-52 [15477095.001]
  • [Cites] Exp Cell Res. 2004 Nov 15;301(1):1-7 [15501438.001]
  • [Cites] J Exp Med. 1965 Sep 1;122(3):467-81 [4953873.001]
  • [Cites] Nature. 1972 Jan 21;235(5334):137-40 [4110535.001]
  • [Cites] Br J Cancer. 1987 Sep;56(3):361-5 [3311112.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2843-77 [8874347.001]
  • [Cites] J Cell Biol. 1997 Oct 6;139(1):129-44 [9314534.001]
  • [Cites] J Exp Med. 1965 Mar 1;121:439-62 [14270243.001]
  • [Cites] Lancet. 2005 Jan 8-14;365(9454):153-65 [15639298.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Clin Colorectal Cancer. 2005 Mar;4(6):396-402 [15807933.001]
  • [Cites] Anal Chem. 2005 May 1;77(9):2745-55 [15859589.001]
  • [Cites] Proteomics. 2005 Jul;5(10):2602-11 [15924290.001]
  • [Cites] Proteomics. 2005 Aug;5(12):3205-13 [16003825.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6550-7 [16166432.001]
  • [Cites] Am J Epidemiol. 2006 Apr 1;163(7):670-5 [16410346.001]
  • [Cites] Mol Cell Proteomics. 2006 Apr;5(4):671-85 [16332732.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1917-9 [16697755.001]
  • [Cites] Mol Cell Proteomics. 2006 Jun;5(6):1119-30 [16554294.001]
  • [Cites] Mol Cell Proteomics. 2006 Sep;5(9):1647-57 [16854844.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1811-8 [16735302.001]
  • [Cites] Mol Cell Proteomics. 2006 Nov;5(11):2092-101 [16893879.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1389-98 [17332280.001]
  • [Cites] Crit Rev Clin Lab Sci. 2007;44(2):151-78 [17364691.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):246-55 [17384580.001]
  • [Cites] Mol Cell Proteomics. 2007 Oct;6(10):1798-808 [17627933.001]
  • [Cites] Mol Cell Proteomics. 2007 Dec;6(12):2150-64 [17848589.001]
  • [Cites] Mol Cell Proteomics. 2008 Mar;7(3):612-25 [18056921.001]
  • [Cites] Proteomics. 2008 May;8(10):2136-49 [18425728.001]
  • [Cites] Mol Cell Proteomics. 2008 Sep;7(9):1639-50 [18458027.001]
  • [Cites] BMC Syst Biol. 2008;2:72 [18691435.001]
  • [Cites] Am J Surg Pathol. 2009 Feb;33(2):218-26 [18830121.001]
  • (PMID = 19460759.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Desmin
  • [Other-IDs] NLM/ PMC2722764
  •  go-up   go-down


28. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A; 2007 Jan 16;104(3):973-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma.
  • Like many epithelial tumors, head and neck squamous cell carcinoma (HNSCC) contains a heterogeneous population of cancer cells.
  • We developed an immunodeficient mouse model to test the tumorigenic potential of different populations of cancer cells derived from primary, unmanipulated human HNSCC samples.
  • We show that a minority population of CD44(+) cancer cells, which typically comprise <10% of the cells in a HNSCC tumor, but not the CD44(-) cancer cells, gave rise to new tumors in vivo.
  • Immunohistochemistry revealed that the CD44(+) cancer cells have a primitive cellular morphology and costain with the basal cell marker Cytokeratin 5/14, whereas the CD44(-) cancer cells resemble differentiated squamous epithelium and express the differentiation marker Involucrin.
  • Taken together, these data demonstrate that cells within the CD44(+) population of human HNSCC possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation and form unique histological microdomains that may aid in cancer diagnosis.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Stem Cells.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Cell Pathol. 1999;19(2):53-8 [10746434.001]
  • [Cites] Genes Dev. 2005 Jun 15;19(12):1432-7 [15964994.001]
  • [Cites] N Engl J Med. 2001 Feb 22;344(8):601-2 [11207357.001]
  • [Cites] Nature. 2001 Nov 1;414(6859):105-11 [11689955.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • [Cites] Gene Ther. 2002 May;9(10):606-12 [12032706.001]
  • [Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]
  • [Cites] Science. 2002 Sep 27;297(5590):2256-9 [12215650.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 [12629218.001]
  • [Cites] Nature. 2003 May 15;423(6937):255-60 [12714970.001]
  • [Cites] Nature. 2003 May 15;423(6937):302-5 [12714971.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Nature. 2003 Oct 30;425(6961):962-7 [14574365.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):175-9 [14722607.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):895-902 [14737120.001]
  • [Cites] N Engl J Med. 2004 Aug 12;351(7):657-67 [15306667.001]
  • [Cites] Cell. 2004 Aug 20;118(4):409-18 [15315754.001]
  • [Cites] Curr Probl Cancer. 2004 Sep-Oct;28(5):265-86 [15375804.001]
  • [Cites] J Pathol. 1985 Apr;145(4):329-40 [3889247.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3290-4 [1373493.001]
  • [Cites] Nature. 1994 Feb 17;367(6464):645-8 [7509044.001]
  • [Cites] Blood. 1997 May 1;89(9):3104-12 [9129012.001]
  • [Cites] Nat Med. 1997 Jul;3(7):730-7 [9212098.001]
  • [Cites] Br J Haematol. 1998 Nov;103(2):335-42 [9827902.001]
  • [Cites] Breast Cancer Res. 2004;6(6):R605-15 [15535842.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] J Exp Med. 2005 May 16;201(10):1579-89 [15897275.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7521-6 [10861016.001]
  • (PMID = 17210912.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA097248; United States / NCI NIH HHS / CA / 5P50 CA 097248
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44
  • [Other-IDs] NLM/ PMC1783424
  •  go-up   go-down


29. Lu ZJ, Song QF, Jiang SS, Song Q, Wang W, Zhang GH, Kan B, Chen LJ, Yang JL, Luo F, Qian ZY, Wei YQ, Gou LT: Identification of ATP synthase beta subunit (ATPB) on the cell surface as a non-small cell lung cancer (NSCLC) associated antigen. BMC Cancer; 2009;9:16
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of ATP synthase beta subunit (ATPB) on the cell surface as a non-small cell lung cancer (NSCLC) associated antigen.
  • BACKGROUND: Antibody-based immunotherapy has achieved some success for cancer.
  • It is essential to identify more immunogenic antigens (especially cellular membrane markers) for tumor diagnosis and therapy.
  • Furthermore, immunohistochemistry showed that the antigen of McAb4E7 mainly aberrantly expressed in tumor cellular membrane in non-small cell lung cancer (NSCLC), but not in small cell lung cancer (SCLC).
  • The rate of ectopic expressed ATPB in the cellular membrane in lung adenocarcinoma, squamous carcinoma and their adjacent nontumourous lung tissues was 71.88%, 66.67% and 25.81% respectively.
  • CONCLUSION: In the present study, we identified that the ectopic ATPB in tumor cellular membrane was the non-small cell lung cancer (NSCLC) associated antigen.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Feb 26;355(9205):735-40 [10703815.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:59 [18983643.001]
  • [Cites] J Mol Biol. 2002 Feb 1;315(5):1063-73 [11827476.001]
  • [Cites] Leukemia. 2002 Apr;16(4):478-85 [11960325.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99 [12953083.001]
  • [Cites] Mol Cancer Res. 2003 Nov;1(13):931-9 [14638865.001]
  • [Cites] Lung Cancer. 2004 Apr;44(1):99-110 [15013588.001]
  • [Cites] Anal Chem. 2004 Apr 1;76(7):1817-23 [15053638.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3679-86 [15150128.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2184-91 [15169807.001]
  • [Cites] BMC Cancer. 2004 Aug 19;4:51 [15318946.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):273-81 [8006588.001]
  • [Cites] Annu Rev Biochem. 1997;66:717-49 [9242922.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2811-6 [10077593.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):875-82 [16424020.001]
  • [Cites] Proteomics. 2006 Jan;6(2):427-37 [16342244.001]
  • [Cites] Proteomics. 2006 Jan;6(2):438-48 [16419015.001]
  • [Cites] Curr Opin Lipidol. 2006 Jun;17(3):279-84 [16680033.001]
  • [Cites] J Bioenerg Biomembr. 2005 Dec;37(6):461-5 [16691484.001]
  • [Cites] Ann Oncol. 2006 Jun;17(6):1007-13 [16533873.001]
  • [Cites] Ann Med. 2006;38(6):429-38 [17008306.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4716-24 [17510399.001]
  • [Cites] Cancer Biother Radiopharm. 2007 Oct;22(5):704-12 [17979573.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Rev Recent Clin Trials. 2008 Sep;3(3):217-27 [18782080.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6656-61 [11381144.001]
  • (PMID = 19144153.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; EC 3.6.3.- / Mitochondrial Proton-Translocating ATPases; EC 3.6.3.14 / ATP5B protein, human
  • [Other-IDs] NLM/ PMC2654462
  •  go-up   go-down


30. Herr JK, Smith JE, Medley CD, Shangguan D, Tan W: Aptamer-conjugated nanoparticles for selective collection and detection of cancer cells. Anal Chem; 2006 May 1;78(9):2918-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aptamer-conjugated nanoparticles for selective collection and detection of cancer cells.
  • Fluorescent imaging and flow cytometry were used for cellular detection to demonstrate the potential application of this method for medical diagnostics.
  • [MeSH-major] Aptamers, Nucleotide / chemistry. Leukemia / diagnosis. Nanoparticles / chemistry

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16642976.001).
  • [ISSN] 0003-2700
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aptamers, Nucleotide; 0 / Fluorescent Dyes
  •  go-up   go-down


31. Kam Y, Guess C, Estrada L, Weidow B, Quaranta V: A novel circular invasion assay mimics in vivo invasive behavior of cancer cell lines and distinguishes single-cell motility in vitro. BMC Cancer; 2008 Jul 14;8:198
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel circular invasion assay mimics in vivo invasive behavior of cancer cell lines and distinguishes single-cell motility in vitro.
  • We examined 3 cancer cell lines (MCF-7, SCOV-3, and MDA-MB-231), each with a different established degree of aggressiveness, to test our assay's ability to detect diverse levels of invasiveness.
  • We also applied the CIA technique to DLD-1 cells in the presence of lysophosphatidic acid (LPA), a bioactive lipid that was recently shown to stimulate cancer cell colony dispersal into single migratory cells, in order to validate our method's ability to detect collective and individual motility.
  • CONCLUSION: Given its ability to both determine pseudo-realistic invasive cell behavior in vitro and capture subtle differences in cell motility, we propose that our CIA method may shed some light on the cellular mechanisms underlying cancer invasion and deserves inclusion in further studies.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 1997 Dec 29;833:137-46 [9616746.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1529-37 [9362419.001]
  • [Cites] Methods Mol Biol. 2005;294:97-105 [15576908.001]
  • [Cites] Trends Cell Biol. 2005 Mar;15(3):138-45 [15752977.001]
  • [Cites] Physiology (Bethesda). 2005 Jun;20:194-200 [15888576.001]
  • [Cites] J Cell Physiol. 2006 Feb;206(2):337-46 [16110477.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 [16493418.001]
  • [Cites] Trends Cell Biol. 2006 May;16(5):250-6 [16580836.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Jul;291(1):C68-75 [16495370.001]
  • [Cites] Cell. 2006 Nov 17;127(4):679-95 [17110329.001]
  • [Cites] Mol Cancer Res. 2006 Dec;4(12):905-13 [17189381.001]
  • [Cites] Nat Protoc. 2007;2(2):329-33 [17406593.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Oct 9;104(41):15988-93 [17905871.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):298-309 [17716713.001]
  • [Cites] Cell Mol Life Sci. 2007 Dec;64(24):3201-18 [17957337.001]
  • [Cites] J Biochem Mol Biol. 2003 Jan 31;36(1):128-37 [12542983.001]
  • [Cites] Cell Mol Life Sci. 2000 Jan 20;57(1):41-64 [10949580.001]
  • [Cites] Anal Biochem. 2001 May 15;292(2):287-95 [11355863.001]
  • [Cites] Science. 2001 Nov 23;294(5547):1708-12 [11721053.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5301-7 [12235000.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):362-74 [12724734.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):921-30 [14737122.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1554-9 [14747654.001]
  • [Cites] Curr Opin Cell Biol. 2004 Feb;16(1):14-23 [15037300.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17634-9 [14744855.001]
  • [Cites] Histochem Cell Biol. 2004 Sep;122(3):183-90 [15258769.001]
  • [Cites] J Natl Cancer Inst. 1977 Jul;59(1):221-6 [327080.001]
  • [Cites] In Vitro. 1978 Nov;14(11):911-5 [730202.001]
  • [Cites] Cancer Res. 1979 Mar;39(3):1020-5 [427742.001]
  • [Cites] Nature. 1980 Mar 6;284(5751):67-8 [6243750.001]
  • [Cites] Cancer Res. 1987 Jun 15;47(12):3239-45 [2438036.001]
  • [Cites] Cancer Res. 1992 Apr 15;52(8):2353-6 [1313744.001]
  • [Cites] Int J Cancer. 1992 Sep 9;52(2):234-40 [1521911.001]
  • [Cites] Cancer. 1993 Jan 15;71(2):315-21 [8422623.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Jun 15;193(2):497-503 [8390242.001]
  • [Cites] J Clin Gastroenterol. 1995;21 Suppl 1:S40-4 [8774989.001]
  • [Cites] Gan To Kagaku Ryoho. 1997 Jan;24(2):187-95 [9030229.001]
  • [Cites] Science. 1997 Apr 4;276(5309):75-81 [9082989.001]
  • [Cites] Clin Exp Metastasis. 1997 May;15(3):272-306 [9174129.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4574-7 [10493510.001]
  • (PMID = 18625060.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA047858; United States / NCI NIH HHS / CA / U54 CA113007; United States / NCI NIH HHS / CA / CA47858-17A2; United States / NCI NIH HHS / CA / U54CA113007-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2491634
  •  go-up   go-down


32. Kim K, Aronov P, Zakharkin SO, Anderson D, Perroud B, Thompson IM, Weiss RH: Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cell Proteomics; 2009 Mar;8(3):558-70
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urine metabolomics analysis for kidney cancer detection and biomarker discovery.

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Biochem. 2002 Feb 15;301(2):298-307 [11814300.001]
  • [Cites] Urol Oncol. 2003 Jan-Feb;21(1):39-44 [12684126.001]
  • [Cites] J Natl Cancer Inst. 2004 May 19;96(10):732-4 [15150298.001]
  • [Cites] Environ Health Perspect. 2004 May;112(7):A396-7 [15159211.001]
  • [Cites] J Am Soc Nephrol. 2005 Apr;16(4):1126-34 [15744000.001]
  • [Cites] BMC Bioinformatics. 2005;6:214 [16124883.001]
  • [Cites] Kidney Int. 2008 Apr;73(7):863-9 [18059454.001]
  • [Cites] Bioinformatics. 2006 Jun 15;22(12):1540-2 [16595560.001]
  • [Cites] Anal Biochem. 2007 Apr 15;363(2):185-95 [17316536.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2007 Nov;16(6):557-64 [18089971.001]
  • [Cites] Clin Chem. 2008 Jan;54(1):53-60 [18024530.001]
  • [Cites] BMC Bioinformatics. 2007;8:412 [17961233.001]
  • [Cites] Kidney Int. 2006 Jan;69(2):224-32 [16408110.001]
  • (PMID = 19008263.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA135401; United States / NCI NIH HHS / CA / U01 CA086402; United States / NCI NIH HHS / CA / 5U01CA86402
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2649817
  •  go-up   go-down


33. Yang X, Lazar IM: MRM screening/biomarker discovery with linear ion trap MS: a library of human cancer-specific peptides. BMC Cancer; 2009 Mar 27;9:96
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRM screening/biomarker discovery with linear ion trap MS: a library of human cancer-specific peptides.
  • BACKGROUND: The discovery of novel protein biomarkers is essential in the clinical setting to enable early disease diagnosis and increase survivability rates.
  • METHODS: MCF-7 breast cancer protein cellular extracts were analyzed by 2D-strong cation exchange (SCX)/reversed phase liquid chromatography (RPLC) separations interfaced to linear ion trap MS detection.
  • RESULTS: In this work, we report on the generation of a library of 9,677 peptides (p < 0.001), representing approximately 1,572 proteins from human breast cancer cells, that can be used for MRM/MS-based biomarker screening studies.
  • The highest-abundance proteins in the cellular extract had a molecular weight (MW)<50,000.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proteomics. 2004 Apr;4(4):1175-86 [15048997.001]
  • [Cites] Proteomics. 2003 Nov;3(11):2208-20 [14595820.001]
  • [Cites] J Proteome Res. 2004 May-Jun;3(3):644-52 [15253448.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):4193-201 [15253663.001]
  • [Cites] J Cell Biol. 1993 Nov;123(3):513-22 [8227122.001]
  • [Cites] Biochem J. 1995 Dec 15;312 ( Pt 3):863-70 [8554532.001]
  • [Cites] Nat Biotechnol. 1999 Oct;17(10):994-9 [10504701.001]
  • [Cites] J Proteome Res. 2004 Nov-Dec;3(6):1234-42 [15595733.001]
  • [Cites] Genome Biol. 2005;6(1):R9 [15642101.001]
  • [Cites] Drug Discov Today. 2005 Mar 1;10(5):353-63 [15749284.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):409-18 [15684407.001]
  • [Cites] J Proteome Res. 2005 Mar-Apr;4(2):377-86 [15822913.001]
  • [Cites] J Proteome Res. 2005 May-Jun;4(3):674-89 [15952714.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jul;6(7):577-83 [15957003.001]
  • [Cites] J Proteome Res. 2005 Jul-Aug;4(4):1427-33 [16083296.001]
  • [Cites] Mol Cell Proteomics. 2005 Aug;4(8):1134-44 [15923565.001]
  • [Cites] Proteomics. 2005 Aug;5(13):3537-45 [16041671.001]
  • [Cites] Mol Cell Proteomics. 2005 Sep;4(9):1265-72 [15958392.001]
  • [Cites] Expert Rev Proteomics. 2006 Feb;3(1):63-74 [16445351.001]
  • [Cites] Mol Cell Proteomics. 2006 Apr;5(4):573-88 [16332733.001]
  • [Cites] Electrophoresis. 2006 Apr;27(8):1609-16 [16550497.001]
  • [Cites] Mol Cell Proteomics. 2006 Jun;5(6):1146-57 [16546994.001]
  • [Cites] Curr Drug Metab. 2006 Jun;7(5):525-39 [16787160.001]
  • [Cites] Brief Funct Genomic Proteomic. 2006 Jun;5(2):112-20 [16772272.001]
  • [Cites] J Biotechnol. 2006 Aug 5;124(4):758-87 [16600411.001]
  • [Cites] Anal Chem. 2006 Aug 15;78(16):5762-7 [16906721.001]
  • [Cites] Rapid Commun Mass Spectrom. 2006;20(20):3039-55 [16986208.001]
  • [Cites] Pac Symp Biocomput. 2006;:219-30 [17094241.001]
  • [Cites] Thromb Haemost. 2007 Jan;97(1):67-80 [17200773.001]
  • [Cites] Nat Biotechnol. 2007 Jan;25(1):125-31 [17195840.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5860-5 [17389395.001]
  • [Cites] Assay Drug Dev Technol. 2007 Apr;5(2):247-64 [17477833.001]
  • [Cites] BMC Bioinformatics. 2007;8 Suppl 7:S23 [18047723.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1529-41 [18311902.001]
  • [Cites] Rapid Commun Mass Spectrom. 2008 May;22(9):1359-66 [18381620.001]
  • [Cites] Brief Funct Genomic Proteomic. 2008 Sep;7(5):340-54 [18579614.001]
  • [Cites] Proteomics. 2001 Oct;1(10):1216-32 [11721634.001]
  • [Cites] Mol Cell Proteomics. 2002 May;1(5):376-86 [12118079.001]
  • [Cites] Genome Res. 2002 Aug;12(8):1231-45 [12176931.001]
  • [Cites] Trends Biotechnol. 2002 Dec;20(12 Suppl):S23-9 [12570156.001]
  • [Cites] J Proteome Res. 2003 Jan-Feb;2(1):43-50 [12643542.001]
  • [Cites] J Proteome Res. 2002 Sep-Oct;1(5):459-65 [12645918.001]
  • [Cites] Mass Spectrom Rev. 2003 May-Jun;22(3):182-94 [12838544.001]
  • [Cites] J Proteome Res. 2004 May-Jun;3(3):350-63 [15253416.001]
  • (PMID = 19327145.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA126669-01A1; United States / NCI NIH HHS / CA / R21 CA126669; United States / NCI NIH HHS / CA / R21 CA126669-01A1; United States / NCI NIH HHS / CA / R21CA126669
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Peptides
  • [Other-IDs] NLM/ PMC2670839
  •  go-up   go-down


34. Santra S, Kaittanis C, Perez JM: Cytochrome C encapsulating theranostic nanoparticles: a novel bifunctional system for targeted delivery of therapeutic membrane-impermeable proteins to tumors and imaging of cancer therapy. Mol Pharm; 2010 Aug 2;7(4):1209-22
MedlinePlus Health Information. consumer health - Diagnostic Imaging.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytochrome C encapsulating theranostic nanoparticles: a novel bifunctional system for targeted delivery of therapeutic membrane-impermeable proteins to tumors and imaging of cancer therapy.
  • In an effort to advance the targeted delivery of a functional apoptosis-initiating protein (cytochrome c) to cancer cells, we formulated theranostic polymeric nanoparticles for the simultaneous encapsulation of cytochrome c and a near-infrared dye to folate-expressing cancer cells.
  • Furthermore, targeted delivery of cytochrome c to folate-receptor-positive cancer cells was achieved via conjugation of folic acid to the nanoparticle's surface, whereas the nanoparticle's theranostic properties were conferred via the coencapsulation of cytochrome c and a fluorescent dye.
  • Considering that these theranostic nanoparticles can carry an endogenous cellular apoptotic initiator (cytochrome c) and a fluorescent tag (ICG) commonly used in the clinic, their use and potential translation into the clinic is anticipated, facilitating the monitoring of tumor regression.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mayo Clin Proc. 2000 Jun;75(6):568-80 [10852417.001]
  • [Cites] Blood. 2000 Jul 1;96(1):307-13 [10891466.001]
  • [Cites] Monaldi Arch Chest Dis. 2000 Jun;55(3):256-66 [10948677.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):770-6 [11048727.001]
  • [Cites] J Control Release. 2001 Jan 29;70(1-2):1-20 [11166403.001]
  • [Cites] J Am Chem Soc. 2001 Aug 22;123(33):8155-6 [11506588.001]
  • [Cites] Curr Pharm Des. 2001 Nov;7(17):1745-80 [11562309.001]
  • [Cites] Bioconjug Chem. 2002 Jul-Aug;13(4):773-85 [12121133.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):750-63 [12360278.001]
  • [Cites] J Am Chem Soc. 2003 May 7;125(18):5316-23 [12720443.001]
  • [Cites] Nat Mater. 2003 Jun;2(6):408-12 [12738959.001]
  • [Cites] Bioconjug Chem. 2003 Sep-Oct;14(5):979-88 [13129402.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7431-57 [14576850.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Mar;45(3):943-7 [14985315.001]
  • [Cites] J Med Chem. 2004 Jul 15;47(15):3887-91 [15239666.001]
  • [Cites] J Clin Invest. 1993 Apr;91(4):1289-94 [7682567.001]
  • [Cites] Cancer Res. 1993 May 15;53(10 Suppl):2368-73 [8485723.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4480-92 [9192772.001]
  • [Cites] Nature. 1998 Jan 29;391(6666):496-9 [9461218.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):4997-5002 [9560217.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1309-12 [9721092.001]
  • [Cites] J Biomed Mater Res. 1998 Nov;42(2):331-8 [9773830.001]
  • [Cites] Anal Biochem. 2005 Mar 15;338(2):284-93 [15745749.001]
  • [Cites] Mol Pharm. 2004 Jan 12;1(1):77-84 [15832503.001]
  • [Cites] J Am Chem Soc. 2005 Apr 27;127(16):6021-6 [15839702.001]
  • [Cites] Mol Pharm. 2005 Sep-Oct;2(5):357-66 [16196488.001]
  • [Cites] Nano Lett. 2005 Dec;5(12):2552-6 [16351214.001]
  • [Cites] Angew Chem Int Ed Engl. 2006 Jan 16;45(4):577-81 [16345107.001]
  • [Cites] J Am Chem Soc. 2007 Jul 18;129(28):8845-9 [17589996.001]
  • [Cites] Nanomedicine (Lond). 2007 Feb;2(1):125-32 [17716198.001]
  • [Cites] Int J Pharm. 2008 Feb 4;348(1-2):137-45 [17714896.001]
  • [Cites] Nucl Med Biol. 2008 Apr;35(3):343-51 [18355690.001]
  • [Cites] Semin Cancer Biol. 2008 Jun;18(3):226-35 [18203619.001]
  • [Cites] J Biol Chem. 2008 May 23;283(21):14490-6 [18375382.001]
  • [Cites] Cell Cycle. 2008 Apr 15;7(8):1036-46 [18414036.001]
  • [Cites] Nat Nanotechnol. 2007 Sep;2(9):535-6 [18654361.001]
  • [Cites] Nat Nanotechnol. 2008 May;3(5):242-4 [18654511.001]
  • [Cites] Angew Chem Int Ed Engl. 2009;48(13):2308-12 [19130532.001]
  • [Cites] Small. 2009 Aug 17;5(16):1862-8 [19384879.001]
  • [Cites] Mol Pharm. 2009 Sep-Oct;6(5):1321-32 [19799463.001]
  • [Cites] Angew Chem Int Ed Engl. 2010;49(2):346-50 [19967688.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):981-6 [20080556.001]
  • [Cites] Nanotechnology. 2010 Mar 12;21(10):105105 [20154383.001]
  • [Cites] Langmuir. 2010 Apr 20;26(8):5364-73 [19957939.001]
  • (PMID = 20536259.001).
  • [ISSN] 1543-8392
  • [Journal-full-title] Molecular pharmaceutics
  • [ISO-abbreviation] Mol. Pharm.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / GM084331-02; United States / NIGMS NIH HHS / GM / R01 GM084331; United States / NIGMS NIH HHS / GM / GM 084331; United States / NIGMS NIH HHS / GM / R01 GM084331-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Polymers; 9007-43-6 / Cytochromes c
  • [Other-IDs] NLM/ NIHMS218357; NLM/ PMC2914151
  •  go-up   go-down


35. Deshou H, Changhua W, Qinyan L, Wei L, Wen F: Clinical utility of Liqui-PREP™ cytology system for primary cervical cancer screening in a large urban hospital setting in China. J Cytol; 2009 Jan;26(1):20-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical utility of Liqui-PREP™ cytology system for primary cervical cancer screening in a large urban hospital setting in China.
  • RESULTS: The LPT cytology system adequately preserved cellular structure for morphologic evaluation.
  • There was a significant difference of the histology/cytology diagnosis concordant rate between that of the CPS and LPT systems [93.6 vs. 78.4%, p=0.001].
  • The significant higher concordant rate was also seen in the low grade intraepithelial lesion (LSIL) (95.4 vs. 78.9%, p=0.001) and in high grade intraepithelial lesion (HSIL) (90.2 vs. 76.1%, p=0.001) cytology diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2008 Apr 25;114(2):83-8 [18300235.001]
  • [Cites] Am J Clin Pathol. 1994 Aug;102(2):182-7 [8042586.001]
  • [Cites] Acta Cytol. 1996 Nov-Dec;40(6):1136-42 [8960019.001]
  • [Cites] Anal Quant Cytol Histol. 1997 Jun;19(3):239-45 [9196807.001]
  • [Cites] Med J Aust. 1997 Nov 3;167(9):466-9 [9397059.001]
  • [Cites] Mod Pathol. 1998 Sep;11(9):837-43 [9758363.001]
  • [Cites] Am J Obstet Gynecol. 2001 Aug;185(2):308-17 [11518884.001]
  • [Cites] Acta Cytol. 2001 Sep-Oct;45(5):709-14 [11575648.001]
  • [Cites] J Fam Pract. 2001 Dec;50(12):1040-6 [11742605.001]
  • [Cites] J Clin Microbiol. 2002 Feb;40(2):641-4 [11825985.001]
  • [Cites] BMJ. 2003 Jan 4;326(7379):41-4 [12511463.001]
  • [Cites] Acta Cytol. 2003 Mar-Apr;47(2):124-8 [12685176.001]
  • [Cites] Diagn Cytopathol. 2007 Aug;35(8):488-92 [17636495.001]
  • [Cites] Ann Intern Med. 2000 May 16;132(10):810-9 [10819705.001]
  • [Cites] Ann Intern Med. 2004 Feb 3;140(3):189-202 [14757617.001]
  • [Cites] Lancet. 2006 Jan 14;367(9505):122-32 [16413876.001]
  • [Cites] Am J Epidemiol. 1995 Apr 1;141(7):680-9 [7702044.001]
  • [Cites] Cancer. 1999 Jun 25;87(3):105-12 [10385440.001]
  • [Cites] JAMA. 1999 Sep 15;282(11):1061-6 [10493205.001]
  • [Cites] J Clin Epidemiol. 1999 Oct;52(10):943-51 [10513757.001]
  • (PMID = 21938144.001).
  • [ISSN] 0970-9371
  • [Journal-full-title] Journal of cytology
  • [ISO-abbreviation] J Cytol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3167985
  • [Keywords] NOTNLM ; Cervical carcinoma / Liqui-PREP™ cytology system / cytology screening / liquid-based cytology
  •  go-up   go-down


36. Bagla N, Schofield JB: Rectosigmoid tumours: should we continue sitting on the fence? Colorectal Dis; 2007 Sep;9(7):606-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rectal cancers are currently defined as tumours below 15 cm from the anal verge on rigid sigmoidoscopy.
  • Clinical trials have used this criterion to select patients for neoadjuvant chemoradiotherapy, but several authors have shown that the distance between the fully peritonealized sigmoid colon and the anal canal varies significantly between individuals.
  • The distinction between rectal and sigmoid colon cancers is of particular importance as treatment protocols for rectal cancer management often involve neoadjuvant treatment in contrast to colonic cancers, so it is vital to get the anatomy right.
  • [MeSH-major] Rectal Neoplasms / diagnosis. Rectal Neoplasms / therapy. Sigmoid Neoplasms / diagnosis. Sigmoid Neoplasms / therapy
  • [MeSH-minor] Anal Canal / anatomy & histology. Anal Canal / pathology. Autopsy. Drug Therapy / methods. Humans. Magnetic Resonance Imaging / methods. Neoadjuvant Therapy / methods. Rectum / anatomy & histology. Rectum / pathology. Sigmoidoscopy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17824977.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Maiese K, Chong ZZ, Hou J, Shang YC: Oxidative stress: Biomarkers and novel therapeutic pathways. Exp Gerontol; 2010 Mar;45(3):217-34
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oxidative stress significantly impacts multiple cellular pathways that can lead to the initiation and progression of varied disorders throughout the body.
  • It therefore becomes imperative to elucidate the components and function of novel therapeutic strategies against oxidative stress to further clinical diagnosis and care.
  • In particular, both the growth factor and cytokine erythropoietin (EPO) and members of the mammalian forkhead transcription factors of the O class (FoxOs) may offer the greatest promise for new treatment regimens since these agents and the cellular pathways they oversee cover a range of critical functions that directly influence progenitor cell development, cell survival and degeneration, metabolism, immune function, and cancer cell invasion.
  • Furthermore, both EPO and FoxOs function not only as therapeutic targets, but also as biomarkers of disease onset and progression, since their cellular pathways are closely linked and overlap with several unique signal transduction pathways.
  • Here we present the exciting as well as complicated role EPO and FoxOs possess to uncover the benefits as well as the risks of these agents for cell biology and clinical care in processes that range from stem cell development to uncontrolled cellular proliferation.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Pediatrics. 2006 Sep;118(3):e635-40 [16908620.001]
  • [Cites] Semin Nephrol. 2006 Jul;26(4):296-306 [16949468.001]
  • [Cites] Circulation. 2006 Sep 19;114(12):1269-76 [16952980.001]
  • [Cites] Eur J Endocrinol. 2006 Oct;155(4):609-14 [16990661.001]
  • [Cites] Int J Cardiol. 2006 Oct 10;112(3):341-7 [16309765.001]
  • [Cites] Diabetes. 2006 Oct;55(10):2863-70 [17003354.001]
  • [Cites] J Am Soc Nephrol. 2006 Oct;17(10):2812-20 [16943306.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4675-6 [17028292.001]
  • [Cites] J Med Genet. 2006 Oct;43(10):798-803 [16723389.001]
  • [Cites] Nephron Exp Nephrol. 2006;104(3):e83-8 [16837817.001]
  • [Cites] Fertil Steril. 2006 Nov;86(5):1518-21 [16979636.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16260-5 [17053067.001]
  • [Cites] Eur J Immunol. 2006 Nov;36(11):2971-80 [17051618.001]
  • [Cites] J Thromb Haemost. 2006 Dec;4(12):2656-63 [16961585.001]
  • [Cites] J Control Release. 2006 Nov10;116(1):28-34 [17081643.001]
  • [Cites] Am Heart J. 2006 Dec;152(6):1096.e9-15 [17161060.001]
  • [Cites] Development. 2007 Jan;134(1):199-209 [17164425.001]
  • [Cites] Prog Retin Eye Res. 2007 Jan;26(1):1-37 [17074526.001]
  • [Cites] J Neurooncol. 2007 Jan;81(1):81-91 [16858513.001]
  • [Cites] Int J Mol Med. 2007 Feb;19(2):263-72 [17203200.001]
  • [Cites] J Virol. 2007 Feb;81(3):1511-6 [17108038.001]
  • [Cites] Cell Signal. 2007 Mar;19(3):634-45 [17045782.001]
  • [Cites] Epilepsia. 2007 Jan;48(1):175-81 [17241225.001]
  • [Cites] Cell. 2007 Jan 26;128(2):309-23 [17254969.001]
  • [Cites] Cell. 2007 Jan 26;128(2):325-39 [17254970.001]
  • [Cites] Neurobiol Dis. 2007 Feb;25(2):412-26 [17166730.001]
  • [Cites] Diabetes. 2007 Feb;56(2):295-303 [17259372.001]
  • [Cites] Diabetes. 2007 Feb;56(2):389-93 [17259383.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1627-35 [17062728.001]
  • [Cites] Cell Death Differ. 2007 Mar;14(3):534-47 [16888645.001]
  • [Cites] Curr Neurovasc Res. 2007 Feb;4(1):63-71 [17311546.001]
  • [Cites] J Cereb Blood Flow Metab. 2007 Mar;27(3):469-76 [16804549.001]
  • [Cites] J Clin Neurosci. 2007 Apr;14(4):364-8 [17236773.001]
  • [Cites] Br J Cancer. 2007 Mar 12;96(5):692-700 [17299396.001]
  • [Cites] Exp Neurol. 2007 Mar;204(1):106-17 [17157835.001]
  • [Cites] Mol Cell Biol. 2007 Apr;27(7):2676-86 [17242183.001]
  • [Cites] Mediators Inflamm. 2006;2006(5):18061 [17392570.001]
  • [Cites] Br J Pharmacol. 2007 Apr;150(7):839-50 [17339844.001]
  • [Cites] Clin Exp Dermatol. 2007 May;32(3):287-90 [17397351.001]
  • [Cites] J Biol Chem. 2007 Apr 13;282(15):11590-601 [17308309.001]
  • [Cites] Cell Signal. 2007 Jun;19(6):1150-62 [17289346.001]
  • [Cites] Eur Surg Res. 2007;39(3):189-97 [17377393.001]
  • [Cites] J Cereb Blood Flow Metab. 2007 May;27(5):1043-54 [17077815.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 May;66(5):389-98 [17483696.001]
  • [Cites] Biochim Biophys Acta. 2007 Apr;1769(4):244-52 [17482685.001]
  • [Cites] Mol Cell Biol. 2007 May;27(10):3839-3854 [17353275.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jun;8(6):440-50 [17522590.001]
  • [Cites] Adv Ther. 2007 Mar-Apr;24(2):346-52 [17565925.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3536-44 [17575216.001]
  • [Cites] Mol Cell Biol. 2007 Jul;27(13):4917-30 [17452451.001]
  • [Cites] J Cereb Blood Flow Metab. 2007 Jul;27(7):1369-76 [17264861.001]
  • [Cites] Apoptosis. 2007 Aug;12(8):1365-75 [17508273.001]
  • [Cites] FASEB J. 2007 Jul;21(9):2226-36 [17369508.001]
  • [Cites] Eur J Neurosci. 2007 Jul;26(1):90-100 [17614942.001]
  • [Cites] J Mol Neurosci. 2005;25(2):183-9 [15784966.001]
  • [Cites] Mol Cancer Res. 2005 Mar;3(3):163-9 [15798096.001]
  • [Cites] J Cell Biol. 2005 Apr 25;169(2):331-9 [15837797.001]
  • [Cites] J Am Coll Cardiol. 2005 May 3;45(9):1406-12 [15862410.001]
  • [Cites] Prog Neurobiol. 2005 Feb;75(3):207-46 [15882775.001]
  • [Cites] Nat Med. 2005 Jun;11(6):666-71 [15895074.001]
  • [Cites] Brain Res Brain Res Rev. 2005 Jul;49(1):1-21 [15960984.001]
  • [Cites] Brain Res. 2005 Jul 19;1050(1-2):15-26 [15979589.001]
  • [Cites] Mol Ther. 2005 Aug;12(2):283-9 [15935736.001]
  • [Cites] Dev Cell. 2005 Aug;9(2):261-70 [16054032.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11278-83 [16076959.001]
  • [Cites] J Biol Chem. 2005 Aug 19;280(33):29864-73 [15961397.001]
  • [Cites] Neurosci Lett. 2005 Oct 14;387(1):5-10 [16054296.001]
  • [Cites] Antioxid Redox Signal. 2005 Sep-Oct;7(9-10):1223-33 [16115027.001]
  • [Cites] Endocrinology. 2005 Oct;146(10):4370-6 [16020479.001]
  • [Cites] Curr Neurovasc Res. 2005 Jan;2(1):55-72 [16181100.001]
  • [Cites] Curr Neurovasc Res. 2005 Jul;2(3):197-211 [16181114.001]
  • [Cites] Curr Neurovasc Res. 2005 Oct;2(4):271-85 [16181120.001]
  • [Cites] Curr Neurovasc Res. 2005 Oct;2(4):331-40 [16181124.001]
  • [Cites] J Biol Chem. 2005 Sep 30;280(39):33558-65 [16061480.001]
  • [Cites] Sports Med. 2005;35(10):831-40 [16180943.001]
  • [Cites] Genes Dev. 2005 Oct 15;19(20):2435-46 [16230533.001]
  • [Cites] Biochem J. 2005 Nov 1;391(Pt 3):623-9 [15987244.001]
  • [Cites] Histol Histopathol. 2006 Jan;21(1):103-24 [16267791.001]
  • [Cites] Curr Neurovasc Res. 2005 Dec;2(5):387-99 [16375720.001]
  • [Cites] Curr Neurovasc Res. 2005 Dec;2(5):425-46 [16375723.001]
  • [Cites] Ann Hematol. 2006 Feb;85(2):79-85 [16132904.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):212-20 [16397234.001]
  • [Cites] Gene Expr Patterns. 2006 Jan;6(2):134-40 [16326148.001]
  • [Cites] J Neurochem. 2006 Feb;96(4):1101-10 [16417583.001]
  • [Cites] J Clin Invest. 2006 Feb;116(2):344-56 [16453021.001]
  • [Cites] Curr Neurovasc Res. 2006 Feb;3(1):25-39 [16472123.001]
  • [Cites] Mutat Res. 2006 Feb 22;594(1-2):155-61 [16289600.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Mar;316(3):999-1005 [16306273.001]
  • [Cites] Nat Genet. 2006 Mar;38(3):320-3 [16415884.001]
  • [Cites] Mol Cancer Ther. 2006 Feb;5(2):356-61 [16505109.001]
  • [Cites] J Neurosci Res. 2006 Mar;83(4):584-93 [16435392.001]
  • [Cites] J Infect Dis. 2006 Apr 1;193(7):987-95 [16518761.001]
  • [Cites] Brain Res Bull. 2006 Mar 31;69(2):117-22 [16533659.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Apr;317(1):109-16 [16357210.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Apr;317(1):68-75 [16377761.001]
  • [Cites] J Am Soc Nephrol. 2006 Apr;17(4):932-42 [16481411.001]
  • [Cites] Obesity (Silver Spring). 2006 Feb;14(2):188-93 [16571842.001]
  • [Cites] Curr Med Chem. 2006;13(8):883-95 [16611073.001]
  • [Cites] Neurosci Lett. 2006 May 1;398(1-2):39-43 [16423457.001]
  • [Cites] PLoS Med. 2006 Apr;3(4):e101 [16478293.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Jun;29(6):902-7 [16675226.001]
  • [Cites] Cancer Immunol Immunother. 2006 Sep;55(9):1064-71 [16328385.001]
  • [Cites] Curr Neurovasc Res. 2006 May;3(2):107-17 [16719794.001]
  • [Cites] Curr Drug Targets Cardiovasc Haematol Disord. 2003 Jun;3(2):141-54 [12769640.001]
  • [Cites] J Am Soc Nephrol. 2006 Jun;17(6):1576-84 [16672321.001]
  • [Cites] Nature. 2006 May 25;441(7092):523-7 [16680151.001]
  • [Cites] Cell. 2006 Jun 2;125(5):987-1001 [16751106.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9051-6 [16757565.001]
  • [Cites] Biochem J. 2006 Jul 15;397(2):233-46 [16792526.001]
  • [Cites] J Cardiovasc Pharmacol. 2006 Jun;47(6):736-41 [16810073.001]
  • [Cites] Diabetes. 2006 Aug;55(8):2231-7 [16873685.001]
  • [Cites] Clin Sci (Lond). 2006 Sep;111(3):171-83 [16901264.001]
  • [Cites] Diabet Med. 2006 Aug;23(8):839-44 [16911620.001]
  • [Cites] Acta Biomed. 2005;76 Suppl 3:49-54 [16915797.001]
  • [Cites] Curr Neurovasc Res. 2006 Aug;3(3):187-201 [16918383.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):875-83 [16861905.001]
  • [Cites] Nat Clin Pract Nephrol. 2005 Dec;1(2):87-97 [16932374.001]
  • [Cites] Diabetes. 2006 Sep;55(9):2649-53 [16936217.001]
  • [Cites] Antioxid Redox Signal. 2004 Apr;6(2):277-87 [15025929.001]
  • [Cites] Science. 2004 Mar 26;303(5666):2011-5 [14976264.001]
  • [Cites] Brain Res. 2004 Mar 12;1000(1-2):19-31 [15053948.001]
  • [Cites] Cell. 2004 Apr 16;117(2):225-37 [15084260.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 May;31(5):733-9 [14985868.001]
  • [Cites] Exp Cell Res. 2004 Jun 10;296(2):196-207 [15149850.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9855-60 [15210945.001]
  • [Cites] J Am Coll Cardiol. 2004 Jul 7;44(1):63-7 [15234408.001]
  • [Cites] J Cereb Blood Flow Metab. 2004 Jul;24(7):728-43 [15241181.001]
  • [Cites] Restor Neurol Neurosci. 2004;22(2):87-104 [15272144.001]
  • [Cites] Restor Neurol Neurosci. 2004;22(2):105-19 [15272145.001]
  • [Cites] J Biol Chem. 2004 Aug 13;279(33):34741-9 [15184386.001]
  • [Cites] Immunity. 2004 Aug;21(2):203-13 [15308101.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2500-20 [15353303.001]
  • [Cites] Cancer Lett. 2004 Oct 28;214(2):171-9 [15363543.001]
  • [Cites] J Biol Chem. 2004 Sep 24;279(39):41114-23 [15272020.001]
  • [Cites] J Exp Med. 2004 Oct 18;200(8):1051-62 [15492127.001]
  • [Cites] Trends Pharmacol Sci. 2004 Nov;25(11):577-83 [15491780.001]
  • [Cites] Blood. 1974 Jul;44(1):77-85 [4834517.001]
  • [Cites] Nature. 1985 Feb 28-Mar 6;313(6005):806-10 [3838366.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Nov;82(22):7580-4 [3865178.001]
  • [Cites] Biochemistry. 1988 Jul 26;27(15):5646-54 [3179269.001]
  • [Cites] Cell. 1989 May 19;57(4):645-58 [2566386.001]
  • [Cites] Eur J Biochem. 1990 Mar 10;188(2):405-11 [2156701.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(15):5978-82 [2165612.001]
  • [Cites] Kidney Int. 1990 Nov;38(5):969-75 [2266682.001]
  • [Cites] Blood. 1991 Feb 1;77(3):419-34 [1991159.001]
  • [Cites] Am J Kidney Dis. 1991 Oct;18(4 Suppl 1):14-9 [1928074.001]
  • [Cites] Am Heart J. 1992 Aug;124(2):424-7 [1386184.001]
  • [Cites] Nature. 1993 Jul 29;364(6436):412-20 [8332212.001]
  • [Cites] J Neurosci Res. 1993 Sep 1;36(1):77-87 [8230323.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3974-8 [8171022.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Oct;11(2):79-84 [7529552.001]
  • [Cites] J Cereb Blood Flow Metab. 1995 May;15(3):440-9 [7714002.001]
  • [Cites] Eur J Biochem. 1996 Jul 15;239(2):494-500 [8706759.001]
  • [Cites] J Neurochem. 1997 Feb;68(2):710-4 [9003060.001]
  • [Cites] Circulation. 1997 May 6;95(9):2303-11 [9142009.001]
  • [Cites] J Cereb Blood Flow Metab. 1997 May;17(5):560-6 [9183294.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3714-9 [9345057.001]
  • [Cites] Free Radic Res. 1997 Sep;27(3):311-23 [9350435.001]
  • [Cites] Nature. 1997 Oct 30;389(6654):994-9 [9353126.001]
  • [Cites] Science. 1997 Nov 14;278(5341):1319-22 [9360933.001]
  • [Cites] Biochemistry. 1998 Apr 28;37(17):6179-87 [9558357.001]
  • [Cites] Arch Biochem Biophys. 1998 May 15;353(2):312-21 [9606965.001]
  • [Cites] J Biol Chem. 1998 Sep 25;273(39):25381-7 [9738005.001]
  • [Cites] Exp Neurol. 1999 Jan;155(1):79-94 [9918707.001]
  • [Cites] Exp Cell Res. 1999 Feb 1;246(2):290-300 [9925743.001]
  • [Cites] Cell Biochem Biophys. 1999;30(1):153-66 [10099826.001]
  • [Cites] J Histochem Cytochem. 1999 May;47(5):661-72 [10219058.001]
  • [Cites] J Biol Chem. 1999 Jun 4;274(23):15982-5 [10347145.001]
  • [Cites] J Biol Chem. 1999 Jun 11;274(24):17184-92 [10358076.001]
  • [Cites] J Neurobiol. 1999 Aug;40(2):171-84 [10413448.001]
  • [Cites] Blood. 1950 Apr;5(4):372-80 [15411424.001]
  • [Cites] Science. 2004 Nov 12;306(5699):1190-4 [15498972.001]
  • [Cites] Acta Med Okayama. 2004 Aug;58(4):197-205 [15551757.001]
  • [Cites] Diabetologia. 2004 Oct;47(10):1695-703 [15502930.001]
  • [Cites] Histol Histopathol. 2005 Jan;20(1):299-315 [15578447.001]
  • [Cites] BMC Neurosci. 2004 Nov 29;5:48 [15569384.001]
  • [Cites] Neurosignals. 2004 Nov-Dec;13(6):265-89 [15627815.001]
  • [Cites] JAMA. 2005 Jan 5;293(1):90-5 [15632341.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):284-90 [15665305.001]
  • [Cites] Curr Opin Neurobiol. 2005 Feb;15(1):101-7 [15721751.001]
  • [Cites] Arch Intern Med. 2005 Feb 28;165(4):466-9 [15738380.001]
  • [Cites] Arthritis Rheum. 2005 Mar;52(3):940-50 [15751086.001]
  • [Cites] Br J Ophthalmol. 2009 Dec;93(12):1667-71 [19692373.001]
  • [Cites] J Med Chem. 2009 Dec 10;52(23):7883-6 [19813747.001]
  • [Cites] Oxid Med Cell Longev. 2009 Jan-Mar;2(1):1 [20046637.001]
  • [Cites] Oxid Med Cell Longev. 2009 Jan-Mar;2(1):19-25 [20046641.001]
  • [Cites] Oxid Med Cell Longev. 2009 Jan-Mar;2(1):43-51 [20046644.001]
  • [Cites] Adv Exp Med Biol. 2009;665:242-60 [20429429.001]
  • [Cites] Oxid Med Cell Longev. 2009 Jul-Aug;2(3):119-29 [20592766.001]
  • [Cites] Oxid Med Cell Longev. 2008 Oct-Dec;1(1):1-14 [19750024.001]
  • [Cites] Oxid Med Cell Longev. 2009 Nov-Dec;2(5):279-89 [20716915.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 1):1125-31 [18086112.001]
  • [Cites] Neurobiol Aging. 1999 Nov-Dec;20(6):581-9 [10674423.001]
  • [Cites] J Neurosci Res. 2000 Feb 15;59(4):568-80 [10679797.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):142-6 [10702024.001]
  • [Cites] J Neurosci Res. 1999 Feb 15;55(4):472-85 [10723057.001]
  • [Cites] J Autoimmun. 2000 May;14(3):221-9 [10756084.001]
  • [Cites] Cell Mol Neurobiol. 2000 Jun;20(3):383-400 [10789835.001]
  • [Cites] Int J Dev Neurosci. 2000 Jul-Aug;18(4-5):423-31 [10817926.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2000 Jun;278(6):E1038-44 [10827006.001]
  • [Cites] J Cereb Blood Flow Metab. 2000 Sep;20(9):1380-91 [10994860.001]
  • [Cites] J Neurosci Res. 2000 Oct 15;62(2):257-72 [11020218.001]
  • [Cites] J Biochem. 2000 Nov;128(5):731-7 [11056384.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):39754-61 [10995753.001]
  • [Cites] Biochem J. 2000 Jul 15;349(Pt 2):629-34 [10880363.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2000 Dec;279(6):E1242-8 [11093910.001]
  • [Cites] J Cereb Blood Flow Metab. 2001 Mar;21(3):262-75 [11295881.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Apr;60(4):386-92 [11305874.001]
  • [Cites] Histol Histopathol. 2001 Apr;16(2):633-44 [11332719.001]
  • [Cites] Mamm Genome. 2001 Jun;12(6):416-25 [11353388.001]
  • [Cites] J Biol Chem. 2001 Jan 26;276(4):2571-5 [11073947.001]
  • [Cites] J Am Coll Cardiol. 2001 Jun 1;37(7):1775-80 [11401110.001]
  • [Cites] Neurosci Lett. 2001 Sep 14;310(2-3):173-7 [11585595.001]
  • [Cites] Pediatr Res. 2002 Apr;51(4):472-8 [11919332.001]
  • [Cites] J Cereb Blood Flow Metab. 2002 May;22(5):503-14 [11973422.001]
  • [Cites] J Cell Mol Med. 2002 Jan-Mar;6(1):82-92 [12003671.001]
  • [Cites] J Vasc Res. 2002 Mar-Apr;39(2):131-47 [12011585.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):26729-32 [12048180.001]
  • [Cites] Eur J Neurosci. 2002 Aug;16(4):584-92 [12270034.001]
  • [Cites] Microsc Res Tech. 2002 Nov 15;59(4):331-4 [12424797.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47928-37 [12351634.001]
  • [Cites] Circulation. 2002 Dec 3;106(23):2973-9 [12460881.001]
  • [Cites] Histol Histopathol. 2003 Jan;18(1):173-89 [12507297.001]
  • [Cites] Exp Biol Med (Maywood). 2003 Jan;228(1):1-14 [12524467.001]
  • [Cites] Circulation. 2003 Jan 21;107(2):294-9 [12538431.001]
  • [Cites] J Neurosci Res. 2003 Mar 1;71(5):659-69 [12584724.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):5871-82 [12488318.001]
  • [Cites] J Hematother Stem Cell Res. 2002 Dec;11(6):863-71 [12590701.001]
  • [Cites] J Cereb Blood Flow Metab. 2003 Mar;23(3):320-30 [12621307.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12361-6 [12517744.001]
  • [Cites] Br J Pharmacol. 2003 Mar;138(6):1107-18 [12684267.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):13898-904 [12578834.001]
  • [Cites] Transplantation. 2003 Apr 27;75(8):1356-60 [12717230.001]
  • [Cites] Arch Toxicol. 2003 May;77(5):267-73 [12734640.001]
  • [Cites] Trends Pharmacol Sci. 2003 May;24(5):228-32 [12767721.001]
  • [Cites] Science. 2003 Jul 11;301(5630):215-8 [12855809.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1340-6 [12702503.001]
  • [Cites] Circulation. 2003 Aug 5;108(5):616-22 [12835226.001]
  • [Cites] Mol Pharmacol. 2003 Sep;64(3):557-69 [12920191.001]
  • [Cites] J Neurosci Res. 2003 Oct 1;74(1):37-51 [13130504.001]
  • [Cites] Cell Mol Neurobiol. 2003 Oct;23(4-5):561-78 [14514016.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11285-90 [13679577.001]
  • [Cites] Am J Obstet Gynecol. 2003 Dec;189(6):1764-70 [14710111.001]
  • [Cites] Arch Intern Med. 2004 Feb 9;164(3):262-76 [14769622.001]
  • [Cites] Clin Nephrol. 2004 Feb;61(2):127-9 [14989632.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2975-80 [14978268.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2008 Jul-Aug;56(4):257-66 [18726147.001]
  • [Cites] Hear Res. 2008 Sep;243(1-2):121-6 [18672044.001]
  • [Cites] Carcinogenesis. 2008 Sep;29(9):1837-44 [18390843.001]
  • [Cites] J Neurosci Res. 2008 Oct;86(13):3018-27 [18512763.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2787-94 [18628488.001]
  • [Cites] J Ocul Pharmacol Ther. 2008 Oct;24(5):453-9 [18788995.001]
  • [Cites] J Biol Chem. 2008 Oct 10;283(41):27810-9 [18678867.001]
  • [Cites] J Neurochem. 2008 Oct;107(1):127-40 [18665912.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Nov 14;376(2):251-5 [18774777.001]
  • [Cites] Cell Cycle. 2008 Oct;7(20):3162-70 [18927507.001]
  • [Cites] Surg Neurol. 2008 Nov;70(5):498-502 [18291472.001]
  • [Cites] Epilepsia. 2008 Oct;49(10):1723-32 [18479396.001]
  • [Cites] Neurosci Lett. 2008 Dec 31;448(3):245-9 [18973793.001]
  • [Cites] Perfusion. 2008 May;23(3):187-92 [19029270.001]
  • [Cites] J Physiol. 2008 Dec 1;586(Pt 23):5757-69 [18845609.001]
  • [Cites] Crit Care. 2008;12(5):227 [18983707.001]
  • [Cites] Neuroepidemiology. 2009;32(1):40-6 [19001795.001]
  • [Cites] Ann Neurol. 2008 Nov;64(5):523-34 [19067366.001]
  • [Cites] J Neurosci Res. 2009 Jan;87(1):150-63 [18711747.001]
  • [Cites] Cell Mol Life Sci. 2008 Dec;65(24):4000-18 [18820996.001]
  • [Cites] Clin Sci (Lond). 2009 Feb;116(3):191-203 [19118491.001]
  • [Cites] J Ren Nutr. 2009 Jan;19(1):20-4 [19121765.001]
  • [Cites] Eur J Pharmacol. 2009 Jan 14;602(2-3):406-12 [19061883.001]
  • [Cites] Trends Parasitol. 2009 Jan;25(1):30-6 [19008152.001]
  • [Cites] Cell Cycle. 2008 Dec 15;7(24):3829-39 [19066462.001]
  • [Cites] J Biol Chem. 2009 Jan 23;284(4):2001-11 [19047055.001]
  • [Cites] Exp Cell Res. 2009 Feb 1;315(3):419-31 [19056379.001]
  • [Cites] Eur J Pharmacol. 2009 Jan 28;603(1-3):50-5 [19105952.001]
  • [Cites] Life Sci. 2009 Feb 13;84(7-8):205-10 [19101571.001]
  • [Cites] Brain Behav Immun. 2009 Feb;23(2):193-203 [18835350.001]
  • [Cites] FASEB J. 2009 Feb;23(2):351-61 [18827024.001]
  • [Cites] Acta Pharmacol Sin. 2009 Feb;30(2):202-8 [19122671.001]
  • [Cites] Pharmacol Biochem Behav. 2009 Apr;92(2):251-9 [19138703.001]
  • [Cites] Neonatology. 2009;95(2):105-16 [18776724.001]
  • [Cites] Placenta. 2009 Mar;30(3):256-62 [19150739.001]
  • [Cites] Crit Care Med. 2009 Mar;37(3):889-98 [19237893.001]
  • [Cites] Adv Exp Med Biol. 2009;643:359-68 [19239167.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1329-35 [18952918.001]
  • [Cites] J Urol. 2009 Mar;181(3):1434-43 [19157461.001]
  • [Cites] Mech Ageing Dev. 2009 Apr;130(4):253-61 [19162061.001]
  • [Cites] Trends Cell Biol. 2009 Mar;19(3):119-29 [19208479.001]
  • [Cites] Immunol Rev. 2009 Mar;228(1):149-69 [19290926.001]
  • [Cites] Cell Calcium. 2009 Apr;45(4):358-68 [19201465.001]
  • [Cites] Chin Med J (Engl). 2009 Mar 5;122(5):566-70 [19323909.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Apr 17;381(4):491-5 [19233143.001]
  • [Cites] Hellenic J Cardiol. 2009 Mar-Apr;50(2):127-32 [19329414.001]
  • [Cites] J Neurochem. 2009 Apr;109(2):360-70 [19220704.001]
  • [Cites] Free Radic Biol Med. 2009 Apr 15;46(8):1032-41 [19136057.001]
  • [Cites] Med Res Rev. 2009 May;29(3):395-418 [18985696.001]
  • [Cites] Glia. 2009 May;57(7):734-43 [18985732.001]
  • [Cites] Curr Neurovasc Res. 2009 Feb;6(1):20-31 [19355923.001]
  • [Cites] J Comp Neurol. 2009 Jun 1;514(4):403-14 [19330822.001]
  • [Cites] Brain. 2009 Apr;132(Pt 4):879-88 [19244253.001]
  • [Cites] Brain Res. 2009 Mar 31;1263:23-32 [19368821.001]
  • [Cites] Stem Cells Dev. 2009 Apr;18(3):411-21 [18590375.001]
  • [Cites] J Neurochem. 2009 May;109(4):1157-67 [19302476.001]
  • [Cites] J Cell Mol Med. 2009 Apr;13(4):701-11 [18410524.001]
  • [Cites] Molecules. 2009;14(9):3446-85 [19783937.001]
  • [Cites] Cell Stem Cell. 2009 Oct 2;5(4):396-408 [19796620.001]
  • [Cites] ScientificWorldJournal. 2009;9:1072-104 [19802503.001]
  • [Cites] J Am Med Dir Assoc. 2009 Nov;10(9):607-16 [19883882.001]
  • [Cites] Curr Neurovasc Res. 2009 Nov;6(4):223-38 [19807657.001]
  • [Cites] Lab Invest. 2009 Dec;89(12):1397-409 [19841616.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20097-102 [19897733.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9018-23 [17909003.001]
  • [Cites] Antioxid Redox Signal. 2007 Oct;9(10):1659-75 [17867931.001]
  • [Cites] Cancer Sci. 2007 Dec;98(12):1949-58 [17900262.001]
  • [Cites] Neurol Clin. 2007 Nov;25(4):891-924, vii [17964020.001]
  • [Cites] Oncogene. 2007 Nov 1;26(50):7081-91 [17496928.001]
  • [Cites] Genes Dev. 2007 Nov 1;21(21):2775-87 [17974917.001]
  • [Cites] J Clin Invest. 2007 Nov;117(11):3211-23 [17965779.001]
  • [Cites] Virology. 2007 Nov 25;368(2):249-61 [17669459.001]
  • [Cites] Cancer Gene Ther. 2007 Dec;14(12):945-52 [17885675.001]
  • [Cites] Cardiology. 2007;108(4):228-36 [17106196.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Dec;323(3):759-62 [17717190.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2007 Dec;245(12):1859-67 [17828550.001]
  • [Cites] J Cell Physiol. 2008 Feb;214(2):491-503 [17960565.001]
  • [Cites] Mol Med. 2007 Nov-Dec;13(11-12):561-6 [17873969.001]
  • [Cites] Curr Neurovasc Res. 2007 Nov;4(4):295-302 [18045156.001]
  • [Cites] Nucleic Acids Res. 2007;35(20):6984-94 [17940099.001]
  • [Cites] Oncogene. 2007 Dec 6;26(55):7647-55 [17563745.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1785(1):63-84 [17980712.001]
  • [Cites] World J Gastroenterol. 2007 Dec 14;13(46):6172-82 [18069756.001]
  • [Cites] J Pharmacol Exp Ther. 2008 Jan;324(1):160-9 [17928571.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20517-22 [18077353.001]
  • [Cites] Mol Cell Endocrinol. 2008 Jan 16;281(1-2):47-55 [18035477.001]
  • [Cites] Mol Cell. 2007 Dec 28;28(6):941-53 [18158893.001]
  • [Cites] Cell Death Differ. 2008 Feb;15(2):299-311 [17992191.001]
  • [Cites] Resuscitation. 2008 Mar;76(3):397-404 [18037223.001]
  • [Cites] Rejuvenation Res. 2008 Feb;11(1):139-50 [18069916.001]
  • [Cites] Gynecol Oncol. 2008 Mar;108(3):609-18 [18234299.001]
  • [Cites] Diabetes. 2008 Mar;57(3):563-76 [18162510.001]
  • [Cites] Clin Dev Immunol. 2007;2007:89195 [18317534.001]
  • [Cites] Br J Haematol. 2008 Apr;141(1):14-31 [18324962.001]
  • [Cites] Cell Signal. 2008 May;20(5):892-906 [18276109.001]
  • [Cites] Expert Rev Cardiovasc Ther. 2008 Mar;6(3):281-4 [18327989.001]
  • [Cites] Proteomics. 2008 Mar;8(6):1237-47 [18338825.001]
  • [Cites] Cytokine Growth Factor Rev. 2008 Apr;19(2):145-55 [18299246.001]
  • [Cites] Endocrinology. 2008 Apr;149(4):1942-50 [18096667.001]
  • [Cites] Cell Stem Cell. 2007 Jun 7;1(1):101-12 [18371339.001]
  • [Cites] Circ Res. 2008 Mar 28;102(6):686-94 [18218983.001]
  • [Cites] J Biol Chem. 2008 Apr 4;283(14):9224-30 [18250171.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):152-9 [17967510.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):3001-9 [18413770.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R21 [18312651.001]
  • [Cites] Adv Exp Med Biol. 2008;615:13-23 [18437889.001]
  • [Cites] Pharmacol Ther. 2008 Apr;118(1):58-81 [18313758.001]
  • [Cites] Acta Trop. 2008 May;106(2):104-8 [18359468.001]
  • [Cites] BJU Int. 2008 Jun;101(11):1454-60 [18336616.001]
  • [Cites] Biomed Pharmacother. 2008 Apr-May;62(4):218-32 [18342481.001]
  • [Cites] Trends Mol Med. 2008 May;14(5):219-27 [18403263.001]
  • [Cites] Curr Neurovasc Res. 2008 May;5(2):125-42 [18473829.001]
  • [Cites] N Engl J Med. 2008 May 15;358(20):2107-16 [18480203.001]
  • [Cites] Prog Neurobiol. 2008 Jun;85(2):194-213 [18396368.001]
  • [Cites] Brain Res Bull. 2008 Jul 1;76(4):424-38 [18502319.001]
  • [Cites] Neuropsychopharmacology. 2008 Jul;33(8):1942-51 [17805306.001]
  • [Cites] Eur J Pharmacol. 2008 Jul 7;588(2-3):178-88 [18502414.001]
  • [Cites] Expert Opin Ther Targets. 2008 Jul;12(7):905-16 [18554157.001]
  • [Cites] Biochim Biophys Acta. 2008 Jul-Aug;1777(7-8):834-46 [18452700.001]
  • [Cites] Neurochem Res. 2008 Aug;33(8):1599-609 [18461448.001]
  • [Cites] Neuroscience. 2008 Jul 17;154(4):1458-66 [18555616.001]
  • [Cites] J Nephrol. 2008 Jul-Aug;21(4):543-9 [18651544.001]
  • [Cites] Oncogene. 2008 Jul 24;27(32):4422-33 [18391984.001]
  • [Cites] Oncogene. 2008 Aug 7;27(34):4733-44 [18408765.001]
  • [Cites] Curr Neurovasc Res. 2008 Aug;5(3):159-70 [18691073.001]
  • [Cites] J Mol Cell Cardiol. 2008 Aug;45(2):250-60 [18586265.001]
  • [Cites] J Immunol. 2008 Sep 1;181(5):2980-9 [18713968.001]
  • [Cites] Mol Cancer Ther. 2008 Aug;7(8):2263-71 [18687658.001]
  • [Cites] Anal Bioanal Chem. 2007 Aug;388(7):1521-9 [17516052.001]
  • [Cites] Cancer Lett. 2007 Aug 18;253(2):170-9 [17462819.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H274-83 [17337594.001]
  • [Cites] Curr Med Chem. 2007;14(16):1729-38 [17627510.001]
  • [Cites] J Biol Chem. 2007 Jul 20;282(29):21542-50 [17522055.001]
  • [Cites] Semin Hematol. 2007 Jul;44(3):212-7 [17631185.001]
  • [Cites] Mod Pathol. 2007 Aug;20(8):835-42 [17491598.001]
  • [Cites] Antioxid Redox Signal. 2007 Aug;9(8):1059-96 [17571960.001]
  • [Cites] Free Radic Biol Med. 2007 Aug 15;43(4):477-503 [17640558.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Aug;322(2):789-94 [17470644.001]
  • [Cites] Histol Histopathol. 2007 Nov;22(11):1251-67 [17647198.001]
  • [Cites] BMC Genet. 2007;8:43 [17601350.001]
  • [Cites] Arthritis Rheum. 2007 Jul;56(7):2180-91 [17599731.001]
  • [Cites] Curr Neurovasc Res. 2007 Aug;4(3):194-204 [17691973.001]
  • [Cites] JAMA. 2007 Aug 15;298(7):765-75 [17699010.001]
  • [Cites] N Engl J Med. 2007 Aug 16;357(7):673-81 [17699817.001]
  • [Cites] Biomed Pharmacother. 2007 Aug;61(7):390-9 [17178208.001]
  • [Cites] J Biol Chem. 2007 Aug 24;282(34):24574-82 [17604275.001]
  • [Cites] Dev Neurosci. 2007;29(4-5):321-30 [17762200.001]
  • [Cites] J Cell Physiol. 2007 Nov;213(2):434-9 [17520690.001]
  • [Cites] N Engl J Med. 2007 Sep 6;357(10):965-76 [17804841.001]
  • [Cites] Br J Pharmacol. 2007 Sep;152(2):230-9 [17641676.001]
  • [Cites] J Glaucoma. 2007 Sep;16(6):567-71 [17873720.001]
  • [Cites] J Cardiovasc Pharmacol Ther. 2007 Sep;12(3):237-47 [17875952.001]
  • [Cites] Mol Ther. 2007 Oct;15(10):1751-66 [17680029.001]
  • [Cites] Curr Med Chem. 2007;14(21):2278-87 [17896976.001]
  • [Cites] Pharmacol Rep. 2007 Jul-Aug;59(4):393-401 [17901567.001]
  • (PMID = 20064603.001).
  • [ISSN] 1873-6815
  • [Journal-full-title] Experimental gerontology
  • [ISO-abbreviation] Exp. Gerontol.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES06639; United States / NINDS NIH HHS / NS / R01 NS053946-01A2; United States / NINDS NIH HHS / NS / R01 NS053946-03S1; United States / NINDS NIH HHS / NS / R01 NS053946-03; United States / NIEHS NIH HHS / ES / P30 ES006639; United States / NINDS NIH HHS / NS / R01 NS053946-02; United States / NINDS NIH HHS / NS / R01 NS053946
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / FOXO1 protein, human; 0 / FOXO3 protein, human; 0 / Forkhead Transcription Factors; 0 / Receptors, Erythropoietin; 11096-26-7 / Erythropoietin
  • [Number-of-references] 407
  • [Other-IDs] NLM/ NIHMS169922; NLM/ PMC2827206
  •  go-up   go-down


38. Shim MS, Kim CS, Ahn YC, Chen Z, Kwon YJ: Combined multimodal optical imaging and targeted gene silencing using stimuli-transforming nanotheragnostics. J Am Chem Soc; 2010 Jun 23;132(24):8316-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Combined diagnosis and therapy for cancer has been of great interest in medicine.
  • Simultaneously, Au NP dissociation exposes the siRNA-carrying polyplex with elevated surface charge and results in enhanced cellular uptake and transfection (stimuli-enhanced therapy).
  • In this study, the feasibility of achieving combined diagnosis and therapy for cancer (theragnostics) is demonstrated by (1) microscopic and spectrophotometric confirmation of acid-transformation of the nanoparticles, (2) reduced scattering intensity and increased variance of Doppler frequency in an acidic pH upon the nanoparticle's transformation, and (3) simultaneous optical signal changes and gene silencing in vitro under a tumor pH-mimicking condition.
  • This novel type of stimuli-responsive nanotheragnostics will provide a new paradigm for pinpointed, multimodal, and combined imaging and therapy for cancer.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2003 May 1;63(9):1999-2004 [12727808.001]
  • [Cites] Adv Enzyme Regul. 1999;39:13-30 [10470364.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13549-54 [14597719.001]
  • [Cites] J Biomed Opt. 2004 Jan-Feb;9(1):47-74 [14715057.001]
  • [Cites] Clin Immunol. 2000 Sep;96(3):252-63 [10964544.001]
  • [Cites] Biotechnol Bioeng. 2001 Feb 5;72(3):331-8 [11135203.001]
  • [Cites] Adv Drug Deliv Rev. 2003 Feb 24;55(3):403-19 [12628324.001]
  • [Cites] Technol Cancer Res Treat. 2004 Feb;3(1):33-40 [14750891.001]
  • [Cites] Int J Hyperthermia. 1995 Mar-Apr;11(2):211-6 [7790735.001]
  • [Cites] Nano Lett. 2005 Apr;5(4):709-11 [15826113.001]
  • [Cites] Nat Biotechnol. 2005 Jun;23(6):741-5 [15908940.001]
  • [Cites] Colloids Surf B Biointerfaces. 2006 Jan 15;47(1):71-7 [16406519.001]
  • [Cites] J Am Chem Soc. 2006 Feb 15;128(6):2115-20 [16464114.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):227-39 [16498445.001]
  • [Cites] Gene Ther. 2007 Jan;14(1):68-77 [16915290.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2449-54 [17438104.001]
  • [Cites] Anal Chem. 2007 Jun 1;79(11):4215-21 [17458937.001]
  • [Cites] Nano Lett. 2007 Jul;7(7):1929-34 [17550297.001]
  • [Cites] Lab Chip. 2008 Jan;8(1):125-33 [18094770.001]
  • [Cites] Rev Sci Instrum. 2007 Dec;78(12):126103 [18163752.001]
  • [Cites] Acc Chem Res. 2008 Dec;41(12):1842-51 [19053240.001]
  • [Cites] J Biomed Opt. 2009 May-Jun;14(3):034008 [19566301.001]
  • [Cites] Nano Lett. 2010 Apr 14;10(4):1398-404 [20196552.001]
  • [Cites] Bioconjug Chem. 2009 Mar 18;20(3):488-99 [19199781.001]
  • [Cites] Bioconjug Chem. 2009 Mar 18;20(3):619-24 [19220052.001]
  • [Cites] Opt Lett. 2003 Sep 1;28(17):1546-8 [12956374.001]
  • (PMID = 20518502.001).
  • [ISSN] 1520-5126
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 5P30CA062203-13; None / None / / P41 RR001192-31; United States / NCRR NIH HHS / RR / P41 RR001192-31; United States / NIBIB NIH HHS / EB / R01 EB010090; United States / NCRR NIH HHS / RR / RR-01192; United States / NCRR NIH HHS / RR / P41 RR001192-30; United States / NIDCR NIH HHS / DE / R21 DE019298; United States / NCI NIH HHS / CA / R01 CA091717; United States / NCRR NIH HHS / RR / RR001192-298612; United States / NIBIB NIH HHS / EB / EB000293-08; United States / NCI NIH HHS / CA / CA-91717; United States / NIBIB NIH HHS / EB / R01 EB010090-01; United States / NIBIB NIH HHS / EB / EB010090-01; United States / NCRR NIH HHS / RR / P41 RR001192-298612; United States / NIBIB NIH HHS / EB / R01 EB000293-08; United States / NIDCR NIH HHS / DE / 3R21DE19298-02S1; United States / NCRR NIH HHS / RR / P41 RR001192; United States / NCI NIH HHS / CA / P30 CA062203; United States / NIBIB NIH HHS / EB / EB-00293; United States / NIBIB NIH HHS / EB / R01 EB000293
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 30IQX730WE / Polyethylene Glycols; 7440-57-5 / Gold; 9002-98-6 / Polyethyleneimine
  • [Other-IDs] NLM/ NIHMS211083; NLM/ PMC2903751
  •  go-up   go-down


39. Maiese K, Hou J, Chong ZZ, Shang YC: Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology. ScientificWorldJournal; 2009 Oct 02;9:1072-104
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oxidative stress significantly impacts multiple cellular pathways that can lead to the initiation and progression of varied disorders throughout the body.
  • It therefore becomes imperative to elucidate the components and function of novel therapeutic strategies against oxidative stress to further clinical diagnosis and care.
  • In particular, both the growth factor and cytokine erythropoietin (EPO), and members of the mammalian forkhead transcription factors of the O class (FoxOs), may offer the greatest promise for new treatment regimens, since these agents and the cellular pathways they oversee cover a range of critical functions that directly influence progenitor cell development, cell survival and degeneration, metabolism, immune function, and cancer cell invasion.
  • Furthermore, both EPO and FoxOs function not only as therapeutic targets, but also as biomarkers of disease onset and progression, since their cellular pathways are closely linked and overlap with several unique signal transduction pathways.
  • Here we present the exciting as well as the complex role that EPO and FoxOs possess to uncover the benefits as well as the risks of these agents for cell biology and clinical care in processes that range from stem cell development to uncontrolled cellular proliferation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Exp Med. 2004 Oct 18;200(8):1051-62 [15492127.001]
  • [Cites] Trends Pharmacol Sci. 2004 Nov;25(11):577-83 [15491780.001]
  • [Cites] Blood. 1974 Jul;44(1):77-85 [4834517.001]
  • [Cites] Nature. 1985 Feb 28-Mar 6;313(6005):806-10 [3838366.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Nov;82(22):7580-4 [3865178.001]
  • [Cites] Biochemistry. 1988 Jul 26;27(15):5646-54 [3179269.001]
  • [Cites] Cell. 1989 May 19;57(4):645-58 [2566386.001]
  • [Cites] Eur J Biochem. 1990 Mar 10;188(2):405-11 [2156701.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(15):5978-82 [2165612.001]
  • [Cites] Kidney Int. 1990 Nov;38(5):969-75 [2266682.001]
  • [Cites] Blood. 1991 Feb 1;77(3):419-34 [1991159.001]
  • [Cites] Neurobiol Aging. 1999 Nov-Dec;20(6):581-9 [10674423.001]
  • [Cites] J Neurosci Res. 2000 Feb 15;59(4):568-80 [10679797.001]
  • [Cites] Genes Dev. 2000 Jan 15;14(2):142-6 [10702024.001]
  • [Cites] J Neurosci Res. 1999 Feb 15;55(4):472-85 [10723057.001]
  • [Cites] J Autoimmun. 2000 May;14(3):221-9 [10756084.001]
  • [Cites] Cell Mol Neurobiol. 2000 Jun;20(3):383-400 [10789835.001]
  • [Cites] Int J Dev Neurosci. 2000 Jul-Aug;18(4-5):423-31 [10817926.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2000 Jun;278(6):E1038-44 [10827006.001]
  • [Cites] J Cereb Blood Flow Metab. 2000 Sep;20(9):1380-91 [10994860.001]
  • [Cites] J Neurosci Res. 2000 Oct 15;62(2):257-72 [11020218.001]
  • [Cites] J Biochem. 2000 Nov;128(5):731-7 [11056384.001]
  • [Cites] J Biol Chem. 2000 Dec 15;275(50):39754-61 [10995753.001]
  • [Cites] Biochem J. 2000 Jul 15;349(Pt 2):629-34 [10880363.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2000 Dec;279(6):E1242-8 [11093910.001]
  • [Cites] ScientificWorldJournal. 2008;8:270-4 [18661049.001]
  • [Cites] Oncogene. 2008 Aug 7;27(34):4733-44 [18408765.001]
  • [Cites] Curr Neurovasc Res. 2008 Aug;5(3):159-70 [18691073.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 1):1125-31 [18086112.001]
  • [Cites] J Mol Cell Cardiol. 2008 Aug;45(2):250-60 [18586265.001]
  • [Cites] J Immunol. 2008 Sep 1;181(5):2980-9 [18713968.001]
  • [Cites] Mol Cancer Ther. 2008 Aug;7(8):2263-71 [18687658.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2008 Jul-Aug;56(4):257-66 [18726147.001]
  • [Cites] Hear Res. 2008 Sep;243(1-2):121-6 [18672044.001]
  • [Cites] Carcinogenesis. 2008 Sep;29(9):1837-44 [18390843.001]
  • [Cites] J Neurosci Res. 2008 Oct;86(13):3018-27 [18512763.001]
  • [Cites] J Cereb Blood Flow Metab. 2001 Mar;21(3):262-75 [11295881.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Apr;60(4):386-92 [11305874.001]
  • [Cites] Mamm Genome. 2001 Jun;12(6):416-25 [11353388.001]
  • [Cites] J Biol Chem. 2001 Jan 26;276(4):2571-5 [11073947.001]
  • [Cites] J Am Coll Cardiol. 2001 Jun 1;37(7):1775-80 [11401110.001]
  • [Cites] Pediatr Res. 2002 Apr;51(4):472-8 [11919332.001]
  • [Cites] J Cereb Blood Flow Metab. 2002 May;22(5):503-14 [11973422.001]
  • [Cites] J Cell Mol Med. 2002 Jan-Mar;6(1):82-92 [12003671.001]
  • [Cites] J Vasc Res. 2002 Mar-Apr;39(2):131-47 [12011585.001]
  • [Cites] J Biol Chem. 2002 Jul 26;277(30):26729-32 [12048180.001]
  • [Cites] Eur J Neurosci. 2002 Aug;16(4):584-92 [12270034.001]
  • [Cites] Microsc Res Tech. 2002 Nov 15;59(4):331-4 [12424797.001]
  • [Cites] J Biol Chem. 2002 Dec 6;277(49):47928-37 [12351634.001]
  • [Cites] Circulation. 2002 Dec 3;106(23):2973-9 [12460881.001]
  • [Cites] Histol Histopathol. 2003 Jan;18(1):173-89 [12507297.001]
  • [Cites] Exp Biol Med (Maywood). 2003 Jan;228(1):1-14 [12524467.001]
  • [Cites] Circulation. 2003 Jan 21;107(2):294-9 [12538431.001]
  • [Cites] J Neurosci Res. 2003 Mar 1;71(5):659-69 [12584724.001]
  • [Cites] J Biol Chem. 2003 Feb 21;278(8):5871-82 [12488318.001]
  • [Cites] J Hematother Stem Cell Res. 2002 Dec;11(6):863-71 [12590701.001]
  • [Cites] J Cereb Blood Flow Metab. 2003 Mar;23(3):320-30 [12621307.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12361-6 [12517744.001]
  • [Cites] Br J Pharmacol. 2003 Mar;138(6):1107-18 [12684267.001]
  • [Cites] J Biol Chem. 2003 Apr 18;278(16):13898-904 [12578834.001]
  • [Cites] Transplantation. 2003 Apr 27;75(8):1356-60 [12717230.001]
  • [Cites] Arch Toxicol. 2003 May;77(5):267-73 [12734640.001]
  • [Cites] Trends Pharmacol Sci. 2003 May;24(5):228-32 [12767721.001]
  • [Cites] Science. 2003 Jul 11;301(5630):215-8 [12855809.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1340-6 [12702503.001]
  • [Cites] Circulation. 2003 Aug 5;108(5):616-22 [12835226.001]
  • [Cites] Mol Pharmacol. 2003 Sep;64(3):557-69 [12920191.001]
  • [Cites] J Neurosci Res. 2003 Oct 1;74(1):37-51 [13130504.001]
  • [Cites] Cell Mol Neurobiol. 2003 Oct;23(4-5):561-78 [14514016.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11285-90 [13679577.001]
  • [Cites] Am J Obstet Gynecol. 2003 Dec;189(6):1764-70 [14710111.001]
  • [Cites] Arch Intern Med. 2004 Feb 9;164(3):262-76 [14769622.001]
  • [Cites] Clin Nephrol. 2004 Feb;61(2):127-9 [14989632.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2975-80 [14978268.001]
  • [Cites] Antioxid Redox Signal. 2004 Apr;6(2):277-87 [15025929.001]
  • [Cites] Science. 2004 Mar 26;303(5666):2011-5 [14976264.001]
  • [Cites] Cell. 2004 Apr 16;117(2):225-37 [15084260.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 May;31(5):733-9 [14985868.001]
  • [Cites] Exp Cell Res. 2004 Jun 10;296(2):196-207 [15149850.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9855-60 [15210945.001]
  • [Cites] J Am Coll Cardiol. 2004 Jul 7;44(1):63-7 [15234408.001]
  • [Cites] J Cereb Blood Flow Metab. 2004 Jul;24(7):728-43 [15241181.001]
  • [Cites] Restor Neurol Neurosci. 2004;22(2):87-104 [15272144.001]
  • [Cites] Restor Neurol Neurosci. 2004;22(2):105-19 [15272145.001]
  • [Cites] J Biol Chem. 2004 Aug 13;279(33):34741-9 [15184386.001]
  • [Cites] Immunity. 2004 Aug;21(2):203-13 [15308101.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2500-20 [15353303.001]
  • [Cites] Cancer Lett. 2004 Oct 28;214(2):171-9 [15363543.001]
  • [Cites] J Biol Chem. 2004 Sep 24;279(39):41114-23 [15272020.001]
  • [Cites] J Neuroimmunol. 2009 Jun 25;211(1-2):92-100 [19428125.001]
  • [Cites] Clin Transl Oncol. 2009 Jul;11(7):411-27 [19574199.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2009;16(4):530-7 [19333535.001]
  • [Cites] Neurobiol Dis. 2009 Aug;35(2):278-85 [19481149.001]
  • [Cites] Glia. 2009 Sep;57(12):1351-61 [19229997.001]
  • [Cites] Clin Pharmacol Ther. 2009 Aug;86(2):154-9 [19458615.001]
  • [Cites] Eur J Heart Fail. 2009 Aug;11(8):732-8 [19633100.001]
  • [Cites] ScientificWorldJournal. 2009;9:781-91 [19705038.001]
  • [Cites] Am J Nephrol. 2009;30(3):253-60 [19494484.001]
  • [Cites] Molecules. 2009;14(9):3446-85 [19783937.001]
  • [Cites] J Alzheimers Dis. 2009;17(2):267-76 [19221404.001]
  • [Cites] Am J Kidney Dis. 1991 Oct;18(4 Suppl 1):14-9 [1928074.001]
  • [Cites] Am Heart J. 1992 Aug;124(2):424-7 [1386184.001]
  • [Cites] Nature. 1993 Jul 29;364(6436):412-20 [8332212.001]
  • [Cites] J Neurosci Res. 1993 Sep 1;36(1):77-87 [8230323.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3974-8 [8171022.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Oct;11(2):79-84 [7529552.001]
  • [Cites] J Cereb Blood Flow Metab. 1995 May;15(3):440-9 [7714002.001]
  • [Cites] Eur J Biochem. 1996 Jul 15;239(2):494-500 [8706759.001]
  • [Cites] J Neurochem. 1997 Feb;68(2):710-4 [9003060.001]
  • [Cites] Circulation. 1997 May 6;95(9):2303-11 [9142009.001]
  • [Cites] J Cereb Blood Flow Metab. 1997 May;17(5):560-6 [9183294.001]
  • [Cites] Blood. 1997 Nov 1;90(9):3714-9 [9345057.001]
  • [Cites] Free Radic Res. 1997 Sep;27(3):311-23 [9350435.001]
  • [Cites] Nature. 1997 Oct 30;389(6654):994-9 [9353126.001]
  • [Cites] Science. 1997 Nov 14;278(5341):1319-22 [9360933.001]
  • [Cites] Biochemistry. 1998 Apr 28;37(17):6179-87 [9558357.001]
  • [Cites] Arch Biochem Biophys. 1998 May 15;353(2):312-21 [9606965.001]
  • [Cites] J Biol Chem. 1998 Sep 25;273(39):25381-7 [9738005.001]
  • [Cites] Exp Neurol. 1999 Jan;155(1):79-94 [9918707.001]
  • [Cites] Exp Cell Res. 1999 Feb 1;246(2):290-300 [9925743.001]
  • [Cites] Cell Biochem Biophys. 1999;30(1):153-66 [10099826.001]
  • [Cites] J Histochem Cytochem. 1999 May;47(5):661-72 [10219058.001]
  • [Cites] J Biol Chem. 1999 Jun 4;274(23):15982-5 [10347145.001]
  • [Cites] J Biol Chem. 1999 Jun 11;274(24):17184-92 [10358076.001]
  • [Cites] J Neurobiol. 1999 Aug;40(2):171-84 [10413448.001]
  • [Cites] Blood. 1950 Apr;5(4):372-80 [15411424.001]
  • [Cites] Science. 2004 Nov 12;306(5699):1190-4 [15498972.001]
  • [Cites] Acta Med Okayama. 2004 Aug;58(4):197-205 [15551757.001]
  • [Cites] Diabetologia. 2004 Oct;47(10):1695-703 [15502930.001]
  • [Cites] Circ Res. 2008 Mar 28;102(6):686-94 [18218983.001]
  • [Cites] J Biol Chem. 2008 Apr 4;283(14):9224-30 [18250171.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):152-9 [17967510.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):3001-9 [18413770.001]
  • [Cites] Breast Cancer Res. 2008;10(1):R21 [18312651.001]
  • [Cites] Adv Exp Med Biol. 2008;615:13-23 [18437889.001]
  • [Cites] Pharmacol Ther. 2008 Apr;118(1):58-81 [18313758.001]
  • [Cites] Acta Trop. 2008 May;106(2):104-8 [18359468.001]
  • [Cites] BJU Int. 2008 Jun;101(11):1454-60 [18336616.001]
  • [Cites] Biomed Pharmacother. 2008 Apr-May;62(4):218-32 [18342481.001]
  • [Cites] Trends Mol Med. 2008 May;14(5):219-27 [18403263.001]
  • [Cites] Curr Neurovasc Res. 2008 May;5(2):125-42 [18473829.001]
  • [Cites] N Engl J Med. 2008 May 15;358(20):2107-16 [18480203.001]
  • [Cites] Prog Neurobiol. 2008 Jun;85(2):194-213 [18396368.001]
  • [Cites] Brain Res Bull. 2008 Jul 1;76(4):424-38 [18502319.001]
  • [Cites] Neuropsychopharmacology. 2008 Jul;33(8):1942-51 [17805306.001]
  • [Cites] Eur J Pharmacol. 2008 Jul 7;588(2-3):178-88 [18502414.001]
  • [Cites] Expert Opin Ther Targets. 2008 Jul;12(7):905-16 [18554157.001]
  • [Cites] Brain Res. 2008 Jul 7;1218:224-9 [18533137.001]
  • [Cites] Biochim Biophys Acta. 2008 Jul-Aug;1777(7-8):834-46 [18452700.001]
  • [Cites] Neurochem Res. 2008 Aug;33(8):1599-609 [18461448.001]
  • [Cites] Neuroscience. 2008 Jul 17;154(4):1458-66 [18555616.001]
  • [Cites] J Nephrol. 2008 Jul-Aug;21(4):543-9 [18651544.001]
  • [Cites] Oncogene. 2008 Jul 24;27(32):4422-33 [18391984.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Apr;317(1):68-75 [16377761.001]
  • [Cites] J Am Soc Nephrol. 2006 Apr;17(4):932-42 [16481411.001]
  • [Cites] Obesity (Silver Spring). 2006 Feb;14(2):188-93 [16571842.001]
  • [Cites] Curr Med Chem. 2006;13(8):883-95 [16611073.001]
  • [Cites] Neurosci Lett. 2006 May 1;398(1-2):39-43 [16423457.001]
  • [Cites] PLoS Med. 2006 Apr;3(4):e101 [16478293.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Jun;29(6):902-7 [16675226.001]
  • [Cites] Cancer Immunol Immunother. 2006 Sep;55(9):1064-71 [16328385.001]
  • [Cites] Curr Neurovasc Res. 2006 May;3(2):107-17 [16719794.001]
  • [Cites] J Am Soc Nephrol. 2006 Jun;17(6):1576-84 [16672321.001]
  • [Cites] Nature. 2006 May 25;441(7092):523-7 [16680151.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2787-94 [18628488.001]
  • [Cites] J Ocul Pharmacol Ther. 2008 Oct;24(5):453-9 [18788995.001]
  • [Cites] J Biol Chem. 2008 Oct 10;283(41):27810-9 [18678867.001]
  • [Cites] J Neurochem. 2008 Oct;107(1):127-40 [18665912.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Nov 14;376(2):251-5 [18774777.001]
  • [Cites] Cell Cycle. 2008 Oct;7(20):3162-70 [18927507.001]
  • [Cites] Epilepsia. 2008 Oct;49(10):1723-32 [18479396.001]
  • [Cites] Neurosci Lett. 2008 Dec 31;448(3):245-9 [18973793.001]
  • [Cites] Perfusion. 2008 May;23(3):187-92 [19029270.001]
  • [Cites] J Physiol. 2008 Dec 1;586(Pt 23):5757-69 [18845609.001]
  • [Cites] Crit Care. 2008;12(5):227 [18983707.001]
  • [Cites] Neuroepidemiology. 2009;32(1):40-6 [19001795.001]
  • [Cites] Ann Neurol. 2008 Nov;64(5):523-34 [19067366.001]
  • [Cites] J Neurosci Res. 2009 Jan;87(1):150-63 [18711747.001]
  • [Cites] Cell Mol Life Sci. 2008 Dec;65(24):4000-18 [18820996.001]
  • [Cites] Clin Sci (Lond). 2009 Feb;116(3):191-203 [19118491.001]
  • [Cites] J Ren Nutr. 2009 Jan;19(1):20-4 [19121765.001]
  • [Cites] Brain Res. 2009 Jan 16;1249:212-21 [18977207.001]
  • [Cites] Eur J Pharmacol. 2009 Jan 14;602(2-3):406-12 [19061883.001]
  • [Cites] Trends Parasitol. 2009 Jan;25(1):30-6 [19008152.001]
  • [Cites] Cell Cycle. 2008 Dec 15;7(24):3829-39 [19066462.001]
  • [Cites] J Biol Chem. 2009 Jan 23;284(4):2001-11 [19047055.001]
  • [Cites] Exp Cell Res. 2009 Feb 1;315(3):419-31 [19056379.001]
  • [Cites] Life Sci. 2009 Feb 13;84(7-8):205-10 [19101571.001]
  • [Cites] Brain Behav Immun. 2009 Feb;23(2):193-203 [18835350.001]
  • [Cites] FASEB J. 2009 Feb;23(2):351-61 [18827024.001]
  • [Cites] Acta Pharmacol Sin. 2009 Feb;30(2):202-8 [19122671.001]
  • [Cites] Pharmacol Biochem Behav. 2009 Apr;92(2):251-9 [19138703.001]
  • [Cites] Neonatology. 2009;95(2):105-16 [18776724.001]
  • [Cites] Placenta. 2009 Mar;30(3):256-62 [19150739.001]
  • [Cites] Crit Care Med. 2009 Mar;37(3):889-98 [19237893.001]
  • [Cites] Adv Exp Med Biol. 2009;643:359-68 [19239167.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2009 Mar;50(3):1329-35 [18952918.001]
  • [Cites] J Urol. 2009 Mar;181(3):1434-43 [19157461.001]
  • [Cites] Mech Ageing Dev. 2009 Apr;130(4):253-61 [19162061.001]
  • [Cites] Trends Cell Biol. 2009 Mar;19(3):119-29 [19208479.001]
  • [Cites] Immunol Rev. 2009 Mar;228(1):149-69 [19290926.001]
  • [Cites] Cell Calcium. 2009 Apr;45(4):358-68 [19201465.001]
  • [Cites] Chin Med J (Engl). 2009 Mar 5;122(5):566-70 [19323909.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Apr 17;381(4):491-5 [19233143.001]
  • [Cites] Hellenic J Cardiol. 2009 Mar-Apr;50(2):127-32 [19329414.001]
  • [Cites] J Neurochem. 2009 Apr;109(2):360-70 [19220704.001]
  • [Cites] Free Radic Biol Med. 2009 Apr 15;46(8):1032-41 [19136057.001]
  • [Cites] Med Res Rev. 2009 May;29(3):395-418 [18985696.001]
  • [Cites] Glia. 2009 May;57(7):734-43 [18985732.001]
  • [Cites] Curr Neurovasc Res. 2009 Feb;6(1):20-31 [19355923.001]
  • [Cites] J Comp Neurol. 2009 Jun 1;514(4):403-14 [19330822.001]
  • [Cites] Brain. 2009 Apr;132(Pt 4):879-88 [19244253.001]
  • [Cites] Brain Res. 2009 Mar 31;1263:23-32 [19368821.001]
  • [Cites] Stem Cells Dev. 2009 Apr;18(3):411-21 [18590375.001]
  • [Cites] J Neurochem. 2009 May;109(4):1157-67 [19302476.001]
  • [Cites] Neuropharmacology. 2009 May-Jun;56(6-7):1027-34 [19268480.001]
  • [Cites] J Cell Mol Med. 2009 Apr;13(4):701-11 [18410524.001]
  • [Cites] Cell Signal. 2007 Jun;19(6):1150-62 [17289346.001]
  • [Cites] Eur Surg Res. 2007;39(3):189-97 [17377393.001]
  • [Cites] J Cereb Blood Flow Metab. 2007 May;27(5):1043-54 [17077815.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 May;66(5):389-98 [17483696.001]
  • [Cites] Biochim Biophys Acta. 2007 Apr;1769(4):244-52 [17482685.001]
  • [Cites] Mol Cell Biol. 2007 May;27(10):3839-3854 [17353275.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Jun;8(6):440-50 [17522590.001]
  • [Cites] Adv Ther. 2007 Mar-Apr;24(2):346-52 [17565925.001]
  • [Cites] Clin Cancer Res. 2007 Jun 15;13(12):3536-44 [17575216.001]
  • [Cites] Mol Cell Biol. 2007 Jul;27(13):4917-30 [17452451.001]
  • [Cites] J Cereb Blood Flow Metab. 2007 Jul;27(7):1369-76 [17264861.001]
  • [Cites] Biochim Biophys Acta. 2010 Jan;1802(1):167-85 [19751830.001]
  • [Cites] Oxid Med Cell Longev. 2009 Jan-Mar;2(1):1 [20046637.001]
  • [Cites] Oxid Med Cell Longev. 2009 Jan-Mar;2(1):19-25 [20046641.001]
  • [Cites] Oxid Med Cell Longev. 2009 Jan-Mar;2(1):43-51 [20046644.001]
  • [Cites] Adv Exp Med Biol. 2009;665:242-60 [20429429.001]
  • [Cites] Oxid Med Cell Longev. 2008 Oct-Dec;1(1):1-14 [19750024.001]
  • [Cites] BMC Neurosci. 2004 Nov 29;5:48 [15569384.001]
  • [Cites] Neurosignals. 2004 Nov-Dec;13(6):265-89 [15627815.001]
  • [Cites] JAMA. 2005 Jan 5;293(1):90-5 [15632341.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):284-90 [15665305.001]
  • [Cites] Curr Opin Neurobiol. 2005 Feb;15(1):101-7 [15721751.001]
  • [Cites] Arch Intern Med. 2005 Feb 28;165(4):466-9 [15738380.001]
  • [Cites] Arthritis Rheum. 2005 Mar;52(3):940-50 [15751086.001]
  • [Cites] J Mol Neurosci. 2005;25(2):183-9 [15784966.001]
  • [Cites] Mol Cancer Res. 2005 Mar;3(3):163-9 [15798096.001]
  • [Cites] J Cell Biol. 2005 Apr 25;169(2):331-9 [15837797.001]
  • [Cites] J Am Coll Cardiol. 2005 May 3;45(9):1406-12 [15862410.001]
  • [Cites] Prog Neurobiol. 2005 Feb;75(3):207-46 [15882775.001]
  • [Cites] Nat Med. 2005 Jun;11(6):666-71 [15895074.001]
  • [Cites] Brain Res Brain Res Rev. 2005 Jul;49(1):1-21 [15960984.001]
  • [Cites] Brain Res. 2005 Jul 19;1050(1-2):15-26 [15979589.001]
  • [Cites] Mol Ther. 2005 Aug;12(2):283-9 [15935736.001]
  • [Cites] Dev Cell. 2005 Aug;9(2):261-70 [16054032.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11278-83 [16076959.001]
  • [Cites] J Biol Chem. 2005 Aug 19;280(33):29864-73 [15961397.001]
  • [Cites] Neurosci Lett. 2005 Oct 14;387(1):5-10 [16054296.001]
  • [Cites] Antioxid Redox Signal. 2005 Sep-Oct;7(9-10):1223-33 [16115027.001]
  • [Cites] Endocrinology. 2005 Oct;146(10):4370-6 [16020479.001]
  • [Cites] Curr Neurovasc Res. 2005 Jan;2(1):55-72 [16181100.001]
  • [Cites] Curr Neurovasc Res. 2005 Jul;2(3):197-211 [16181114.001]
  • [Cites] Curr Neurovasc Res. 2005 Oct;2(4):271-85 [16181120.001]
  • [Cites] Curr Neurovasc Res. 2005 Oct;2(4):331-40 [16181124.001]
  • [Cites] J Biol Chem. 2005 Sep 30;280(39):33558-65 [16061480.001]
  • [Cites] Sports Med. 2005;35(10):831-40 [16180943.001]
  • [Cites] Genes Dev. 2005 Oct 15;19(20):2435-46 [16230533.001]
  • [Cites] Biochem J. 2005 Nov 1;391(Pt 3):623-9 [15987244.001]
  • [Cites] Histol Histopathol. 2006 Jan;21(1):103-24 [16267791.001]
  • [Cites] Curr Neurovasc Res. 2005 Dec;2(5):387-99 [16375720.001]
  • [Cites] Curr Neurovasc Res. 2005 Dec;2(5):425-46 [16375723.001]
  • [Cites] Ann Hematol. 2006 Feb;85(2):79-85 [16132904.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):212-20 [16397234.001]
  • [Cites] Gene Expr Patterns. 2006 Jan;6(2):134-40 [16326148.001]
  • [Cites] J Neurochem. 2006 Feb;96(4):1101-10 [16417583.001]
  • [Cites] J Clin Invest. 2006 Feb;116(2):344-56 [16453021.001]
  • [Cites] Curr Neurovasc Res. 2006 Feb;3(1):25-39 [16472123.001]
  • [Cites] Mutat Res. 2006 Feb 22;594(1-2):155-61 [16289600.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Mar;316(3):999-1005 [16306273.001]
  • [Cites] Nat Genet. 2006 Mar;38(3):320-3 [16415884.001]
  • [Cites] Mol Cancer Ther. 2006 Feb;5(2):356-61 [16505109.001]
  • [Cites] J Neurosci Res. 2006 Mar;83(4):584-93 [16435392.001]
  • [Cites] J Infect Dis. 2006 Apr 1;193(7):987-95 [16518761.001]
  • [Cites] Brain Res Bull. 2006 Mar 31;69(2):117-22 [16533659.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Apr;317(1):109-16 [16357210.001]
  • [Cites] Mol Cell Endocrinol. 2008 Jan 16;281(1-2):47-55 [18035477.001]
  • [Cites] Mol Cell. 2007 Dec 28;28(6):941-53 [18158893.001]
  • [Cites] Cell Death Differ. 2008 Feb;15(2):299-311 [17992191.001]
  • [Cites] Resuscitation. 2008 Mar;76(3):397-404 [18037223.001]
  • [Cites] Rejuvenation Res. 2008 Feb;11(1):139-50 [18069916.001]
  • [Cites] Gynecol Oncol. 2008 Mar;108(3):609-18 [18234299.001]
  • [Cites] Diabetes. 2008 Mar;57(3):563-76 [18162510.001]
  • [Cites] Clin Dev Immunol. 2007;2007:89195 [18317534.001]
  • [Cites] Br J Haematol. 2008 Apr;141(1):14-31 [18324962.001]
  • [Cites] Cell Signal. 2008 May;20(5):892-906 [18276109.001]
  • [Cites] Expert Rev Cardiovasc Ther. 2008 Mar;6(3):281-4 [18327989.001]
  • [Cites] Cell. 2006 Jun 2;125(5):987-1001 [16751106.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):9051-6 [16757565.001]
  • [Cites] Biochem J. 2006 Jul 15;397(2):233-46 [16792526.001]
  • [Cites] J Cardiovasc Pharmacol. 2006 Jun;47(6):736-41 [16810073.001]
  • [Cites] Diabetes. 2006 Aug;55(8):2231-7 [16873685.001]
  • [Cites] Clin Sci (Lond). 2006 Sep;111(3):171-83 [16901264.001]
  • [Cites] Eur J Neurosci. 2006 Jul;24(2):361-70 [16903847.001]
  • [Cites] Diabet Med. 2006 Aug;23(8):839-44 [16911620.001]
  • [Cites] Acta Biomed. 2005;76 Suppl 3:49-54 [16915797.001]
  • [Cites] Curr Neurovasc Res. 2006 Aug;3(3):187-201 [16918383.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):875-83 [16861905.001]
  • [Cites] Nat Clin Pract Nephrol. 2005 Dec;1(2):87-97 [16932374.001]
  • [Cites] Diabetes. 2006 Sep;55(9):2649-53 [16936217.001]
  • [Cites] Pediatrics. 2006 Sep;118(3):e635-40 [16908620.001]
  • [Cites] Semin Nephrol. 2006 Jul;26(4):296-306 [16949468.001]
  • [Cites] Circulation. 2006 Sep 19;114(12):1269-76 [16952980.001]
  • [Cites] Eur J Endocrinol. 2006 Oct;155(4):609-14 [16990661.001]
  • [Cites] Int J Cardiol. 2006 Oct 10;112(3):341-7 [16309765.001]
  • [Cites] Diabetes. 2006 Oct;55(10):2863-70 [17003354.001]
  • [Cites] J Am Soc Nephrol. 2006 Oct;17(10):2812-20 [16943306.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4675-6 [17028292.001]
  • [Cites] J Med Genet. 2006 Oct;43(10):798-803 [16723389.001]
  • [Cites] Nephron Exp Nephrol. 2006;104(3):e83-8 [16837817.001]
  • [Cites] Fertil Steril. 2006 Nov;86(5):1518-21 [16979636.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16260-5 [17053067.001]
  • [Cites] Eur J Immunol. 2006 Nov;36(11):2971-80 [17051618.001]
  • [Cites] J Thromb Haemost. 2006 Dec;4(12):2656-63 [16961585.001]
  • [Cites] J Control Release. 2006 Nov10;116(1):28-34 [17081643.001]
  • [Cites] Am Heart J. 2006 Dec;152(6):1096.e9-15 [17161060.001]
  • [Cites] Development. 2007 Jan;134(1):199-209 [17164425.001]
  • [Cites] Prog Retin Eye Res. 2007 Jan;26(1):1-37 [17074526.001]
  • [Cites] J Neurooncol. 2007 Jan;81(1):81-91 [16858513.001]
  • [Cites] Int J Mol Med. 2007 Feb;19(2):263-72 [17203200.001]
  • [Cites] J Virol. 2007 Feb;81(3):1511-6 [17108038.001]
  • [Cites] Cell Signal. 2007 Mar;19(3):634-45 [17045782.001]
  • [Cites] Epilepsia. 2007 Jan;48(1):175-81 [17241225.001]
  • [Cites] Cell. 2007 Jan 26;128(2):309-23 [17254969.001]
  • [Cites] Cell. 2007 Jan 26;128(2):325-39 [17254970.001]
  • [Cites] Neurobiol Dis. 2007 Feb;25(2):412-26 [17166730.001]
  • [Cites] Diabetes. 2007 Feb;56(2):295-303 [17259372.001]
  • [Cites] Diabetes. 2007 Feb;56(2):389-93 [17259383.001]
  • [Cites] Blood. 2007 Feb 15;109(4):1627-35 [17062728.001]
  • [Cites] Cell Death Differ. 2007 Mar;14(3):534-47 [16888645.001]
  • [Cites] Curr Neurovasc Res. 2007 Feb;4(1):63-71 [17311546.001]
  • [Cites] J Cereb Blood Flow Metab. 2007 Mar;27(3):469-76 [16804549.001]
  • [Cites] J Clin Neurosci. 2007 Apr;14(4):364-8 [17236773.001]
  • [Cites] Br J Cancer. 2007 Mar 12;96(5):692-700 [17299396.001]
  • [Cites] Exp Neurol. 2007 Mar;204(1):106-17 [17157835.001]
  • [Cites] Mol Cell Biol. 2007 Apr;27(7):2676-86 [17242183.001]
  • [Cites] Mediators Inflamm. 2006;2006(5):18061 [17392570.001]
  • [Cites] Br J Pharmacol. 2007 Apr;150(7):839-50 [17339844.001]
  • [Cites] Clin Exp Dermatol. 2007 May;32(3):287-90 [17397351.001]
  • [Cites] J Biol Chem. 2007 Apr 13;282(15):11590-601 [17308309.001]
  • [Cites] Apoptosis. 2007 Aug;12(8):1365-75 [17508273.001]
  • [Cites] FASEB J. 2007 Jul;21(9):2226-36 [17369508.001]
  • [Cites] Eur J Neurosci. 2007 Jul;26(1):90-100 [17614942.001]
  • [Cites] Anal Bioanal Chem. 2007 Aug;388(7):1521-9 [17516052.001]
  • [Cites] Cancer Lett. 2007 Aug 18;253(2):170-9 [17462819.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H274-83 [17337594.001]
  • [Cites] Curr Med Chem. 2007;14(16):1729-38 [17627510.001]
  • [Cites] J Biol Chem. 2007 Jul 20;282(29):21542-50 [17522055.001]
  • [Cites] Semin Hematol. 2007 Jul;44(3):212-7 [17631185.001]
  • [Cites] Mod Pathol. 2007 Aug;20(8):835-42 [